
<html lang="en"     class="pb-page"  data-request-id="da3edb77-41a8-4a6b-b423-74c30379a403"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.0c00441;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-10"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme" /></meta><meta name="dc.Creator" content="Urvashi  Sharma" /></meta><meta name="dc.Creator" content="Gyles E.  Cozier" /></meta><meta name="dc.Creator" content="Edward D.  Sturrock" /></meta><meta name="dc.Creator" content="K. Ravi  Acharya" /></meta><meta name="dc.Description" content="Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dependent metallopeptidases in the natriuretic peptide and kinin systems and renin–angiotensin–aldosterone system, respecti..." /></meta><meta name="Description" content="Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dependent metallopeptidases in the natriuretic peptide and kinin systems and renin–angiotensin–aldosterone system, respecti..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 27, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00441" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00441" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00441" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00441" /></link>
        
    
    

<title>Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00441" /></meta><meta property="og:title" content="Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0010.jpeg" /></meta><meta property="og:description" content="Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dependent metallopeptidases in the natriuretic peptide and kinin systems and renin–angiotensin–aldosterone system, respectively. They play an important role in blood pressure regulation and reducing the risk of heart failure. Vasopeptidase inhibitors omapatrilat and sampatrilat possess dual activity against these enzymes by blocking the ACE-dependent conversion of angiotensin I to the potent vasoconstrictor angiotensin II while simultaneously halting the NEP-dependent degradation of vasodilator atrial natriuretic peptide. Here, we report crystal structures of omapatrilat, sampatrilat, and sampatrilat-ASP (a sampatrilat analogue) in complex with NEP at 1.75, 2.65, and 2.6 Å, respectively. A detailed analysis of these structures and the corresponding structures of ACE with these inhibitors has provided the molecular basis of dual inhibitor recognition involving the catalytic site in both enzymes. This new information will be very useful in the design of safer and more selective vasopeptidase inhibitors of NEP and ACE for effective treatment in hypertension and heart failure." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00441"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00441">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00441&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00441&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00441&amp;href=/doi/10.1021/acs.jmedchem.0c00441" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 5488-5500</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00406" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00442" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Urvashi Sharma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Urvashi Sharma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Urvashi++Sharma">Urvashi Sharma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gyles E. Cozier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gyles E. Cozier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gyles+E.++Cozier">Gyles E. Cozier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Edward D. Sturrock</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Edward D. Sturrock</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, 7935 Cape Town, Republic of South Africa</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Edward+D.++Sturrock">Edward D. Sturrock</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">K. Ravi Acharya</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">K. Ravi Acharya</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#2d4f5e5e465f4c6d4f4c5945034c4e035846"><span class="__cf_email__" data-cfemail="9ffdececf4edfedffdfeebf7b1fefcb1eaf4">[email protected]</span></a>. Tel: (+44) 1225-386238. Fax: (+44) 1225-386779.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=K.+Ravi++Acharya">K. Ravi Acharya</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3009-4058" title="Orcid link">http://orcid.org/0000-0002-3009-4058</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00441&amp;href=/doi/10.1021%2Facs.jmedchem.0c00441" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 5488–5500</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 27, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 March 2020</li><li><span class="item_label"><b>Published</b> online</span>27 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 May 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00441" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00441</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00441"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1316</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00441" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Urvashi&quot;,&quot;last_name&quot;:&quot;Sharma&quot;},{&quot;first_name&quot;:&quot;Gyles&quot;,&quot;last_name&quot;:&quot;E. Cozier&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;D. Sturrock&quot;},{&quot;first_name&quot;:&quot;K.&quot;,&quot;last_name&quot;:&quot;Ravi Acharya&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;5488-5500&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00441&quot;},&quot;abstract&quot;:&quot;Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dependent metallopeptidases in the natriuretic peptide and kinin systems and renin–angiotensin–aldosterone system, respectively. They play an important role in blood pressure regulation and reducing the risk of heart failure. Vasopeptidase inhibitors omapatrilat and sampatrilat possess dual activity against these enzymes by blocking the ACE-dependent conversion of angiotensin I to the potent vasoconstrictor angiotensin II while simultaneously halting the NEP-dependent degradation of vasodilator atrial natriuretic peptide. Here, we report crystal structures of omapatrilat, sampatrilat, and sampatrilat-ASP (a sampatrilat analogue) in complex with NEP at 1.75, 2.65, and 2.6 Å, respectively. A detailed analysis of these structures and the corresponding structures of ACE with these inhibitors has provided the molecular basis of dual inhibitor recognition involving the catalytic site in both enzymes. This new information will be very useful i&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00441&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00441" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00441&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00441" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00441&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00441" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00441&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00441&amp;href=/doi/10.1021/acs.jmedchem.0c00441" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00441" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00441" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (10 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00441%26sid%3Dliteratum%253Aachs%26pmid%3D32337993%26genre%3Darticle%26aulast%3DSharma%26date%3D2020%26atitle%3DMolecular%2BBasis%2Bfor%2BOmapatrilat%2Band%2BSampatrilat%2BBinding%2Bto%2BNeprilysin%25E2%2580%2594Implications%2Bfor%2BDual%2BInhibitor%2BDesign%2Bwith%2BAngiotensin-Converting%2BEnzyme%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D10%26spage%3D5488%26epage%3D5500%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291399" title="Zinc">Zinc</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=291984" title="Molecular mechanics">Molecular mechanics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/jmcmar.2020.63.issue-10/20200528/jmcmar.2020.63.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dependent metallopeptidases in the natriuretic peptide and kinin systems and renin–angiotensin–aldosterone system, respectively. They play an important role in blood pressure regulation and reducing the risk of heart failure. Vasopeptidase inhibitors omapatrilat and sampatrilat possess dual activity against these enzymes by blocking the ACE-dependent conversion of angiotensin I to the potent vasoconstrictor angiotensin II while simultaneously halting the NEP-dependent degradation of vasodilator atrial natriuretic peptide. Here, we report crystal structures of omapatrilat, sampatrilat, and sampatrilat-ASP (a sampatrilat analogue) in complex with NEP at 1.75, 2.65, and 2.6 Å, respectively. A detailed analysis of these structures and the corresponding structures of ACE with these inhibitors has provided the molecular basis of dual inhibitor recognition involving the catalytic site in both enzymes. This new information will be very useful in the design of safer and more selective vasopeptidase inhibitors of NEP and ACE for effective treatment in hypertension and heart failure.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24434" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24434" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cardiovascular disease (CVD) is responsible for ∼30% of all deaths worldwide, most of which occur in developing countries. Hypertension is the main risk factor for CVD, and despite the large number of drugs on the market for treating hypertension, the global CVD burden continues to rise.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">In addition, many patients receiving treatment suffer from severe side effects such as angioedema and persistent cough and still eventually develop nephropathy, retinopathy, and heart failure.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> The renin-angiotensin-aldosterone system (RAAS), the endothelin system (ES), and the natriuretic peptides and kinin system (NPKS) play important roles in blood pressure regulation; thus, peptidases and receptors within these systems are important drug targets for the treatment of hypertension.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Single drugs targeting both angiotensin-converting enzyme (ACE, EC 3.4.15.1) and neprilysin (NEP, EC 3.4.24.11), key zinc-dependent metalloproteases in RAAS and NPKS, respectively, are an attractive therapeutic approach for the treatment of hypertension and have been termed vasopeptidase inhibitors.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> The rationale behind this approach is to block the ACE-dependent conversion of angiotensin I to the potent vasoconstrictor angiotensin II while simultaneously decreasing the NEP-dependent degradation of vasodilators atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP). NEP has a broad substrate specificity and is structurally similar to ACE,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> thereby facilitating the design of inhibitors that target both enzymes.</div><div class="NLM_p">In clinical studies, omapatrilat (4<i>S</i>,7<i>S</i>,10<i>aS</i>)-5-oxo-4-[(2<i>S</i>)-3-phenyl-2-sulfanylpropanoyl]amino-2,3,4,7,8,9,10,10<i>a</i>-octahydropyrido[2,1-<i>b</i>][1,3]thiazepine-7-carboxylic acid (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), an extensively studied dual ACE/NEP inhibitor,<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> was highly effective at lowering blood pressure in hypertensive patients.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> However, it also increased the incidence of the potentially fatal adverse reaction, angioedema. In addition to this, omapatrilat caused a substantial increase in the incidence of cough, flushing, and transient facial redness as well as the incidence of gastrointestinal disturbances compared to placebo. The accumulation of the vasodilator peptide bradykinin has been associated with side effects commonly observed for ACE inhibitors. Bradykinin is degraded by both ACE and NEP as well as aminopeptidase 2 (APP2), a third enzyme inhibited by omapatrilat;<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> as such, inhibiting these three enzymes simultaneously exacerbates the problems associated with the buildup of bradykinin. The poor safety profile of omapatrilat stalled the development of this otherwise promising class of vasopeptidase inhibitors. The C-domain (cACE) catalytic site of ACE is primarily responsible for the hydrolysis of angiotensin I. Thus, C-domain-selective inhibition allows the N-domain (nACE) catalytic site to inactivate bradykinin and decreases the potential for ACE inhibitor-induced adverse effects.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures of Inhibitors Used in This Structural Study with NEP along with Their Published Inhibition Data against NEP and the Two sACE Domains<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0009.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Inhibition data references: NEP–omapatrilat,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> NEP–sampatrilat,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> ACE–omapatrilat,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> ACE–sampatrilat,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and ACE–samASP.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></p></div></div><div></div></div><div class="NLM_p">Sampatrilat, (<i>S</i>,<i>S</i>,<i>S</i>)-<i>N</i>-{1-[2-carboxy-3-(<i>N</i>-mesyllysylamino)propyl]-1-cyclopentylcarbonyl}tyrosine (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), is also a vasopeptidase inhibitor of ACE and NEP with the potential for the treatment of hypertension and congestive heart failure.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> It is hydrophilic containing one weakly acidic phenolic (tyrosine) group, two more acidic carboxylate groups (tyrosine carboxylate and the central carboxylate), and one basic primary amine (lysine) group. Sampatrilat has a moderate 12.5-fold selectivity for cACE, whereas sampatrilat-ASP (samASP), an analogue that has an aspartate substituted for the P<sub>2</sub> lysine of sampatrilat, is nonselective.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">Lisinopril ((2<i>S</i>)-1-[(2<i>S</i>)-6-amino-2-{[(1<i>S</i>)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid) is a potent inhibitor of both ACE domains with a fourfold selectivity for cACE, whereas Lis-W ((2<i>S</i>)-2-[[(2<i>S</i>)-6-amino-1-[[(1<i>R</i>)-1-carboxy-2-(1<i>H</i>-indol-3-yl)ethyl]amino]-1-oxohexan-2-yl]amino]-4-phenylbutanoic acid), an analogue with a P<sub>2</sub>′ indole group, retains the potency for cACE, but has a 243-fold cACE selectivity.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a><i>In vivo</i> studies showed that Lis-W could reduce angiotensin II levels and blood pressure, while bradykinin levels did not increase.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Other studies showed that only lisinopril and not Lis-W caused a decrease in nACE-specific substrates Ac-SDKP and Ang 1–7 levels.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> These results show that low levels of cACE selectivity are unlikely to give the desired reduction in side effects and highlight the importance of including a good level of selectivity for cACE in the design of future vasopeptidase inhibitors.</div><div class="NLM_p">Previously, we reported the high-resolution crystal structures of individual domains of ACE in complex with omapatrilat, sampatrilat, and samASP.<a onclick="showRef(event, 'ref9 ref23'); return false;" href="javascript:void(0);" class="ref ref9 ref23">(9,23)</a> Omapatrilat displayed nonselective inhibition, inhibiting both nACE and cACE in the subnanomolar range, and the structural results highlighted conserved protein–inhibitor interactions for the Zn<sup>2+</sup>-bound omapatrilat molecule within the active site of each domain. Further, the complex with cACE showed that two additional omapatrilat molecules were able to bind in the binding site cavity, consistent with binding of an omapatrilat dimer. This lends support for the design of an extended molecule exploiting the larger active site groove to provide enhanced specificity for cACE. The crystal structures of sampatrilat and samASP in complex with ACE domains provided a molecular basis for differences in inhibitor affinity and selectivity for nACE and cACE.</div><div class="NLM_p last">Here, we describe the crystal structures of NEP in complex with omapatrilat, sampatrilat, and samASP. The structural data are consistent with the inhibition data and show clear protein–inhibitor interactions involving the Zn<sup>2+</sup> ion at the active site and S<sub>1</sub>′ to S<sub>2</sub>′ subsites in all three complexes. Our findings and analysis also provide clear differences and experimental insights into ligand binding in comparison to domain-specific ACE active site pockets that are important for the design of highly specific dual NEP/ACE inhibitors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04450" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04450" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Overall Structure of Inhibitor–NEP Complexes</h3><div class="NLM_p">Crystals of NEP extracellular domain (residues 51Y-749W) in complex with omapatrilat, sampatrilat, and samASP (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) were grown by either co-crystallization or soaking. The crystals of all three complexes belonged to the <i>P</i>3<sub>2</sub>21 space group and contained one molecule of the protein in the asymmetric unit. The structures were solved by molecular replacement using the substrate-free NEP structure PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GID">6GID</a> with resolutions of 1.75, 2.65, and 2.6 Å for NEP–omapatrilat, NEP–sampatrilat, and NEP–samASP complexes, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Crystallographic Data Collection and Structure Refinement Statistics<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="center">omapatrilat</th><th class="colsep0 rowsep0" align="center">sampatrilat</th><th class="colsep0 rowsep0" align="center">samASP</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution (Å)</td><td class="colsep0 rowsep0" align="left">[93.47–9.09]</td><td class="colsep0 rowsep0" align="left">[93.61–8.79]</td><td class="colsep0 rowsep0" align="left">[112.96–9.01]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(1.78–1.75)</td><td class="colsep0 rowsep0" align="left">(2.78–2.65)</td><td class="colsep0 rowsep0" align="left">(2.72–2.60)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left"><i>P</i>3<sub>2</sub>21</td><td class="colsep0 rowsep0" align="left"><i>P</i>3<sub>2</sub>21</td><td class="colsep0 rowsep0" align="left"><i>P</i>3<sub>2</sub>21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell dimensions (<i>a</i>, <i>b</i>, <i>c</i>) (Å)</td><td class="colsep0 rowsep0" align="left">107.94, 107.94, 112.84</td><td class="colsep0 rowsep0" align="left">108.09, 108.09, 112.83</td><td class="colsep0 rowsep0" align="left">108.17, 108.17, 112.95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">angles (α, β, γ) (deg)</td><td class="colsep0 rowsep0" align="left">90.0, 90.0, 120.0</td><td class="colsep0 rowsep0" align="left">90.0, 90.0, 120.0</td><td class="colsep0 rowsep0" align="left">90.0, 90.0, 120.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">molecules/asymmetric unit</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">total/unique reflections</td><td class="colsep0 rowsep0" align="left">3 068 569</td><td class="colsep0 rowsep0" align="left">838 522</td><td class="colsep0 rowsep0" align="left">826 971</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">76 891</td><td class="colsep0 rowsep0" align="left">22 602</td><td class="colsep0 rowsep0" align="left">24 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness (%)</td><td class="colsep0 rowsep0" align="left">[99.9] 100.0 (100.0)</td><td class="colsep0 rowsep0" align="left">[100.0] 100.0 (100.0)</td><td class="colsep0 rowsep0" align="left">[100.0] 100.0 (99.9)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>merge</sub></td><td class="colsep0 rowsep0" align="left">[0.031] 0.137 (4.105)</td><td class="colsep0 rowsep0" align="left">[0.102] 0.472 (4.442)</td><td class="colsep0 rowsep0" align="left">[0.194] 0.587 (5.026)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>pim</sub></td><td class="colsep0 rowsep0" align="left">[0.005] 0.022 (0.711)</td><td class="colsep0 rowsep0" align="left">[0.018] 0.078 (0.865)</td><td class="colsep0 rowsep0" align="left">[0.035] 0.101 (0.852)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">⟨<i>I</i>/σ(<i>I</i>)⟩</td><td class="colsep0 rowsep0" align="left">[86.2] 18.4 (1.2)</td><td class="colsep0 rowsep0" align="left">[26.1] 7.8 (1.1)</td><td class="colsep0 rowsep0" align="left">[15.3] 5.9 (1.2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CC<sub>1/2</sub></td><td class="colsep0 rowsep0" align="left">[1.000] 1.000 (0.507)</td><td class="colsep0 rowsep0" align="left">[0.999] 0.997 (0.535)</td><td class="colsep0 rowsep0" align="left">[0.996] 0.994 (0.546)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">multiplicity</td><td class="colsep0 rowsep0" align="left">[34.4] 39.9 (34.1)</td><td class="colsep0 rowsep0" align="left">[34.9] 37.1 (26.9)</td><td class="colsep0 rowsep0" align="left">[29.2] 34.5 (35.3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Refinement Statistics</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>work</sub>/<i>R</i><sub>free</sub></td><td class="colsep0 rowsep0" align="left">0.166/0.200</td><td class="colsep0 rowsep0" align="left">0.191/0.238</td><td class="colsep0 rowsep0" align="left">0.208/0.254</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>msd</sub> in bond lengths (Å)</td><td class="colsep0 rowsep0" align="left">0.003</td><td class="colsep0 rowsep0" align="left">0.003</td><td class="colsep0 rowsep0" align="left">0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>msd</sub> in bond angles (deg)</td><td class="colsep0 rowsep0" align="left">0.683</td><td class="colsep0 rowsep0" align="left">0.540</td><td class="colsep0 rowsep0" align="left">0.481</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Ramachandran Statistics (%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">favored</td><td class="colsep0 rowsep0" align="left">98.1</td><td class="colsep0 rowsep0" align="left">96.7</td><td class="colsep0 rowsep0" align="left">98.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">allowed</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">outliers</td><td class="colsep0 rowsep0" align="left">0.0</td><td class="colsep0 rowsep0" align="left">0.0</td><td class="colsep0 rowsep0" align="left">0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Average B-Factors (Å<sup>2</sup>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein</td><td class="colsep0 rowsep0" align="left">37.5</td><td class="colsep0 rowsep0" align="left">55.6</td><td class="colsep0 rowsep0" align="left">52.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ligand</td><td class="colsep0 rowsep0" align="left">56.2</td><td class="colsep0 rowsep0" align="left">67.3</td><td class="colsep0 rowsep0" align="left">58.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">water</td><td class="colsep0 rowsep0" align="left">42.7</td><td class="colsep0 rowsep0" align="left">35.8</td><td class="colsep0 rowsep0" align="left">42.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Number of Atoms</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein</td><td class="colsep0 rowsep0" align="left">5669</td><td class="colsep0 rowsep0" align="left">5603</td><td class="colsep0 rowsep0" align="left">5625</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ligand</td><td class="colsep0 rowsep0" align="left">118</td><td class="colsep0 rowsep0" align="left">109</td><td class="colsep0 rowsep0" align="left">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">water</td><td class="colsep0 rowsep0" align="left">553</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDB code</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Inner shell, overall, and outer shell statistics are given in square brackets, unbracketed, and round brackets, respectively.</p></div></div></div><div class="NLM_p">The overall structure of all three complexes shows the typical, mainly α-helical ellipsoid shape previously observed for NEP, which is composed of subdomain 1 (mostly N-domain residues), a linker region, and subdomain 2 (mostly C-terminal residues) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). All of the structures show N-linked glycosylation of asparagines 144, 284, and 324 from subdomain 2 and 627 from subdomain 1, with a single <i>N</i>-acetylglucosamine residue observed at each site (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic overlay representation showing the subdomain arrangement of the omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>), and samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>) complex structures colored in green, blue, and orange, respectively. Active site zinc ions are depicted as spheres, inhibitor molecules as sticks, and the glycosylation sites as glycoblocks (labeled with the corresponding asparagine residue number). Loop regions have been shortened for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The subdomains and linker region form a large central cavity, which contains the catalytic site that is located within subdomain 1 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). This catalytic site comprises a zinc ion, a zinc-binding residue Glu-646, and the conserved zinc metalloprotease motif <sup>583</sup>HEXXH<sup>587</sup> (His-583 and His-587 complete the zinc binding, while Glu-584 is a catalytic residue). Examination of the mFo–DFc omit and final 2mFo–DFc maps adjacent to the zinc ion of the complex structures revealed clear and unambiguous electron density for the bound inhibitors (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), the details of which are described below.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic representation of inhibitors bound to NEP overlayed with the final 2mFo–DFc (blue, contoured at 1σ level) electron density map and the mFo–DFc (green, contoured at 3σ level) electron density omit map for (A) omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), (B) sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>), and (C) samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>) complexes. The zinc ion is shown as a lilac sphere with the inhibitors shown as sticks. α-Helices and β-strands are shown in rose and dark cyan, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Omapatrilat Binding Site</h3><div class="NLM_p">The omapatrilat molecule interacts with NEP along its entire length (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A); a full list of these interactions is shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Omapatrilat was designed as a tripeptide mimic with the aim of binding to the S<sub>1</sub>, S<sub>1</sub>′, and S<sub>2</sub>′ subsites of the target metalloproteases. However, in the NEP complex structure, it is largely bound in the S<sub>1</sub>′ and S<sub>2</sub>′ subsites, with part of the bicyclic group extending toward the S<sub>3</sub>′ region (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. LigPlot representation of the binding site interactions of (A) omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), (B) sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>), and (C) samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>) complexes. Hydrogen-bond/electrostatic interactions are shown in green, hydrophobic interactions in red, and water molecules as red spheres. Residues solely involved in hydrophobic interactions are represented by red, semicircular symbols. The inhibitor moieties are given their “P” number based on the enzyme S-subsite to which they bind.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Close-up views of (A) omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), (B) sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>), and (C) samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVY">6XVY</a>) binding sites showing hydrogen-bond/electrostatic interactions (dashed lines). The inhibitor molecules are depicted as fat sticks, protein chain as a cartoon with α-helices and β-strands in rose and dark cyan, respectively, zinc ion as lilac sphere, and water molecules as red spheres. The inhibitor moieties are given their P number based on the enzyme S-subsite to which they bind.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>), and samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>) binding sites colored green, blue, and orange, respectively. Inhibitors are depicted as sticks and zinc ions as spheres. (A) Overlay of inhibitors from the crystal structures with the subsite binding pockets indicated. (B) Close-up overlay view of the S<sub>1</sub>′ pocket. (C) Close-up overlay view of the S<sub>2</sub>′ pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Comparison of Amino Acid Residues Involved in Omapatrilat, Sampatrilat, and SamASP Binding to NEP<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="rowsep1 colsep0" colspan="3" align="center">omapatrilat</th><th class="rowsep1 colsep0" colspan="3" align="center">sampatrilat</th><th class="rowsep1 colsep0" colspan="3" align="center">samASP</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">subsite</th><th class="colsep0 rowsep0" align="center">DHB</th><th class="colsep0 rowsep0" align="center">WIM</th><th class="colsep0 rowsep0" align="center">HPB</th><th class="colsep0 rowsep0" align="center">DHB</th><th class="colsep0 rowsep0" align="center">WIM</th><th class="colsep0 rowsep0" align="center">HPB</th><th class="colsep0 rowsep0" align="center">DHB</th><th class="colsep0 rowsep0" align="center">WIM</th><th class="colsep0 rowsep0" align="center">HPB</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">S<sub>3</sub>′</td><td class="colsep0 rowsep0" align="left">Arg110</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His711</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">S<sub>2</sub>′</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Arg102</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Arg102</td><td class="colsep0 rowsep0" align="left">Arg102</td><td class="colsep0 rowsep0" align="left">Arg110</td><td class="colsep0 rowsep0" align="left">Arg102</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phe106</td><td class="colsep0 rowsep0" align="left">Asp107</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phe106</td><td class="colsep0 rowsep0" align="left">Asp107</td><td class="colsep0 rowsep0" align="left">Trp693</td><td class="colsep0 rowsep0" align="left">Phe106</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Asn542</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Asn542</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Asn542</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Asp107</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Arg110</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Arg110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Trp693</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Trp693</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His711</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">S<sub>1</sub>′</td><td class="colsep0 rowsep0" align="left">Arg717</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phe106</td><td class="colsep0 rowsep0" align="left">Arg717</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phe106</td><td class="colsep0 rowsep0" align="left">Arg717</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phe106</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Asn542</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Asn542</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phe563</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Val580</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Val580</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Val580</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His583</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His583</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His583</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Trp693</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Trp693</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Trp693</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Zn-binding atoms</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Ala543</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His583</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His583</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His583</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His587</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His587</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His587</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Glu646</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Glu646</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Glu646</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His711</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">S<sub>1</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Glu584</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phe544</td><td class="colsep0 rowsep0" align="left">Glu584</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phe544</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His711</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His711</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">S<sub>2</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">His711</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Val710</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">DHB—direct hydrogen-bond interactions, WIM—water-/ion-mediated interactions, HPB—hydrophobic interactions.</p></div></div></div><div class="NLM_p last">The thiol group of omapatrilat coordinates to the zinc ion as well as two water molecules that mediate interactions with His-711 and the backbone of Ala-543. The phenyl group of omapatrilat extends deep inside the S<sub>1</sub>′ pocket, where it forms extensive hydrophobic interactions with Phe-106, Phe-563, Val-580, and Trp-693, as well as a further hydrophobic interaction from its Cα equivalent atom with His-583. The P<sub>1</sub>′ carbonyl group of omapatrilat has a hydrophobic interaction from C11 to His-711 and a bidentate interaction from O4 with Arg-717. Both N2 and O3 of the omapatrilat P<sub>2</sub>′ peptide bond mimic interact with Asn-542, while C2 has a hydrophobic interaction with His-711. The seven-membered fused ring only partially extends into the S<sub>2</sub>′ pocket, but still makes hydrophobic interactions with Phe-106 and Trp-693. The six-membered fused ring of omapatrilat bridges toward the S<sub>3</sub>′ region, and while it does not strongly interact with NEP, the backbone mimic has a hydrophobic interaction from C9 to His-711, and the “C-terminal” carboxylate group has a bidentate interaction with Arg-110.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Sampatrilat Binding Site</h3><div class="NLM_p">Sampatrilat binds to NEP in the S<sub>2</sub>′ and S<sub>1</sub>′ subsites, and unlike omapatrilat, extends past the zinc ion into the S<sub>1</sub>/S<sub>2</sub> region (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The electron densities for the lysine-like moiety and the methanesulfonamide group in the nonprime subsites show that this region is flexible with multiple conformations likely (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). However, there is sufficient clarity to assign which area of electron density corresponds to the methanesulfonamide group due to the strong signal from the sulfur atom being still visible beyond 3σ in the 2mFo–DFc map. All interactions are listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B. The only interactions with NEP for these groups of sampatrilat are two hydrophobic interactions between the lysine-like moiety and His-711, and this is consistent with the flexibility indicated by the electron density.</div><div class="NLM_p last">There are considerably more interactions shown in the zinc-binding region, as well as S<sub>1</sub>′ and S<sub>2</sub>′ subsites. The zinc-binding region has hydrophobic interactions from “backbone” P<sub>1</sub> C15 and P<sub>1</sub>′ C17 of sampatrilat with Phe-544 and Asn-542, respectively. In addition, the P<sub>1</sub> C16 carboxy group is strongly coordinated via a bidentate interaction with the zinc ion and hydrogen-bonds with Glu-584 and His-711. The P<sub>1</sub>′ ring of sampatrilat extends into the S<sub>1</sub>′ subsite, where it has extensive hydrophobic interactions with Phe-106, Val-580, His-583, and Trp-693. The backbone P<sub>1</sub>′ carbonyl and P<sub>2</sub>′ nitrogen have interactions with Arg-717 (bidentate) and Asn-542, respectively. The P<sub>2</sub>′ tyrosine side chain of sampatrilat extends deep into the S<sub>2</sub>′ pocket, where it forms stacking hydrophobic interactions between the ring of Phe-106 and side chain of Arg-102, as well as a further hydrophobic interaction with Arg-110. In addition, the P<sub>2</sub>′ O34 atom forms hydrogen bonds with Asp-107 and a water molecule. Finally, the P<sub>2</sub>′ carboxy terminus of sampatrilat has two hydrogen bonds with Arg-102 and Asn-542.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> SamASP Binding Site</h3><div class="NLM_p">SamASP binds to NEP in a similar orientation to sampatrilat occupying the S<sub>2</sub>′ and S<sub>1</sub>′ subsites, zinc-binding region, and extending into the nonprime subsites (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). In the nonprime region, the secondary amide and aspartate side-chain-like groups on C5 of samASP are of equivalent size. The electron density observed in the maps is not clear enough to unambiguously assign which group should be placed in which patch of density (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). The best-fit model had the aspartate-like carboxy group placed in the strongest patch of density, with the secondary amide positioned such that its C1 and C2 atoms formed hydrophobic interactions with Val-710 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>C). These are the only interactions observed with this section of samASP, along with the ambiguous electron density that is consistent with probable multiple conformations of these groups. All interactions are listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><div class="NLM_p last">The P<sub>1</sub> zinc-binding carboxy group of samASP has a single interaction with the zinc ion as well as two hydrogen bonds with Glu-584 and His-711. The backbone P<sub>1</sub> C13 and P<sub>1</sub>′ C15 atoms on either side of this carboxy group form hydrophobic interactions with Phe-544 and Asn-542, respectively. The S<sub>1</sub>′ subsite residues Phe-106, Val-580, His-583, and Trp-693 form extensive hydrophobic interactions with the P<sub>1</sub>′ cyclopentyl group of samASP, while the P<sub>1</sub>′ backbone carbonyl has a bidentate interaction with Arg-717. Asn-542 forms hydrogen bonds with the P<sub>2</sub>′ backbone nitrogen and carboxy terminus. This carboxy terminus also interacts with Arg-102 and has a water-mediated hydrogen bond with Arg-110. The P<sub>2</sub>′ tyrosine-like side chain forms extensive hydrophobic interactions deep in the S<sub>2</sub>′ pocket with Asp-107, Arg-110, Trp-693, and stacking between Phe-106 and Arg-102. The O32 atom of this P<sub>2</sub>′ side chain has hydrogen bonds with Asp-107 and Trp-693 (water-mediated).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50437" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50437" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Comparison of Omapatrilat–NEP, Sampatrilat–NEP, and SamASP–NEP Structures</h3><div class="NLM_p">An overlay of the three inhibitor–NEP complexes presented here (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) show that the binding of these inhibitors has very little effect on the overall structure, and this is reflected by the root-mean-square deviation (RMSD) values for the 696 Cα atoms observed in all structures being 0.27 Å at most (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Comparison of the inhibitor–NEP structures with a previous NEP structure with no ligand added (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GID">6GID</a>) shows again very little difference in the structure with RMSD values of the 696 Cα atoms all less than 0.37 Å. While this shows that ligand-bound structures are more similar to each other than to native NEP, it is a very small difference, and essentially the structures remain the same.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Comparison of the Overall Inhibitor–NEP Complex Structures<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="center" char=".">sampatrilat</th><th class="colsep0 rowsep0" align="center" char=".">samASP</th><th class="colsep0 rowsep0" align="center" char=".">native (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GID">6GID</a>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">omapatrilat</td><td class="colsep0 rowsep0" align="char" char=".">0.272</td><td class="colsep0 rowsep0" align="char" char=".">0.230</td><td class="colsep0 rowsep0" align="char" char=".">0.334</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sampatrilat</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">0.196</td><td class="colsep0 rowsep0" align="char" char=".">0.370</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">samASP</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">0.356</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">RMSD values (Å) for 696 Cα atoms observed in all structures. Values were generated using the “Structure Alignment and Superposition with Gesamt” program on CCP4 cloud.</p></div></div></div><div class="NLM_p">An overlay of sampatrilat and samASP inhibitors from the NEP complex structures (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) shows that the zinc-binding region and P<sub>1</sub>′ and P<sub>2</sub>′ groups largely bind to NEP in the same position and orientation. There are some small differences in these regions, for example, orientation of the zinc-binding carboxylate and P<sub>2</sub>′ tyrosine side chain, but these all result in changes of less than 1 Å, and nearly all of the interactions are conserved for this part of the inhibitors (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B,C). This is not surprising as the zinc-binding region and P<sub>1</sub>′ and P<sub>2</sub>′ groups are identical between sampatrilat and samASP. In contrast, this overlay shows that the nonprime parts of sampatrilat and samASP, while occupying a similar spatial location in NEP, have significant differences in orientation. This even applies to backbone nitrogen and carbonyl that are immediately adjacent to the zinc-binding region and conserved between sampatrilat and samASP. These atoms are flipped 180° compared to each other (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B,C), although it is unclear from the crystal structures what causes this change considering there are no strong interactions between these atoms and NEP. Instead, this may be driven by the ligand chemical composition itself with the differences in the P<sub>2</sub> groups causing the flip. It is likely that this flip causes the small orientation change of the zinc-binding carboxylate and, subsequently, the P<sub>1</sub>′ and P<sub>2</sub>′ groups described above. These ligands only differ in their P<sub>2</sub> groups, but these groups still largely occupy similar regions of the nonprime NEP binding site, although the lysine-like moiety of sampatrilat does not overlay well with the carbonyl group of samASP (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). However, the electron density indicates that the P<sub>2</sub> groups of both ligands are flexible, in particular the lysine-like side chain of sampatrilat, and this is likely due to the lack of interactions with NEP.</div><div class="NLM_p last">The overlay of omapatrilat with sampatrilat and samASP (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A) shows that omapatrilat occupies a similar space in the prime subsites as the other inhibitors, but as mentioned previously, unlike sampatrilat and samASP, omapatrilat does not extend into the nonprime side of the zinc-binding site. This is because the phenyl group of omapatrilat binds in the S<sub>1</sub>′ pocket of NEP, and as this phenyl group is longer than the P<sub>1</sub>′ ring of sampatrilat and samASP, it extends further into the S<sub>1</sub>′ pocket and is involved in more hydrophobic interactions (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B). In contrast, the bicyclic ring of omapatrilat is too bulky to enter very far into the S<sub>2</sub>′ pocket, but just binds at the entrance. However, the tyrosine-like side chain of sampatrilat and samASP extends deep into the S<sub>2</sub>′ pocket resulting in many more binding interactions than omapatrilat, including the hydrogen bond with Asp-107 and the strong stacking interactions with Phe-106 and Arg-102 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>C). While omapatrilat does extend further toward the S<sub>3</sub>′ subsite than sampatrilat or samASP, because of the binding orientation, its C-terminal mimic carboxylate group is located close to the equivalent carboxylate group of sampatrilat and samASP, but directly interacts with different NEP residues (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A). While overall omapatrilat shows less interactions with NEP than sampatrilat and samASP do, these interactions are spread over the whole molecule, unlike sampatrilat and samASP, which have a significant portion of their structure being weakly bound in the nonprime region of NEP, and this is consistent with omapatrilat and sampatrilat both having high potency for NEP (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> NEP Binding Comparison of Omapatrilat, Sampatrilat, and SamASP with Other Inhibitor–NEP Complexes</h3><div class="NLM_p">NEP has been previously crystallized in complex with phosphoramidon (PDB codes human: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1DMT">1DMT</a> and rabbit: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZR5">4ZR5</a>),<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> thiorphan (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V48">5V48</a>),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and LBQ657 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JMY">5JMY</a>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (chemical structures of these ligands are shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C). Thiorphan and LBQ657 are the active forms of the prodrugs racecadotril and sucubitril, respectively. A recent study using purified enzymes showed that both thiorphan and LBQ657 were equally potent NEP inhibitors (IC<sub>50</sub> values of 20 nM for both) and were highly specific compared to the weak inhibition of ACE (10.2 and >100 μM, respectively).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Furthermore, a previous study using partially purified enzymes showed that phosphoramidon was also a potent and specific inhibitor for NEP over ACE (IC<sub>50</sub> values of 34 nM and 78 μM, respectively).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> As described previously, both omapatrilat and sampatrilat are also potent inhibitors of NEP (IC<sub>50</sub> value of 8 nM for both).<a onclick="showRef(event, 'ref10 ref14'); return false;" href="javascript:void(0);" class="ref ref10 ref14">(10,14)</a> While IC<sub>50</sub> values from different assays and different research groups cannot be directly compared, it is clear that all of these compounds are potent NEP inhibitors, so a comparison of their structures can indicate what modes of binding are able to produce this potent inhibition.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison of omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVP">6SVP</a>), and samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>) binding sites with native NEP and previous inhibitor–NEP complex structures. Structures of native NEP, LBQ657–NEP, thiorphan–NEP, and phosphoramidon–NEP used PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GID">6GID</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JMY">5JMY</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V48">5V48</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1DMT">1DMT</a>, respectively. (A, B) Two views of the S<sub>1</sub>′ and S<sub>2</sub>′ subsites with residues from these subsites involved in interacting with the ligands shown in only one of the views for clarity. Omapatrilat–NEP, sampatrilat–NEP, samASP–NEP, native NEP, phosphoramidon–NEP, thiorphan–NEP, and LBQ657–NEP are shown in green, blue, orange, gray, brown, magenta, and yellow, respectively. (C) Chemical structures of phosphoramidon, thiorphan, and LBQ657. (D–F) LigPlot representation of the binding site interactions of phosphoramidon–NEP, thiorphan–NEP, and LBQ657–NEP complexes. Hydrogen-bond/electrostatic interactions are shown in green, hydrophobic interactions in red, and water molecules as red spheres. Residues solely involved in hydrophobic interactions are represented by red, semicircular symbols. The inhibitor moieties are given their P number based on the enzyme S-subsite to which they bind. Note that the structure of thiorphan is in complex with rabbit NEP with residues having a slightly different numbering.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An overlay of the inhibitors from these NEP complex structures (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) shows that sampatrilat, samASP, and phosphoramidon have groups that extend deep into the S<sub>1</sub>/S<sub>2</sub> subsite region, with only phosphoramidon having a significant number of interactions with NEP (LigPlot+ diagrams showing the interactions of phosphoramidon, thiorphan, and LBQ657 are shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D–F, respectively). These include hydrophobic interactions with Phe-544, Val-710, and His-711, as well as a hydrogen bond with His-711. LBQ657 has a short methyl P<sub>1</sub> group that only interacts with Phe-544 of NEP, whereas both omapatrilat and thiorphan lack P<sub>1</sub> groups, and therefore terminate with the zinc-ion interactions. This is consistent with previous observations that P<sub>1</sub> groups at best only give a small increase in affinity.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a> The other end of the inhibitor molecule can target residues that would bind the P<sub>2</sub>′ backbone carbonyl or C-terminal carboxy group of NEP peptide substrates, and these residues include Arg-102, Arg-110, and Asn-542. All of the inhibitors compared here contain a carboxy group that interacts with one or more of these residues, even omapatrilat which extends a little further into the prime subsites than the other inhibitors.</div><div class="NLM_p last">In contrast to the P<sub>1</sub> position, groups at P<sub>1</sub>′ and P<sub>2</sub>′ are crucial in providing multiple interactions with NEP to produce potent inhibitors. The S<sub>1</sub>′ pocket is hydrophobic; formed by residues Phe-106, Ile-558, Phe-563, Met-579, Val-580, Phe-689, Val-692, Trp-693, and Ile-718; and preferentially binds to large hydrophobic or aromatic P<sub>1</sub>′ groups.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Phe-106 and Trp-693 separate the S<sub>1</sub>′ and S<sub>2</sub>′ pockets, thereby giving a hydrophobic face to the large S<sub>2</sub>′ subsite. Residues Arg-102, Asp-107, Arg-110, and Val-541 form the rest of the S<sub>2</sub>′ pocket, and therefore this subsite is less specific and can bind to a range of moieties to increase affinity. The inhibitors compared here provide a range of examples and different ways to maximize interactions and therefore increase affinity for NEP within the S<sub>1</sub>′ and S<sub>2</sub>′ subsites (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B). First, all of the inhibitors contain a P<sub>1</sub>′ carbonyl and P<sub>2</sub>′ nitrogen peptide backbone mimic, which interact with Arg-717 and Asn-542, respectively. Sampatrilat, samASP, and phosphoramidon contain fairly short P<sub>1</sub>′ groups that only extend partway into the S<sub>1</sub>′ pocket. Therefore, they have less hydrophobic interactions with NEP than omapatrilat and thiorphan do, which have more bulky phenyl groups that extend further into the pocket. LBQ657 has the longest P<sub>1</sub>′ group, a biphenyl, which extends deep into the pocket and can interact with most of the hydrophobic pocket. As mentioned above, Phe-106 and Trp-693 divide the S<sub>1</sub>′ and S<sub>2</sub>′ pockets, and it has been previously reported that a P<sub>1</sub>′ biphenyl causes a conformational change in the side chains of these residues. It is interesting to note that when comparing all of the structures here, this conformational change is also observed with smaller P<sub>1</sub>′ side chains, and the degree of movement correlates with the size of the P<sub>1</sub>′ group. Among these inhibitors, the P<sub>2</sub>′ side chain varies from nothing (LBQ657 and thiorphan), extending partially into the S<sub>2</sub>′ pocket (omapatrilat) and deep into the pocket (sampatrilat, samASP, and phosphoramidon). Therefore, the inhibitors with the most interactions in the S<sub>1</sub>′ pocket (LBQ657, thiorphan, and omapatrilat) have the least in the S<sub>2</sub>′ pocket. The phenyl side chains of sampatrilat and samASP occupy a different position in the S<sub>2</sub>′ pocket than the indole side chain of phosphoramidon and therefore have different interactions with NEP. All three cause a change in the orientation of Arg-102, as does omapatrilat to a lesser extent. In addition, there is a large shift in the side chain of Arg-110 in the phosphoramidon–NEP structure. These side-chain orientation changes show that both the S<sub>1</sub>′ and S<sub>2</sub>′ pockets can adapt to the size and shape of the P<sub>1</sub>′ and P<sub>2</sub>′ groups, but further screens are needed to examine how the size of one P′ group effects the possible size of the other.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Comparison of Omapatrilat, Sampatrilat, and SamASP Binding to NEP and ACE Domains</h3><div class="NLM_p">Crystal structures of both domains of sACE have been solved in complex with omapatrilat (PDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5X">6H5X</a> for nACE and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5W">6H5W</a> for cACE),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> sampatrilat (PDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9V">6F9V</a> for nACE and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9T">6F9T</a> for cACE), and samASP (PDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9R">6F9R</a> for nACE and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9U">6F9U</a> for cACE),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and this allows direct comparison of inhibitor binding with the NEP structures presented here (LigPlot+ diagrams showing the interactions of omapatrilat, sampatrilat, and samASP with nACE and cACE are shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. LigPlot representation of the binding site interactions of omapatrilat–nACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5X">6H5X</a>), omapatrilat–cACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5W">6H5W</a>), sampatrilat–nACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9V">6F9V</a>), sampatrilat–cACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9T">6F9T</a>), samASP–nACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9R">6F9R</a>), and samASP–cACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9U">6F9U</a>) complexes. Hydrogen-bond/electrostatic interactions are shown in green, hydrophobic interactions in red, and water molecules as red spheres. Residues solely involved in hydrophobic interactions are represented by red, semicircular symbols. The inhibitor moieties are given their P number based on the enzyme S-subsite to which they bind.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When the active site zinc and its binding residues are used as the basis to orientate and compare structures of NEP and the ACE domains, the S<sub>1</sub>′ and S<sub>1</sub>/S<sub>2</sub> subsites essentially overlay and occupy the same space (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). All of the inhibitors bind to the ACE domains in a close-to-linear backbone conformation consistent with there being distinctive prime and nonprime lobes on either side of the zinc ion. In contrast, NEP contains a single large cavity that causes ligands to bind in a conformation that is bent between the S<sub>1</sub>′ and S<sub>2</sub>′ subsites. This has the effect that in the NEP and ACE domain comparison, the S<sub>2</sub>′ binding pockets do not overlay (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Comparison of inhibitor binding sites between NEP and ACE domains. The zinc ion and its binding residues were used to overlay the structures. (A) Omapatrilat binding site with NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), nACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5X">6H5X</a>), and cACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5W">6H5W</a>) structures shown in green, magenta, and gray, respectively. NEP, nACE, and cACE binding sites for (B) sampatrilat (blue PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>, magenta PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9V">6F9V</a>, and gray PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9T">6F9T</a>) and (C) samASP (orange PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>, brown PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9R">6F9R</a>, and yellow PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9U">6F9U</a>). The subsite pockets for NEP and ACE domains are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In both ACE domains, omapatrilat binds with the phenyl ring extending into the S<sub>1</sub> subsite and the bicyclic moiety located in the S<sub>1</sub>′ and S<sub>2</sub>′ pockets (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). However, the requirement for ligands to adopt a bent conformation when binding to NEP in the S<sub>1</sub>, S<sub>1</sub>′, and S<sub>2</sub>′ subsites is likely to be the cause of omapatrilat binding in a different manner, not utilizing the S<sub>1</sub> subsite and instead having the phenyl and bicyclic groups in the S<sub>1</sub>′ and S<sub>2</sub>′/S<sub>3</sub>′ pockets, respectively. In contrast, sampatrilat and samASP bind in a similar manner to both NEP and the ACE domains, where the tyrosine-like side-chain and cyclopentane ring occupy the S<sub>2</sub>′ and S<sub>1</sub>′ pockets, respectively, and the remainder of the molecules binds to the S<sub>1</sub> and S<sub>2</sub> subsites (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B,C).</div><div class="NLM_p">A comparison of interactions between inhibitor and protein for the NEP and ACE domain structures (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) provides detailed information on what to target for potency and specificity. With ACE being predominantly a dipeptidase, there are strong interactions possible at the C-terminal carboxy P<sub>2</sub>′ position, as well as with carbonyl or nitrogen peptide backbone mimics in both the S<sub>1</sub>′ and S<sub>2</sub>′ subsites. All three inhibitors studied here utilize all of these interactions with both domains of ACE. Although not quite as extensive in NEP, interactions with ligand backbone atoms are still important for a high affinity inhibitor.</div><div class="NLM_p">In structures of both enzymes, omapatrilat, sampatrilat, and samASP all have hydrophobic interactions in the S<sub>2</sub>′ pocket, and a greater number of interactions are observed when the P<sub>2</sub>′ group is larger. This is highlighted by comparing the tyrosine-like group of sampatrilat and samASP that extends further into the S<sub>2</sub>′ subsite, with the less elongated bicyclic ring of omapatrilat. The hydroxyl group of this tyrosine also shows that direct and water-mediated interactions are possible in this pocket in both NEP and the ACE domains.</div><div class="NLM_p">All three inhibitors have some hydrophobic interactions in the S<sub>1</sub>′ pocket of the ACE domains, and this is likely to be stronger in cACE due to Val-380 being replaced by Thr-358 in nACE. In comparison, there is a much more extensive network of hydrophobic interactions in the NEP S<sub>1</sub>′ pocket, and this is especially apparent with the large P<sub>1</sub>′ phenyl group of omapatrilat.</div><div class="NLM_p">NEP and both ACE domains have more space available in the nonprime binding sites than the prime sites. In NEP, this has the effect of very few interactions observed with the P<sub>1</sub>/P<sub>2</sub> sections of sampatrilat and samASP, and this causes the more ambiguous electron density for this region described above. In contrast, although there is extra space available in the ACE domain nonprime lobe, there are still many residues in the S<sub>1</sub>/S<sub>2</sub> subsites available to target for both hydrophobic interactions as seen with the phenyl group of omapatrilat, and a range of electrostatic and hydrogen bonds (direct and water-mediated) as observed with sampatrilat and samASP.</div><div class="NLM_p last">In summary, the structures of the complexes with these three inhibitors show that the ACE domains have a significant number of interactions with the backbone and side chains throughout the S<sub>2</sub> to S<sub>2</sub>′ subsites, whereas NEP is largely reliant on its zinc-binding region and S<sub>1</sub>′ to S<sub>2</sub>′ subsites, with the added requirement that if the inhibitor extends into the nonprime subsites, then it needs to be able to adopt a bent conformation between P<sub>1</sub>′ and P<sub>2</sub>′.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Conclusions and Structure-Based Design Toward Next-Generation Dual cACE Selective/NEP Inhibitors</h3><div class="NLM_p">As described above, vasopeptidase inhibitors have been designed to increase the control of blood pressure by targeting both RAAS and NPKS. While omapatrilat does this very effectively, it results in even more severe side effects than typical ACE only inhibition. This is thought to be due to the accumulation of bradykinin (and substance P), a substrate for both NEP and ACE, with omapatrilat showing potent inhibition of NEP, nACE, and cACE. It has previously been shown that blood pressure can be controlled by inhibition of cACE alone, which would leave nACE activity intact to control bradykinin levels. This approach would be beneficial for vasopeptidase inhibitors as well as targeting only ACE; therefore, structural data presented here and from previous studies can be used to design inhibitors that are not only potent for NEP but also specific for cACE over nACE. ACE has a <i>K</i><sub>m</sub> value of 0.18 μM for bradykinin,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> which indicates that for an inhibitor with a desired potent low nM affinity for cACE, the specificity over nACE would need to be at least 2 orders of magnitude.</div><div class="NLM_p">The comparison of NEP structures has shown that binding to nonprime subsites only provides a small increase in affinity, and therefore not surprisingly, potent inhibition is possible with binding to the zinc-binding region and S<sub>1</sub>′ to S<sub>2</sub>′ subsites. The S<sub>1</sub>′ and S<sub>2</sub>′ subsites provide backbone hydrogen bonding as well as extensive hydrophobic interactions within the side-chain binding pockets, where the further the side chain extends into the pocket, the greater the number of interactions. In addition, the S<sub>2</sub>′ pocket is less specific than S<sub>1</sub>′ with hydrogen-bonding targets also possible, and both pockets have flexibility in side chains to allow binding of inhibitor moieties of different sizes. It is also important to consider that a potent NEP inhibitor does not need to maximize interactions in both S<sub>1</sub>′ and S<sub>2</sub>′ binding pockets at the same time. This could be beneficial considering thiorphan, phosphoramidon, and, in particular, LBQ657 show specificity for NEP over ACE, and it is potentially the large P<sub>1</sub>′ moieties of these ligands that reduce the potency against ACE by causing steric clashes in the S<sub>1</sub>′ subsite. Therefore, NEP potency can be achieved with moderate size P<sub>1</sub>′ and larger P<sub>2</sub>′ moieties that can be accommodated by ACE.</div><div class="NLM_p">Sampatrilat shows over a 12-fold specificity for cACE over nACE, whereas samASP is nondomain selective and less potent against both ACE domains. This highlights the importance of the nonprime binding region in the design of not only potent ACE inhibitors but also in making them domain-specific. A direct hydrogen bond between the lysine-like side chain of sampatrilat with Glu-403 of cACE, which is mutated to Arg-381 in nACE, explains the domain specificity, while the reduction in nonprime interactions with samASP is consistent with the reduced affinity. RXPA380 is another inhibitor that shows cACE specificity over nACE (3000-fold lower <i>K</i><sub>i</sub>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This was also partly attributed to differences in the S<sub>1</sub> and S<sub>2</sub> subsites between nACE and cACE. RXPA380 contains P<sub>1</sub> and P<sub>2</sub> phenyl rings that form extensive hydrophobic interactions with cACE, and of particular interest are those with Phe-391 and Val-518, which are replaced in nACE by the polar, neutral Tyr-369 and Thr-496, respectively. In addition, RXPA380 has a P<sub>2</sub>′ tryptophan group, and this has also been found to add cACE specificity. As mentioned above, including a larger P<sub>2</sub>′ group would also be a way of increasing NEP potency. Finally a study on a series of phosphinic inhibitors showed that the stereochemistry of the P<sub>1</sub>′ position had a dramatic effect on the affinity for NEP, but not for cACE or endothelin-converting enzyme-1 (ECE-1).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This is likely caused by the nonlinear arrangement of the zinc ion and well-defined, deep S<sub>1</sub>′ and S<sub>2</sub>′ pockets of NEP described above.</div><div class="NLM_p last">In conclusion, combining the requirements of potent NEP and ACE inhibition with those for cACE selectivity allows for the design of a potent vasopeptidase inhibitor with reduced side effects compared to omapatrilat and classical ACE-targeted hypertension treatments. In principle, modification of the already NEP and ACE potent sampatrilat to increase the cACE specificity would be one approach. Combining the current lysine-like side chain, thereby retaining the interaction with the cACE-specific Glu-403, with a bulky hydrophobic moiety like phenyl in the nonprime binding sites would allow interactions with the unique cACE Phe-391 and Val-518 residues. This modification should be tolerated by NEP due to the space available in the nonprime binding region. In addition, changing the P<sub>2</sub>′ phenyl group of sampatrilat to a tryptophan group should further enhance the cACE specificity over nACE. This S<sub>2</sub>′ pocket binding moiety is already shown to bind strongly to NEP by the inhibitor phosphoramidon. In summary, next generation vasopeptidase inhibitors could use zinc-binding P<sub>1</sub>′ and P<sub>2</sub>′ groups to give potency against NEP and ACE, and then P<sub>2</sub>′, P<sub>1</sub>, and P<sub>2</sub> moieties to not only increase potency to ACE but also crucially to provide cACE specificity over nACE.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51433" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51433" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> NEP Expression and Purification</h3><div class="NLM_p">Recombinant His-tagged human NEP (extracellular domain residues 51-742) was expressed as a secreted protein in <i>Pichia pastoris</i> GS115 and purified using Ni-NTA affinity and size exclusion chromatography, as previously described.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Briefly, the cells were incubated at 30 °C for 24 h in a buffered glycerol–complex medium before being transferred into buffered methanol–complex medium. The culture was incubated for a further 72 h at 30 °C with 100% methanol being added at 24 and 48 h to maintain the methanol concentration.</div><div class="NLM_p last">After expression, the supernatant was harvested followed by the addition of Trizma and NaCl to give final concentrations of 25 and 150 mM, respectively. A 5 mL HisTrap affinity column (GE Healthcare Bio-Sciences, Pittsburgh, PA) was used to purify NEP from the clarified supernatant using binding buffer (25 mM Trizma, 150 mM NaCl, and 2 mM MgCl<sub>2</sub>, pH 7.5) supplemented with 250 mM imidazole for elution. A further size exclusion step (16/60 Superdex HiLoad 200 column) using the same binding buffer completed the purification, followed by concentration to 12 mg/mL. Purity was assessed using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) to be >95%.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Ligand Preparation</h3><div class="NLM_p last">Omapatrilat was obtained from Sigma-Aldrich, while sampatrilat and samASP were synthesized as previously described.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The omapatrilat stock solution (50 mM in dimethyl sulfoxide (DMSO)) was diluted to 10 mM with NEP binding buffer. Sampatrilat and samASP stock solutions (20 mM in water) were diluted to 10 mM with NEP crystallization buffer (0.2 M NH<sub>4</sub>Cl, 22% (w/v) PEG 3350).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> X-ray Crystallographic Studies</h3><div class="NLM_p">The omapatrilat–NEP complex was prepared using 12 mg/mL NEP and 10 mM omapatrilat at a 1:10 molar ratio with incubation on ice for 45 min prior to crystallization. The hanging-drop vapor diffusion crystallization method was used with 1 μL of omapatrilat–NEP complex mixed with 1 μL of reservoir solution containing (0.2 M NH<sub>4</sub>Cl, 20–25% (w/v) PEG 3350), followed by incubation at 18 °C. A similar co-crystallization procedure did not yield any crystal for NEP in complex with sampatrilat or samASP. Instead, clusters of native NEP crystals were soaked in crystallization buffer (0.2 M NH<sub>4</sub>Cl, 22% (w/v) PEG 3350) containing 10 mM inhibitors and incubated overnight at 18 °C. Although this process broke up the crystal clusters, fragments of smaller single crystal were suitable for X-ray diffraction. All crystals were briefly soaked in crystallization buffer supplemented with 16% glycerol for cryo-protection and then flash frozen in liquid nitrogen prior to data collection.</div><div class="NLM_p last">X-ray diffraction data for all structures were collected on station i04 at the Diamond Light Source (Didcot, U.K.), with the crystals kept at a constant temperature (100 K) using a nitrogen stream. Images were collected using PILATUS3 6M detectors (Dectris, Switzerland). Raw data images were indexed and integrated with DIALS<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and then scaled using AIMLESS<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> from the CCP4 suite.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Initial phases were obtained by molecular replacement with PHASER<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> using the native NEP structure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GID">6GID</a><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>) as the search model. Further refinement was initially carried out using REFMAC5<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and then Phenix,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> with COOT<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> used for rounds of manual model building. Ligand and water molecules were added based on electron density in the mFo–DFc Fourier difference map. MolProbity<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> was used to help validate the structures. Crystallographic data statistics are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. All figures showing the crystal structures were generated using CCP4mg,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and schematic binding interactions are displayed using LigPlot+.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The coordinates of omapatrilat–NEP, sampatrilat–NEP, and samASP–NEP complexes have been deposited in PDB with accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>, respectively.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00441" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00441?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00441</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00441/suppl_file/jm0c00441_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00441/suppl_file/jm0c00441_si_001.csv">jm0c00441_si_001.csv (0.3 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The atomic coordinates and structure factors for omapatrilat–NEP, sampatrilat–NEP, and samASP–NEP complexes have been deposited in the RCSB Protein Data Bank with codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>, respectively. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00441" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26424" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26424" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">K. Ravi Acharya</span> - <span class="hlFld-Affiliation affiliation">Department
of Biology and Biochemistry, University
of Bath, Claverton Down, Bath BA2 7AY, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3009-4058" title="Orcid link">http://orcid.org/0000-0002-3009-4058</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e08293938b9281a082819488ce8183ce958b"><span class="__cf_email__" data-cfemail="8be9f8f8e0f9eacbe9eaffe3a5eae8a5fee0">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Urvashi Sharma</span> - <span class="hlFld-Affiliation affiliation">Department
of Biology and Biochemistry, University
of Bath, Claverton Down, Bath BA2 7AY, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gyles E. Cozier</span> - <span class="hlFld-Affiliation affiliation">Department
of Biology and Biochemistry, University
of Bath, Claverton Down, Bath BA2 7AY, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward D. Sturrock</span> - <span class="hlFld-Affiliation affiliation">Department
of Integrative Biomedical Sciences, Institute of Infectious Disease
and Molecular Medicine, University of Cape
Town, Observatory, 7935 Cape Town, Republic of South Africa</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>U.S. and G.E.C. contributed equally to this work.</p><span class="author-information-subsection-header">Author Contributions</span><p>U.S. performed protein expression, purification, produced the crystals, collected the data, and contributed to the manuscript. G.E.C. processed, refined, and analyzed the X-ray data and wrote the manuscript. E.D.S. edited the manuscript. K.R.A. supervised the study, analyzed the data, and edited the manuscript. All authors reviewed the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e2295-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63157" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63157" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank the scientists at station i04 (Proposal Number mx17212) of Diamond Light Source, Didcot, Oxfordshire (U.K.), for their support during X-ray diffraction data collection. This work was supported by the Medical Research Council (U.K.) Project Grant MR/M026647/1 (to K.R.A.) and the National Research Foundation (South Africa) CPRR grant 13082029517 (to E.D.S.). K.R.A. and E.D.S. also thank the University of Cape Town (South Africa) and University of Bath (U.K.), respectively, for the Visiting Professorship.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACE</td><td class="NLM_def"><p class="first last">angiotensin-1-converting enzyme</p></td></tr><tr><td class="NLM_term">AnCE</td><td class="NLM_def"><p class="first last">drosophila ACE homologue</p></td></tr><tr><td class="NLM_term">BK</td><td class="NLM_def"><p class="first last">bradykinin</p></td></tr><tr><td class="NLM_term">BPP</td><td class="NLM_def"><p class="first last">bradykinin-potentiating peptide</p></td></tr><tr><td class="NLM_term">cACE</td><td class="NLM_def"><p class="first last">ACE C-domain</p></td></tr><tr><td class="NLM_term">FII</td><td class="NLM_def"><p class="first last">phosphinic tripeptide</p></td></tr><tr><td class="NLM_term">nACE</td><td class="NLM_def"><p class="first last">ACE N-domain</p></td></tr><tr><td class="NLM_term">NEP</td><td class="NLM_def"><p class="first last">neprilysin</p></td></tr><tr><td class="NLM_term">RAAS</td><td class="NLM_def"><p class="first last">renin–angiotensin–aldosterone system</p></td></tr><tr><td class="NLM_term">sACE</td><td class="NLM_def"><p class="first last">somatic ACE</p></td></tr><tr><td class="NLM_term">tACE</td><td class="NLM_def"><p class="first last">testis ACE</p></td></tr><tr><td class="NLM_term">Z-FHL</td><td class="NLM_def"><p class="first last">Cbz-Phe-His-Leu</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27080" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27080" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egan, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjeldsen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancia, G.</span></span> <span> </span><span class="NLM_article-title">The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard?</span>. <i>J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1148</span>– <span class="NLM_lpage">1153</span>, <span class="refDoi"> DOI: 10.1097/HJH.0000000000002021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1097%2FHJH.0000000000002021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=30624370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1Shu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=1148-1153&author=B.+M.+Eganauthor=S.+E.+Kjeldsenauthor=G.+Grassiauthor=M.+Eslerauthor=G.+Mancia&title=The+global+burden+of+hypertension+exceeds+1.4+billion+people%3A+should+a+systolic+blood+pressure+target+below+130+become+the+universal+standard%3F&doi=10.1097%2FHJH.0000000000002021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard?</span></div><div class="casAuthors">Egan, Brent M.; Kjeldsen, Sverre E.; Grassi, Guido; Esler, Murray; Mancia, Guiseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1148-1153</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">: In 2010, 1.4 billion people globally had hypertension, with 14% controlled to systolic blood pressure (SBP, mmHg) below 140, which contributes to 18 million cardiovascular deaths annually.  Recent hypertension guidelines endorsed SBP targets below 130 or lower for all or some hypertensive patients to reduce cardiovascular events (CVEs) more than the prior SBP target less than 140.  In 2016, the Australian Guideline strongly recommended target SBP below 120 for adults at very high risk for CVE or aged above 75 years.  In 2017 and 2018, the Canadian Guideline recommended automated office SBP (AOSBP) below 120 in adults at high risk and aged above 75 years (grade B).  In 2017, the US Guideline recommended SBP below 130 for all adults (moderate-to-high risk class I; lower-risk grade IIb).  In 2018, the European Guideline recommended SBP below 140 for all adults, and, if tolerated, a SBP range of 120-129 for adults aged below 65 years and 130-139 for adults aged at least 65 years (class I).  The guidelines were variably influenced by Systolic blood PRessure INTervention trial and meta-analyses indicating fewer CVE when mean in-trial SBP was below 130 vs. above 130.  Clinicians considering lower SBP targets should be aware that: AOSBP preceded by 5-min rest is approx. 10-15mmHg lower than usual office SBP; hypertensive patients with office SBP consistently vs. intermittently below 140 have fewer CVE; benefits of mean office SBP or AOSBP below 120 remain unproven and could increase adverse events.  Clinicians worldwide will do well to control SBP to below 140 in most hypertensive patients on most visits, which should lead to mean in-clinic SBP of 120-129.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrha8SRcuzFo7Vg90H21EOLACvtfcHk0lgFDzbZqNs1Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1Shu7Y%253D&md5=a7dace6b4ca10c90a545ec3e87c5ef0a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1097%2FHJH.0000000000002021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHJH.0000000000002021%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DB.%2BM.%26aulast%3DKjeldsen%26aufirst%3DS.%2BE.%26aulast%3DGrassi%26aufirst%3DG.%26aulast%3DEsler%26aufirst%3DM.%26aulast%3DMancia%26aufirst%3DG.%26atitle%3DThe%2520global%2520burden%2520of%2520hypertension%2520exceeds%25201.4%2520billion%2520people%253A%2520should%2520a%2520systolic%2520blood%2520pressure%2520target%2520below%2520130%2520become%2520the%2520universal%2520standard%253F%26jtitle%3DJ.%2520Hypertens.%26date%3D2019%26volume%3D37%26spage%3D1148%26epage%3D1153%26doi%3D10.1097%2FHJH.0000000000002021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nussberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cugno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amstutz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicardi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellacani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agostoni, A.</span></span> <span> </span><span class="NLM_article-title">Plasma bradykinin in angio-oedema</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(97)09137-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2FS0140-6736%2897%2909137-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=9734886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK1cXkt1Sls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=1998&pages=1693-1697&author=J.+Nussbergerauthor=M.+Cugnoauthor=C.+Amstutzauthor=M.+Cicardiauthor=A.+Pellacaniauthor=A.+Agostoni&title=Plasma+bradykinin+in+angio-oedema&doi=10.1016%2FS0140-6736%2897%2909137-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma bradykinin in angio-edema</span></div><div class="casAuthors">Nussberger, Juerg; Cugno, Massimo; Amstutz, Catherine; Cicardi, Marco; Pellacani, Andrea; Agostoni, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">9117</span>),
    <span class="NLM_cas:pages">1693-1697</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">Bradykinin is believed to be the main mediator of symptoms in hereditary (HA) and acquired (AA) angio-edema due to C1 esterase inhibitor deficiency, as well as in angio-edema that complicates treatment with inhibitors of angiotensin-converting enzyme (ACE).  Difficulties in the measurement of kinin concns., however, have so far precluded the demonstration of an incontrovertible change in plasma bradykinin concns. in these disorders.  By developing a reliable assay we have been able to follow bradykinin concns. during attacks and during remission in HA and in AA, and also in a patient treated with an ACE-inhibitor.  Liq.-phase extn., high-performance liq. chromatog., and RIA were used for specific measurement of plasma bradykinin concns. in 22 patients with HA and in 22 healthy volunteers of similar age and sex distribution.  Four patients with AA and one hypertensive patient treated with the ACE inhibitor captopril were also studied.  Among the healthy volunteers plasma bradykinin concn. was inversely proportional to age.  The geometric mean plasma bradykinin concn. in the healthy volunteers was 2.2 fmol/mL (SD 2.2), compared with 3.9 fmol/mL (3.7) among patients with HA during remission (p=0.095).  Bradykinin was also high in the patients with AA (10.4 fmol/mL [1.6]).  During acute attacks of edema, in both HA and AA, plasma bradykinin rose to two to 12 times the upper limit of normal.  Infusion of C1-esterase inhibitor (the deficient factor in both HA and AA) immediately lowered bradykinin concns.  In the patient receiving the ACE-inhibitor captopril, bradykinin concn. was very high at 47 fmol/mL during an acute attack of angio-edema, but normal at 3.2 fmol/mL in remission after withdrawal of the drug.  A sensitive method for measurement of plasma bradykinin provided the means to show that concns. of this peptide decrease with age in healthy people.  Although the differences between patients in remission and healthy controls did not reach statistical significance, there were substantial rises in bradykinin during acute attacks of hereditary, acquired, or captopril-induced angio-edema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb4Tr2-3qhp7Vg90H21EOLACvtfcHk0lgqXZtqBeZlvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt1Sls74%253D&md5=16a3faac0fdb640549c75e1b93e2c3be</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2897%2909137-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252897%252909137-X%26sid%3Dliteratum%253Aachs%26aulast%3DNussberger%26aufirst%3DJ.%26aulast%3DCugno%26aufirst%3DM.%26aulast%3DAmstutz%26aufirst%3DC.%26aulast%3DCicardi%26aufirst%3DM.%26aulast%3DPellacani%26aufirst%3DA.%26aulast%3DAgostoni%26aufirst%3DA.%26atitle%3DPlasma%2520bradykinin%2520in%2520angio-oedema%26jtitle%3DLancet%26date%3D1998%26volume%3D351%26spage%3D1693%26epage%3D1697%26doi%3D10.1016%2FS0140-6736%2897%2909137-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artuc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiehstutz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henz, B. M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions</span>. <i>Acta Derm.-Venereol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1080/000155501317140007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1080%2F000155501317140007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=11800136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlCjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2001&pages=321-325&author=U.+M.+Steckelingsauthor=M.+Artucauthor=T.+Wollschlagerauthor=S.+Wiehstutzauthor=B.+M.+Henz&title=Angiotensin-converting+enzyme+inhibitors+as+inducers+of+adverse+cutaneous+reactions&doi=10.1080%2F000155501317140007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions</span></div><div class="casAuthors">Steckelings, U. M.; Artuc, M.; Wollschlager, T.; Wiehstutz, S.; Henz, B. M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Dermato-Venereologica</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">321-325</span>CODEN:
                <span class="NLM_cas:coden">ADVEA4</span>;
        ISSN:<span class="NLM_cas:issn">0001-5555</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Since adverse effects due to angiotensin-converting enzyme (ACE) inhibitors frequently occur in cutaneous locations, this review summarizes the spectrum of expected and unexpected adverse effects of these drugs, possible assocd. mechanisms, and their basic functions for dermatologists.  ACE inhibitors block the activity of the metalloproteinase ACE by binding to its active site, thus displacing angiotensin I and preventing its conversion to vasopressive angiotensin II.  Furthermore, ACE degrades bradykinin, substance P, enkephalins, and some of the reproductive peptide hormones.  The overall incidence of adverse effects to ACE inhibitors is estd. at 28%, approx. half of which occurs in the skin.  General reactions are 1st-dose hypotension, hyperkalemia, and renal failure.  Cutaneous reactions comprise life-threatening angioedema, pruritus, bullous eruptions, urticaria, other generalized rashes, photosensitivity, and hair loss.  ACE inhibitors thus mimic a broad variety of skin diseases, why these drugs should be thought of when sudden, unexplainable skin eruptions are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGIU4lVFQTD7Vg90H21EOLACvtfcHk0lgqXZtqBeZlvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlCjsw%253D%253D&md5=cca6e609e38c73f45a66d7861962952e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F000155501317140007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F000155501317140007%26sid%3Dliteratum%253Aachs%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DArtuc%26aufirst%3DM.%26aulast%3DWollschlager%26aufirst%3DT.%26aulast%3DWiehstutz%26aufirst%3DS.%26aulast%3DHenz%26aufirst%3DB.%2BM.%26atitle%3DAngiotensin-converting%2520enzyme%2520inhibitors%2520as%2520inducers%2520of%2520adverse%2520cutaneous%2520reactions%26jtitle%3DActa%2520Derm.-Venereol.%26date%3D2001%26volume%3D81%26spage%3D321%26epage%3D325%26doi%3D10.1080%2F000155501317140007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messerli, F. H.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1467</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.108.111393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1161%2FHYPERTENSIONAHA.108.111393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=18413486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVahurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1465-1467&author=M.+A.+Weberauthor=F.+H.+Messerli&title=Angiotensin-converting+enzyme+inhibitors+and+angioedema%3A+estimating+the+risk&doi=10.1161%2FHYPERTENSIONAHA.108.111393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk</span></div><div class="casAuthors">Weber, Michael A.; Messerli, Franz H.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1465-1467</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvGFGj7rAMm7Vg90H21EOLACvtfcHk0lizxmZ49UbbqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVahurg%253D&md5=9c00260a5a4f6db0f679058a5db727e2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.108.111393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.108.111393%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DM.%2BA.%26aulast%3DMesserli%26aufirst%3DF.%2BH.%26atitle%3DAngiotensin-converting%2520enzyme%2520inhibitors%2520and%2520angioedema%253A%2520estimating%2520the%2520risk%26jtitle%3DHypertension%26date%3D2008%26volume%3D51%26spage%3D1465%26epage%3D1467%26doi%3D10.1161%2FHYPERTENSIONAHA.108.111393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arendse, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danser, A. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poglitsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touyz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, J. C.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Cortes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlers, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span> <span> </span><span class="NLM_article-title">Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1124/pr.118.017129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1124%2Fpr.118.017129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=31537750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A280%3ADC%252BB3MngsVamtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=539-570&author=L.+B.+Arendseauthor=A.+H.+J.+Danserauthor=M.+Poglitschauthor=R.+M.+Touyzauthor=J.+C.+Burnettauthor=C.+Llorens-Cortesauthor=M.+R.+Ehlersauthor=E.+D.+Sturrock&title=Novel+therapeutic+approaches+targeting+the+renin-angiotensin+system+and+associated+peptides+in+hypertension+and+heart+failure&doi=10.1124%2Fpr.118.017129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure</span></div><div class="casAuthors">Arendse Lauren B; Danser A H Jan; Poglitsch Marko; Touyz Rhian M; Burnett John C Jr; Llorens-Cortes Catherine; Ehlers Mario R; Sturrock Edward D</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">539-570</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite the success of renin-angiotensin system (RAS) blockade by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT1R) blockers, current therapies for hypertension and related cardiovascular diseases are still inadequate.  Identification of additional components of the RAS and associated vasoactive pathways, as well as new structural and functional insights into established targets, have led to novel therapeutic approaches with the potential to provide improved cardiovascular protection and better blood pressure control and/or reduced adverse side effects.  The simultaneous modulation of several neurohumoral mediators in key interconnected blood pressure-regulating pathways has been an attractive approach to improve treatment efficacy, and several novel approaches involve combination therapy or dual-acting agents.  In addition, increased understanding of the complexity of the RAS has led to novel approaches aimed at upregulating the ACE2/angiotensin-(1-7)/Mas axis to counter-regulate the harmful effects of the ACE/angiotensin II/angiotensin III/AT1R axis.  These advances have opened new avenues for the development of novel drugs targeting the RAS to better treat hypertension and heart failure.  Here we focus on new therapies in preclinical and early clinical stages of development, including novel small molecule inhibitors and receptor agonists/antagonists, less conventional strategies such as gene therapy to suppress angiotensinogen at the RNA level, recombinant ACE2 protein, and novel bispecific designer peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAI0aDOrgWeMERNNga7KD-fW6udTcc2ea93zwB09WlrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MngsVamtQ%253D%253D&md5=13d62a245da308da55a0ac09e2ae8d90</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fpr.118.017129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.118.017129%26sid%3Dliteratum%253Aachs%26aulast%3DArendse%26aufirst%3DL.%2BB.%26aulast%3DDanser%26aufirst%3DA.%2BH.%2BJ.%26aulast%3DPoglitsch%26aufirst%3DM.%26aulast%3DTouyz%26aufirst%3DR.%2BM.%26aulast%3DBurnett%26aufirst%3DJ.%2BC.%26aulast%3DLlorens-Cortes%26aufirst%3DC.%26aulast%3DEhlers%26aufirst%3DM.%2BR.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26atitle%3DNovel%2520therapeutic%2520approaches%2520targeting%2520the%2520renin-angiotensin%2520system%2520and%2520associated%2520peptides%2520in%2520hypertension%2520and%2520heart%2520failure%26jtitle%3DPharmacol.%2520Rev.%26date%3D2019%26volume%3D71%26spage%3D539%26epage%3D570%26doi%3D10.1124%2Fpr.118.017129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathisuwan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbert, R. L.</span></span> <span> </span><span class="NLM_article-title">A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1592/phco.22.1.27.33502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1592%2Fphco.22.1.27.33502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=11794428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvVKksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=27-42&author=S.+Nathisuwanauthor=R.+L.+Talbert&title=A+review+of+vasopeptidase+inhibitors%3A+a+new+modality+in+the+treatment+of+hypertension+and+chronic+heart+failure&doi=10.1592%2Fphco.22.1.27.33502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A review of vasopeptidase inhibitors: A new modality in the treatment of hypertension and chronic heart failure</span></div><div class="casAuthors">Nathisuwan, Surakit; Talbert, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-42</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Pharmacotherapy Publications</span>)
        </div><div class="casAbstract">A review.  Vasopeptidase inhibitors are a group of agents capable of inhibiting neutral endopeptidase and angiotensin-converting enzymes, which leads to potentiation of natriuretic peptide actions and suppression of the reninangiotensin-aldosterone system.  With this distinctively characteristic mechanism, these agents have emerged as a new drug class for management of hypertension and heart failure.  Several vasopeptidase inhibitors are under clin. investigation.  Omapatrilat is the most studied agent in this class.  Clin. studies of omapatrilat in hypertension have consistently shown the agent's effectiveness in a variety of patient populations.  In patients with heart failure, omapatrilat significantly improved neurohormonal and hemodynamic status.  Long-term effects of omapatrilat in patients with heart failure recently were compared with those of conventional therapy in a large phase II trial.  Results of the study appear promising.  Large clin. trials are ongoing, and addnl. information regarding safety and efficacy from these studies may help define the place in therapy for this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdG44q7150ybVg90H21EOLACvtfcHk0lizxmZ49UbbqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvVKksw%253D%253D&md5=1cecd58c809de787d03181d29e65169c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1592%2Fphco.22.1.27.33502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1592%252Fphco.22.1.27.33502%26sid%3Dliteratum%253Aachs%26aulast%3DNathisuwan%26aufirst%3DS.%26aulast%3DTalbert%26aufirst%3DR.%2BL.%26atitle%3DA%2520review%2520of%2520vasopeptidase%2520inhibitors%253A%2520a%2520new%2520modality%2520in%2520the%2520treatment%2520of%2520hypertension%2520and%2520chronic%2520heart%2520failure%26jtitle%3DPharmacotherapy%26date%3D2002%26volume%3D22%26spage%3D27%26epage%3D42%26doi%3D10.1592%2Fphco.22.1.27.33502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trindade, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouleau, J. L.</span></span> <span> </span><span class="NLM_article-title">Vasopeptidase inhibitors: potential role in the treatment of heart failure</span>. <i>Heart Failure Monit.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=12634892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD3MXns1Gqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=2-7&author=P.+T.+Trindadeauthor=J.+L.+Rouleau&title=Vasopeptidase+inhibitors%3A+potential+role+in+the+treatment+of+heart+failure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Vasopeptidase inhibitors: Potential role in the treatment of heart failure</span></div><div class="casAuthors">Trindade, Pedro T.; Rouleau, Jean L.</div><div class="citationInfo"><span class="NLM_cas:title">Heart Failure Monitor</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-7</span>CODEN:
                <span class="NLM_cas:coden">HFMEAG</span>;
        ISSN:<span class="NLM_cas:issn">1470-8590</span>.
    
            (<span class="NLM_cas:orgname">ReMEDICA Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Current thinking views the progression of heart failure as the result of sustained activation of vasoconstrictor neurohormones.  In this model, the sustained synthesis of vasoconstrictor neurohormones leads to disease progression through alterations in cardiomyocyte structure and function, which affects myocardial contractility, cardiac metab., and cellular growth.  Ultimately, these events induce irreversible adverse ventricular remodeling through myocyte cell loss and progressive myocardial fibrosis.  In the past decade, several landmark clin. trials tested the neurohormonal hypothesis, by targeting the activation of both the β-adrenergic and the renin-angiotensin-aldosterone systems.  Although the obsd. decrease in mortality using this strategy in heart failure populations was encouraging, morbidity and mortality levels remained elevated, and it has now been shown that several other humoral interactions are at play and potentially deserve antagonizing, or in the case of vasodilator neurohormones, deserve stimulation.  It is known that a family of vasodilator neurohormones, the natriuretic peptides, that have natriuretic, vasodilatory, and antiproliferative effects, endogenously inhibit the renin-angiotensin system.  These peptides are degraded primarily by a neutral endopeptidase (NEP), an endothelial cell-surface zinc metallopeptidase, which shares a similar structure and catalytic site with the angiotensin converting enzyme (ACE).  NEPs have broad substrate specificity, encompassing atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide, but also bradykinin and adrenomedullin.  The recognition that ACE and NEP enzymes had related structures, led to the design and development of a new class of mols. with a dual inhibitory effect on ACE and NEP, referred to as vasopeptidase inhibitors.  Preliminary clin. trials in heart failure with vasopeptidase inhibitors have become available and show promising results.  Thus, the combined inhibition of ACE and NEP, by attenuating excessive vasoconstriction and enhancing vasodilator substances, holds promise as a valuable option in heart failure treatment for the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ-LfqhBLlArVg90H21EOLACvtfcHk0lizxmZ49UbbqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXns1Gqtrg%253D&md5=1e17a1559d9af49c1014ce92333bfc7e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrindade%26aufirst%3DP.%2BT.%26aulast%3DRouleau%26aufirst%3DJ.%2BL.%26atitle%3DVasopeptidase%2520inhibitors%253A%2520potential%2520role%2520in%2520the%2520treatment%2520of%2520heart%2520failure%26jtitle%3DHeart%2520Failure%2520Monit.%26date%3D2001%26volume%3D2%26spage%3D2%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. A.</span></span> <span> </span><span class="NLM_article-title">Vasopeptidase inhibitors</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">1525</span>– <span class="NLM_lpage">1532</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(01)06584-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2FS0140-6736%2801%2906584-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=11705582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A280%3ADC%252BD3MnltFOisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2001&pages=1525-1532&author=M.+A.+Weber&title=Vasopeptidase+inhibitors&doi=10.1016%2FS0140-6736%2801%2906584-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Vasopeptidase inhibitors</span></div><div class="casAuthors">Weber M A</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">9292</span>),
    <span class="NLM_cas:pages">1525-32</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">Vasopeptidase inhibitors are a new class of cardiovascular drug that simultaneously inhibit both neutral endopeptidase and angiotensin-converting enzyme (ACE).  They increase the availability of peptides that have vasodilatory and other vascular effects; they also inhibit production of angiotensin II.  In animal models vasopeptidase inhibitors decrease blood pressure in low, medium, and high renin forms of hypertension, and they also appear to confer benefits in models of heart failure and ischaemic heart disease.  Studies in human hypertension show that these agents are effective in decreasing blood pressure regardless of race or age.  Experience with omapatrilat, the most clinically advanced of these drugs, has shown it to be more effective than currently available ACE inhibitors or other widely used antihypertensive agents.  Studies with omapatrilat in congestive heart failure have shown beneficial effects on haemodynamics and symptoms.  The vasopeptidase inhibitors appear to have safety profiles similar to ACE inhibitors, though the frequency of side-effects such as angio-oedema and cough remains to be established.  Large trials with clinical endpoints, some already in progress, are needed to establish the place of this class of drug beside that of established therapies in conditions such as hypertension, heart failure, ischaemic heart disease, and nephropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNUjLeVs7MGT0O18WR3iAofW6udTcc2eYnFpzIXMZIvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnltFOisA%253D%253D&md5=ed69ac5d07ea379e550a651e6c222121</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2801%2906584-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252801%252906584-9%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DM.%2BA.%26atitle%3DVasopeptidase%2520inhibitors%26jtitle%3DLancet%26date%3D2001%26volume%3D358%26spage%3D1525%26epage%3D1532%26doi%3D10.1016%2FS0140-6736%2801%2906584-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cozier, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendse, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwager, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for multiple omapatrilat binding sites within the ACE C-domain: Implications for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10141</span>– <span class="NLM_lpage">10154</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCisb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10141-10154&author=G.+E.+Cozierauthor=L.+B.+Arendseauthor=S.+L.+Schwagerauthor=E.+D.+Sturrockauthor=K.+R.+Acharya&title=Molecular+basis+for+multiple+omapatrilat+binding+sites+within+the+ACE+C-domain%3A+Implications+for+drug+design&doi=10.1021%2Facs.jmedchem.8b01309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain: Implications for Drug Design</span></div><div class="casAuthors">Cozier, Gyles E.; Arendse, Lauren B.; Schwager, Sylva L.; Sturrock, Edward D.; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10141-10154</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Omapatrilat was designed as a vasopeptidase inhibitor with dual activity against the zinc metallopeptidases angiotensin-1 converting enzyme (ACE) and neprilysin (NEP).  ACE has two homologous catalytic domains (nACE and cACE), which exhibit different substrate specificities.  Here, the authors report high-resoln. crystal structures of omapatrilat in complex with nACE and cACE and show omapatrilat has subnanomolar affinity for both domains.  The structures show nearly identical binding interactions for omapatrilat in each domain, explaining the lack of domain selectivity.  The cACE complex structure revealed an omapatrilat dimer occupying the cavity beyond the S2 subsite, and this dimer had low micromolar inhibition of nACE and cACE.  These results highlight residues beyond the S2 subsite that could be exploited for domain selective inhibition.  In addn., it suggests the possibility of either domain specific allosteric inhibitors that bind exclusively to the nonprime cavity or the potential for targeting specific substrates rather than completely inhibiting the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4n5G90jRNyrVg90H21EOLACvtfcHk0lgGkHZFvPp0wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCisb7J&md5=a71906277e73b0818845e3253ec9ef33</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01309%26sid%3Dliteratum%253Aachs%26aulast%3DCozier%26aufirst%3DG.%2BE.%26aulast%3DArendse%26aufirst%3DL.%2BB.%26aulast%3DSchwager%26aufirst%3DS.%2BL.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DMolecular%2520basis%2520for%2520multiple%2520omapatrilat%2520binding%2520sites%2520within%2520the%2520ACE%2520C-domain%253A%2520Implications%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10141%26epage%3D10154%26doi%3D10.1021%2Facs.jmedchem.8b01309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryono, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpkins, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimarusti, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejneka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarchyk, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarz, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboa-Offei, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathers, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trippodo, N. C.</span></span> <span> </span><span class="NLM_article-title">Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1570</span>– <span class="NLM_lpage">1577</span>, <span class="refDoi"> DOI: 10.1021/jm970041e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970041e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK2sXjtFSjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1570-1577&author=J.+A.+Roblauthor=C.+Q.+Sunauthor=J.+Stevensonauthor=D.+E.+Ryonoauthor=L.+M.+Simpkinsauthor=M.+P.+Cimarustiauthor=T.+Dejnekaauthor=W.+A.+Slusarchykauthor=S.+Chaoauthor=L.+Strattonauthor=R.+N.+Misraauthor=M.+S.+Bednarzauthor=M.+M.+Asaadauthor=H.+S.+Cheungauthor=B.+E.+Abboa-Offeiauthor=P.+L.+Smithauthor=P.+D.+Mathersauthor=M.+Foxauthor=T.+R.+Schaefferauthor=A.+A.+Seymourauthor=N.+C.+Trippodo&title=Dual+metalloprotease+inhibitors%3A+mercaptoacetyl-based+fused+heterocyclic+dipeptide+mimetics+as+inhibitors+of+angiotensin-converting+enzyme+and+neutral+endopeptidase&doi=10.1021%2Fjm970041e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Metalloprotease Inhibitors: Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase</span></div><div class="casAuthors">Robl, Jeffrey A.; Sun, Chong-Qing; Stevenson, Jay; Ryono, Denis E.; Simpkins, Ligaya M.; Cimarusti, Maria P.; Dejneka, Tamara; Slusarchyk, William A.; Chao, Sam; Stratton, Leslie; Misra, Raj N.; Bednarz, Mark S.; Asaad, Magdi M.; Cheung, Hong Son; Abboa-Offei, Benoni E.; Smith, Patricia L.; Mathers, Parker D.; Fox, Maxine; Schaeffer, Thomas R.; Seymour, Andrea A.; Trippodo, Nick C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1570-1577</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 7,6- and 7,5-fused bicyclic thiazepinones and oxazepinones were generated and incorporated as conformationally restricted dipeptide surrogates in mercaptoacyl dipeptides.  These compds. are potent inhibitors of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) both in vitro and in vivo.  Compd. 1a, a 7,6-fused bicyclic thiazepinone, demonstrated excellent blood pressure lowering in a variety of animal models characterized by various levels of plasma renin activity and significantly potentiated urinary sodium, ANP, and cGMP excretion in a cynomolgus monkey assay.  On the basis of its potency and duration of action, compd. 1a (BMS-186716) was advanced into clin. development for the treatment of hypertension and congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA1AhNVtyuOrVg90H21EOLACvtfcHk0liLiw9Gi6JnbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtFSjtbY%253D&md5=e255086829b24dd59c25c1991ba04264</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm970041e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970041e%26sid%3Dliteratum%253Aachs%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DSun%26aufirst%3DC.%2BQ.%26aulast%3DStevenson%26aufirst%3DJ.%26aulast%3DRyono%26aufirst%3DD.%2BE.%26aulast%3DSimpkins%26aufirst%3DL.%2BM.%26aulast%3DCimarusti%26aufirst%3DM.%2BP.%26aulast%3DDejneka%26aufirst%3DT.%26aulast%3DSlusarchyk%26aufirst%3DW.%2BA.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DStratton%26aufirst%3DL.%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DAsaad%26aufirst%3DM.%2BM.%26aulast%3DCheung%26aufirst%3DH.%2BS.%26aulast%3DAbboa-Offei%26aufirst%3DB.%2BE.%26aulast%3DSmith%26aufirst%3DP.%2BL.%26aulast%3DMathers%26aufirst%3DP.%2BD.%26aulast%3DFox%26aufirst%3DM.%26aulast%3DSchaeffer%26aufirst%3DT.%2BR.%26aulast%3DSeymour%26aufirst%3DA.%2BA.%26aulast%3DTrippodo%26aufirst%3DN.%2BC.%26atitle%3DDual%2520metalloprotease%2520inhibitors%253A%2520mercaptoacetyl-based%2520fused%2520heterocyclic%2520dipeptide%2520mimetics%2520as%2520inhibitors%2520of%2520angiotensin-converting%2520enzyme%2520and%2520neutral%2520endopeptidase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1570%26epage%3D1577%26doi%3D10.1021%2Fjm970041e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azizi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvol, P.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1226</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.35.6.1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1161%2F01.HYP.35.6.1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10856268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVCntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=1226-1231&author=M.+Aziziauthor=C.+Massienauthor=A.+Michaudauthor=P.+Corvol&title=In+vitro+and+in+vivo+inhibition+of+the+2+active+sites+of+ACE+by+omapatrilat%2C+a+vasopeptidase+inhibitor&doi=10.1161%2F01.HYP.35.6.1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor</span></div><div class="casAuthors">Azizi, Michel; Massien, Christine; Michaud, Annie; Corvol, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1226-1231</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The vasopeptidase inhibitor omapatrilat inhibits both neutral endopeptidase and angiotensin-converting enzyme (ACE).  The in vitro and in vivo inhibitory potency of omapatrilat and the specific ACE inhibitor fosinopril toward the 2 active sites of ACE (called N- and C-domains) was investigated with the use of 3 substrates: angiotensin I, which is equally cleaved by the 2 ACE domains; hippuryl-histidyl-leucine, specific synthetic substrate of the C-domain in high-salt conditions; and a newly synthesized specific substrate of the N-domain designed by acetylating the lysine residue of AcSDKP.  In vitro, omapatrilat was 5 times more potent than fosinoprilat in inhibiting angiotensin I hydrolysis.  Omapatrilat inhibited similarly both N- and C-domain hydrolysis, whereas fosinoprilat was slightly more specific for the N-domain.  The in vivo selective inhibitory potency of single oral doses of 10 mg omapatrilat and 20 mg fosinopril were investigated in a double-blind, placebo-controlled, cross-over study in 9 mildly sodium-depleted normotensive subjects.  In accordance with the in vitro results, fosinopril appeared to be more specific for the N-domain than the C-domain in vivo, since plasma and urine AcSDKP concns. were significantly higher than those obsd. with omapatrilat.  This study shows that it is possible to assess sep. in vitro and in vivo the selectivity of ACE or ACE/neutral endopeptidase inhibitors.  A differential selectivity may explain some peculiar properties obsd. with some ACE inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpEX7zuaqkurVg90H21EOLACvtfcHk0liLiw9Gi6JnbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVCntr0%253D&md5=961802b4e2984e1d80acb5e49dbac749</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.35.6.1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.35.6.1226%26sid%3Dliteratum%253Aachs%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DMassien%26aufirst%3DC.%26aulast%3DMichaud%26aufirst%3DA.%26aulast%3DCorvol%26aufirst%3DP.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520inhibition%2520of%2520the%25202%2520active%2520sites%2520of%2520ACE%2520by%2520omapatrilat%252C%2520a%2520vasopeptidase%2520inhibitor%26jtitle%3DHypertension%26date%3D2000%26volume%3D35%26spage%3D1226%26epage%3D1231%26doi%3D10.1161%2F01.HYP.35.6.1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostis, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmieder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, E.</span></span> <span> </span><span class="NLM_article-title">Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial</span>. <i>Am. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.amjhyper.2003.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2Fj.amjhyper.2003.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=14751650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvF2gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=103-111&author=J.+B.+Kostisauthor=M.+Packerauthor=H.+R.+Blackauthor=R.+Schmiederauthor=D.+Henryauthor=E.+Levy&title=Omapatrilat+and+enalapril+in+patients+with+hypertension%3A+the+Omapatrilat+Cardiovascular+Treatment+vs.+Enalapril+%28OCTAVE%29+trial&doi=10.1016%2Fj.amjhyper.2003.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial</span></div><div class="casAuthors">Kostis, John B.; Packer, Milton; Black, Henry R.; Schmieder, Roland; Henry, David; Levy, Elliott</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hypertension</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-111</span>CODEN:
                <span class="NLM_cas:coden">AJHYE6</span>;
        ISSN:<span class="NLM_cas:issn">0895-7061</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Recent reports suggest that existing antihypertensive agents may not have sufficient efficacy to control blood pressure (BP) in many patients.  Omapatrilat, an agent under development, has been shown to have significantly greater antihypertensive efficacy than existing agents, but may also carry increased risk of angioedema.  We compared the efficacy and safety of omapatrilat to a representative angiotensin-converting enzyme (ACE) inhibitor, enalapril.  The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial is a multicenter, randomized, double-blind, active-controlled, 24-wk trial in 25,302 patients with untreated or uncontrolled hypertension conducted in 3298 office-based sites in 12 countries.  Subjects were randomized to omapatrilat 10 mg or enalapril 5 mg as initial therapy for hypertension (group 1, n = 9292), replacement for existing antihypertensive therapy (group 2, n = 11,224), or in addn. to existing antihypertensive therapy (group 3, n = 4751).  Study drug was force-titrated at week 2 and electively titrated at weeks 4 and 6 to a max. of omapatrilat 80 mg or enalapril 40 mg once daily.  At weeks 8 and 16, adjunctive antihypertensive medications were added electively to achieve target BP.  Omapatrilat reduced systolic BP 3.6 mm Hg more than enalapril at week 8, and was assocd. with less use of adjunctive antihypertensive therapy by week 24 (19% v 27%; P < 0.001 for both comparisons).  Subjects randomized to omapatrilat were more likely to reach BP target, regardless of demographics or comorbid conditions and whether omapatrilat was used as initial therapy, replacement for existing therapy, or in addn. to existing therapy.  Angioedema was more frequent with omapatrilat than enalapril (2.17% v 0.68%).  Two omapatrilat-treated subjects experienced angioedema with airway compromise, which was successfully treated.  Omapatrilat provided broadly superior antihypertensive efficacy when used in a setting resembling clin. practice.  Angioedema was more common than with enalapril but life-threatening angioedema was rare.  The risk-benefit profile for omapatrilat in clin. use therefore appears likely to be favorable in appropriate patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPTjmO9Y1hr7Vg90H21EOLACvtfcHk0liLiw9Gi6JnbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvF2gtw%253D%253D&md5=a783f9aa5c8d243ac3c077b601918535</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.amjhyper.2003.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjhyper.2003.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DKostis%26aufirst%3DJ.%2BB.%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DBlack%26aufirst%3DH.%2BR.%26aulast%3DSchmieder%26aufirst%3DR.%26aulast%3DHenry%26aufirst%3DD.%26aulast%3DLevy%26aufirst%3DE.%26atitle%3DOmapatrilat%2520and%2520enalapril%2520in%2520patients%2520with%2520hypertension%253A%2520the%2520Omapatrilat%2520Cardiovascular%2520Treatment%2520vs.%2520Enalapril%2520%2528OCTAVE%2529%2520trial%26jtitle%3DAm.%2520J.%2520Hypertens.%26date%3D2004%26volume%3D17%26spage%3D103%26epage%3D111%26doi%3D10.1016%2Fj.amjhyper.2003.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fryer, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segreti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfor, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widomski, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backes, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballaron, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevillyan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Geldern, T. W.</span></span> <span> </span><span class="NLM_article-title">Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1038%2Fsj.bjp.0707641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=18084312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislWis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2008&pages=947-955&author=R.+M.+Fryerauthor=J.+Segretiauthor=P.+N.+Banforauthor=D.+L.+Widomskiauthor=B.+J.+Backesauthor=C.+W.+Linauthor=S.+J.+Ballaronauthor=B.+F.+Coxauthor=J.+M.+Trevillyanauthor=G.+A.+Reinhartauthor=T.+W.+von+Geldern&title=Effect+of+bradykinin+metabolism+inhibitors+on+evoked+hypotension+in+rats%3A+rank+efficacy+of+enzymes+associated+with+bradykinin-mediated+angioedema&doi=10.1038%2Fsj.bjp.0707641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema</span></div><div class="casAuthors">Fryer, R. M.; Segreti, J.; Banfor, P. N.; Widomski, D. L.; Backes, B. J.; Lin, C. W.; Ballaron, S. J.; Cox, B. F.; Trevillyan, J. M.; Reinhart, G. A.; von Geldern, T. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">947-955</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of bradykinin metabolizing enzymes (BMEs) can cause acute angioedema, as demonstrated in a recent clin. trial in patients administered the antihypertensive, omapatrilat.  However, the relative contribution of specific BMEs to this effect is unclear and confounded by the lack of a predictive pre-clin. model of angioedema.  Rats were instrumented to record blood pressure and heart rate; inhibitors were infused for 35 min and bradykinin was infused during the last 5 min to elicit hypotension, as a functional marker of circulating bradykinin and relative angioedema risk.  In the presence of omapatrilat, bradykinin produced dose-dependent hypotension, an effect abolished by B2 blockade.  In the presence of lisinopril (ACE inhibitor), but not candoxatril (NEP inhibitor) or apstatin (APP inhibitor), bradykinin also elicited hypotension.  Lisinopril-mediated hypotension was unchanged with concomitant blockade of NEP or NEP/DPPIV (candoxatril + A-899301).  However, hypotension was enhanced upon concomitant blockade of APP and further intensified in the presence of NEP inhibition to values not different from omapatrilat alone.  We demonstrated that bradykinin is degraded in vivo with an enzyme rank-efficacy of ACE>APP»NEP or DPPIV.  These results suggest the effects of omapatrilat are mediated by inhibition of three BMEs, ACE/APP/NEP.  However, dual inhibition of ACE/NEP or ACE/NEP/DPPIV elicits no increased risk of angioedema compared to ACE inhibition alone.  Thus, novel BME inhibitors must display no activity against APP to avoid angioedema risk due to high prevalence of ACE inhibitor therapy in patients with diabetes and cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHe-dQxhoWF7Vg90H21EOLACvtfcHk0lhJIptD3yO59w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislWis7Y%253D&md5=e3067cd71575b8f32a623ef6a0303569</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707641%26sid%3Dliteratum%253Aachs%26aulast%3DFryer%26aufirst%3DR.%2BM.%26aulast%3DSegreti%26aufirst%3DJ.%26aulast%3DBanfor%26aufirst%3DP.%2BN.%26aulast%3DWidomski%26aufirst%3DD.%2BL.%26aulast%3DBackes%26aufirst%3DB.%2BJ.%26aulast%3DLin%26aufirst%3DC.%2BW.%26aulast%3DBallaron%26aufirst%3DS.%2BJ.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DTrevillyan%26aufirst%3DJ.%2BM.%26aulast%3DReinhart%26aufirst%3DG.%2BA.%26aulast%3Dvon%2BGeldern%26aufirst%3DT.%2BW.%26atitle%3DEffect%2520of%2520bradykinin%2520metabolism%2520inhibitors%2520on%2520evoked%2520hypotension%2520in%2520rats%253A%2520rank%2520efficacy%2520of%2520enzymes%2520associated%2520with%2520bradykinin-mediated%2520angioedema%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D153%26spage%3D947%26epage%3D955%26doi%3D10.1038%2Fsj.bjp.0707641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span> <span> </span><span class="NLM_article-title">Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">948</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1996.tb15763.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1111%2Fj.1476-5381.1996.tb15763.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=8922744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK28XmvVSmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=1996&pages=943-948&author=J.+E.+Kirkauthor=M.+R.+Wilkins&title=Renal+effects+of+concurrent+E-24.11+and+ACE+inhibition+in+the+aorto-venocaval+fistula+rat&doi=10.1111%2Fj.1476-5381.1996.tb15763.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat</span></div><div class="casAuthors">Kirk, Jane E.; Wilkins, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">943-948</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The present studies compare the early renal response to (a) an endopeptidase-24.11 (E-24.11) inhibitor (candoxatrilat) (b) an angiotensin-converting enzyme (ACE) inhibitor (lisinopril) and (c) the combination of endopeptidase-24.11 and ACE inhibition in the rat A-V fistula model of chronic vol. overload.  Candoxatrilat (3 and 10 mg kg-1) i.v. produced a prompt 3 fold increase in urinary sodium and cGMP excretion without affecting significantly blood pressure or glomerular filtration rate (GFR).  Lisinopril (0.03 mg kg-1) alone inhibited the pressor response to angiotensin I but had no significant effect on urinary sodium excretion or blood pressure.  Lisinopril (0.03 mg kg-1) attenuated significantly the early natriuretic response to candoxatrilat (3 mg kg-1) and the assocd. rise in urinary cGMP, but sodium excretion eventually reached levels assocd. with acute E-24.11 inhibition.  Doses of the dual E-24.11/ACE inhibitor, sampatrilat, that inhibited the pressor response to angiotensin I reduced mean arterial blood pressure and produced a delayed natriuresis and rise in urinary cGMP excretion when compared to candoxatrilat alone.  Concurrent administration of an ACE inhibitor reduces the early renal response to E-24.11 inhibition in the A-V fistula rat, an effect attributable to the hypotensive action of this combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrza9Wz_KQUtbVg90H21EOLACvtfcHk0lhJIptD3yO59w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmvVSmsb0%253D&md5=c2c774afa874ee4e8e89cb73812ee932</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1996.tb15763.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1996.tb15763.x%26sid%3Dliteratum%253Aachs%26aulast%3DKirk%26aufirst%3DJ.%2BE.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26atitle%3DRenal%2520effects%2520of%2520concurrent%2520E-24.11%2520and%2520ACE%2520inhibition%2520in%2520the%2520aorto-venocaval%2520fistula%2520rat%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D119%26spage%3D943%26epage%3D948%26doi%3D10.1111%2Fj.1476-5381.1996.tb15763.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinoza-Moraga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poblete, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">The dynamic nonprime binding of sampatrilat to the C-domain of angiotensin-converting enzyme</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2486</span>– <span class="NLM_lpage">2494</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGrtb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=2486-2494&author=R.+K.+Sharmaauthor=M.+Espinoza-Moragaauthor=H.+Pobleteauthor=R.+G.+Douglasauthor=E.+D.+Sturrockauthor=J.+Caballeroauthor=K.+Chibale&title=The+dynamic+nonprime+binding+of+sampatrilat+to+the+C-domain+of+angiotensin-converting+enzyme&doi=10.1021%2Facs.jcim.6b00524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme</span></div><div class="casAuthors">Sharma, Rajni K.; Espinoza-Moraga, Marlene; Poblete, Horacio; Douglas, Ross G.; Sturrock, Edward D.; Caballero, Julio; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2486-2494</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sampatrilat is a vasopeptidase inhibitor that inhibits both angiotensin I-converting enzyme (ACE) and neutral endopeptidase (NEP).  ACE is a zinc dipeptidyl carboxypeptidase that contains two extracellular domains (nACE and cACE).  In this study the mol. basis for the selectivity of sampatrilat for nACE and cACE was investigated.  Enzyme inhibition assays were performed to evaluate the in vitro ACE domain selectivity of sampatrilat.  The inhibition of the C-domain (Ki 13.8 nM) by sampatrilat was 12.4-fold more potent than that for the N-domain (171.9 nM) indicating differences in affinities for the resp. ACE domain binding sites.  Interestingly, replacement of the P2 group of sampatrilat with an aspartate abrogated its C-selectivity, and lowered the potency of the inhibitor with activities in the micromolar range.  The mol. basis for this selective profile was evaluated using mol. modeling methods.  The authors found that the C-domain selectivity of sampatrilat is due to occupation of the lysine side chain in the S1 and S2 subsites and interactions with Glu 748 and Glu 1008, resp.  This study provides new insights into ligand interactions with the non-prime binding site that can be exploited for the design of domain-selective ACE inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnJlhUEhuTprVg90H21EOLACvtfcHk0lhJIptD3yO59w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGrtb3K&md5=bc40414bf5b79a1d921c275457f9c6e7</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00524%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DR.%2BK.%26aulast%3DEspinoza-Moraga%26aufirst%3DM.%26aulast%3DPoblete%26aufirst%3DH.%26aulast%3DDouglas%26aufirst%3DR.%2BG.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DCaballero%26aufirst%3DJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DThe%2520dynamic%2520nonprime%2520binding%2520of%2520sampatrilat%2520to%2520the%2520C-domain%2520of%2520angiotensin-converting%2520enzyme%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26spage%3D2486%26epage%3D2494%26doi%3D10.1021%2Facs.jcim.6b00524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venn, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, K. C.</span></span> <span> </span><span class="NLM_article-title">Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA)</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1016/S0731-7085(97)00127-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2FS0731-7085%2897%2900127-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=9535200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK1cXhsVKhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=883-892&author=R.+F.+Vennauthor=G.+Barnardauthor=B.+Kayeauthor=P.+V.+Macraeauthor=K.+C.+Saunders&title=Clinical+analysis+of+sampatrilat%2C+a+combined+renal+endopeptidase+and+angiotensin-converting+enzyme+inhibitor+II%3A+assay+in+the+plasma+and+urine+of+human+volunteers+by+dissociation+enhanced+lanthanide+fluorescence+immunoassay+%28DELFIA%29&doi=10.1016%2FS0731-7085%2897%2900127-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor. II: Assay in the plasma and urine of human volunteers by dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA)</span></div><div class="casAuthors">Venn, Richard F.; Barnard, Geoff; Kaye, Barry; Macrae, Paul V.; Saunders, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">An immunoassay for sampatrilat was developed which uses time-resolved fluorescence as an end-point and which has lower limits of quantification of 0.2 ng/mL plasma assay and 5 ng/mL urine.  This assay is a 96-well-plate-based competitive immunoassay; the end-point is the detn. of a (nonradioactive) europium label by time-resolved fluorimetry.  Sampatrilat is labeled with chelated europium via isothiocyanate chem.  The advantage of this assay is its extremely high throughput, allowing rapid anal. of many thousands of samples.  The DELFIA method was successfully cross-validated with the previously described HPLC-atm.-pressure chem. ionization mass-spectrometric method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI9iRZ2RsM-LVg90H21EOLACvtfcHk0ljAV_sTJzwtQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsVKhu7Y%253D&md5=fbdf57f0398d3c14e9abcb9f05d69d24</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0731-7085%2897%2900127-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0731-7085%252897%252900127-1%26sid%3Dliteratum%253Aachs%26aulast%3DVenn%26aufirst%3DR.%2BF.%26aulast%3DBarnard%26aufirst%3DG.%26aulast%3DKaye%26aufirst%3DB.%26aulast%3DMacrae%26aufirst%3DP.%2BV.%26aulast%3DSaunders%26aufirst%3DK.%2BC.%26atitle%3DClinical%2520analysis%2520of%2520sampatrilat%252C%2520a%2520combined%2520renal%2520endopeptidase%2520and%2520angiotensin-converting%2520enzyme%2520inhibitor%2520II%253A%2520assay%2520in%2520the%2520plasma%2520and%2520urine%2520of%2520human%2520volunteers%2520by%2520dissociation%2520enhanced%2520lanthanide%2520fluorescence%2520immunoassay%2520%2528DELFIA%2529%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D1998%26volume%3D16%26spage%3D883%26epage%3D892%26doi%3D10.1016%2FS0731-7085%2897%2900127-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venn, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, K. C.</span></span> <span> </span><span class="NLM_article-title">Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1016/S0731-7085(97)00126-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2FS0731-7085%2897%2900126-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=9535199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK1cXhsVKhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=875-881&author=R.+F.+Vennauthor=B.+Kayeauthor=P.+V.+Macraeauthor=K.+C.+Saunders&title=Clinical+analysis+of+sampatrilat%2C+a+combined+renal+endopeptidase+and+angiotensin-converting+enzyme+inhibitor+I%3A+assay+in+plasma+of+human+volunteers+by+atmospheric-pressure+ionisation+mass-spectrometry+following+derivatisation+with+BF3-methanol&doi=10.1016%2FS0731-7085%2897%2900126-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor. I: Assay in plasma of human volunteers by atmospheric-pressure ionization mass spectrometry following derivatization with BF3-methanol</span></div><div class="casAuthors">Venn, Richard F.; Kaye, Barry; Macrae, Paul V.; Saunders, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">875-881</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A selective and sensitive method for detg. sampatrilat in plasma, employing HPLC and atm.-pressure ionization mass spectrometry (APCI-MS-MS), was developed.  The plasma samples were extd. on solid-phase extn. cartridges, derivatized with BF3-MeOH, dild., extd. again and then subjected to HPLC-APCI-MS-MS.  Derivatization was necessary because the two COOH groups in the mol. prevented efficient ionization in the heated nebulizer source.  The calibration range was 0.5-20 ng/mL and the lower limit of quantification was 0.5 ng/mL.  Imprecision and inaccuracy were detd. on 3 sep. occasions at 3 concns. (0.5, 5 and 20 ng/mL) and were <10% in every case.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptAzuhofkmxrVg90H21EOLACvtfcHk0ljAV_sTJzwtQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsVKhu7k%253D&md5=d4e689de04d4ff213d3030693e487bb6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0731-7085%2897%2900126-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0731-7085%252897%252900126-X%26sid%3Dliteratum%253Aachs%26aulast%3DVenn%26aufirst%3DR.%2BF.%26aulast%3DKaye%26aufirst%3DB.%26aulast%3DMacrae%26aufirst%3DP.%2BV.%26aulast%3DSaunders%26aufirst%3DK.%2BC.%26atitle%3DClinical%2520analysis%2520of%2520sampatrilat%252C%2520a%2520combined%2520renal%2520endopeptidase%2520and%2520angiotensin-converting%2520enzyme%2520inhibitor%2520I%253A%2520assay%2520in%2520plasma%2520of%2520human%2520volunteers%2520by%2520atmospheric-pressure%2520ionisation%2520mass-spectrometry%2520following%2520derivatisation%2520with%2520BF3-methanol%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D1998%26volume%3D16%26spage%3D875%26epage%3D881%26doi%3D10.1016%2FS0731-7085%2897%2900126-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hettiarachchi, J.</span></span> <span> </span><span class="NLM_article-title">Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1016/S0009-9236(98)90075-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2FS0009-9236%2898%2990075-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=9797801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A280%3ADyaK1M%252FhsVGgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1998&pages=439-449&author=E.+J.+Wallisauthor=L.+E.+Ramsayauthor=J.+Hettiarachchi&title=Combined+inhibition+of+neutral+endopeptidase+and+angiotensin-converting+enzyme+by+sampatrilat+in+essential+hypertension&doi=10.1016%2FS0009-9236%2898%2990075-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension</span></div><div class="casAuthors">Wallis E J; Ramsay L E; Hettiarachchi J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-49</span>
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">BACKGROUND:  The antihypertensive response to angiotensin-converting enzyme (ACE) inhibitors may be attenuated by a compensatory decrease in atrial natriuretic factor production.  If so, inhibition of atrial natriuretic factor breakdown by neutral endopeptidase (NEP) may enhance the antihypertensive effects of ACE inhibition.  We compared effects of the combined ACE-NEP inhibitor sampatrilat, lisinopril, and placebo on blood pressure, plasma ACE, and renin activity and urinary cyclic guanosine monophosphate (cGMP) of patients with hypertension.  METHODS AND RESULTS:  After a 4-week placebo run-in period, 124 patients with a mean blood pressure of 162/102 mm Hg were randomized in a double-blind parallel-group design to 1 of 5 treatments, given once daily for 10 days: 50 mg, 100 mg, or 200 mg sampatrilat; 20 mg lisinopril; or placebo.  The first dose of sampatrilat did not lower clinic or ambulatory blood pressure.  Lisinopril had an immediate antihypertensive effect that differed significantly from all doses of sampatrilat.  After 10 days of treatment, sampatrilat lowered clinic and ambulatory blood pressure significantly at all doses, with a trend toward a dose response for systolic ambulatory blood pressure.  Sampatrilat inhibited plasma ACE in a dose-dependent fashion but significantly less so than lisinopril on days 1 and 10 of treatment.  Lisinopril but not sampatrilat significantly increased plasma renin activity, whereas sampatrilat but not lisinopril significantly increased urinary cGMP excretion.  CONCLUSION:  The increasing efficacy of sampatrilat compared with lisinopril over 10 days could not be attributed to an increase in plasma ACE inhibition, suggesting that the NEP inhibitor activity of sampatrilat may have contributed to its antihypertensive action.  NEP inhibition may enhance the antihypertensive effect of ACE inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjVN-vZ51TwsrRqEXsZufAfW6udTcc2ebAV2MnseomKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FhsVGgtw%253D%253D&md5=a1e186848d1983dddd5cfc69d1b1585f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0009-9236%2898%2990075-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-9236%252898%252990075-3%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DE.%2BJ.%26aulast%3DRamsay%26aufirst%3DL.%2BE.%26aulast%3DHettiarachchi%26aufirst%3DJ.%26atitle%3DCombined%2520inhibition%2520of%2520neutral%2520endopeptidase%2520and%2520angiotensin-converting%2520enzyme%2520by%2520sampatrilat%2520in%2520essential%2520hypertension%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1998%26volume%3D64%26spage%3D439%26epage%3D449%26doi%3D10.1016%2FS0009-9236%2898%2990075-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watermeyer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroger, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span> <span> </span><span class="NLM_article-title">Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1042/BJ20100056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1042%2FBJ20100056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=20233165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1Cmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2010&pages=67-74&author=J.+M.+Watermeyerauthor=W.+L.+Krogerauthor=H.+G.+O%E2%80%99Neillauthor=B.+T.+Sewellauthor=E.+D.+Sturrock&title=Characterization+of+domain-selective+inhibitor+binding+in+angiotensin-converting+enzyme+using+a+novel+derivative+of+lisinopril&doi=10.1042%2FBJ20100056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril</span></div><div class="casAuthors">Watermeyer, Jean M.; Kroeger, Wendy L.; O'Neill, Hester G.; Sewell, B. Trevor; Sturrock, Edward D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-74</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Human ACE (angiotensin-converting enzyme) (EC 3.4.15.1) is an important drug target because of its role in the regulation of blood pressure via the renin-angiotensin-aldosterone system.  Somatic ACE comprises two homologous domains, the differing substrate preferences of which present a new avenue for domain-selective inhibitor design.  LisW-S, a C-domain-selective deriv. of the drug lisinopril, was co-crystd. with human testis ACE and a crystal structure was detd. using X-ray crystallog. to a resoln. of 2.30 Å (1 Å=0.1 nm).  In this structure, lisW-S is seen to have a similar binding mode to its parent compd. lisinopril, but the P2' tryptophan moiety takes a different conformation to that seen in other inhibitors having a tryptophan residue in this position.  The domain-specific interactions of this inhibitor was examd. further by mutating C-domain-specific active-site residues to their N domain equiv., then assessing the effect of the mutation on inhibition by lisW-S using a fluorescence-based assay.  Kinetics anal. shows a 258-fold domain-selectivity that is largely due to the co-operative effect of C-domain-specific residues in the S2' subsite.  The high affinity and selectivity of this inhibitor make it a good lead candidate for cardiovascular drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV_1gE3mSs_LVg90H21EOLACvtfcHk0lib8z9ZvbtN7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1Cmtr8%253D&md5=1957d1bed6004296c886e8a8088c256c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1042%2FBJ20100056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100056%26sid%3Dliteratum%253Aachs%26aulast%3DWatermeyer%26aufirst%3DJ.%2BM.%26aulast%3DKroger%26aufirst%3DW.%2BL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DH.%2BG.%26aulast%3DSewell%26aufirst%3DB.%2BT.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26atitle%3DCharacterization%2520of%2520domain-selective%2520inhibitor%2520binding%2520in%2520angiotensin-converting%2520enzyme%2520using%2520a%2520novel%2520derivative%2520of%2520lisinopril%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D428%26spage%3D67%26epage%3D74%26doi%3D10.1042%2FBJ20100056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reudelhuber, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touyz, R. M.</span></span> <span> </span><span class="NLM_article-title">Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1042/CS20130808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1042%2FCS20130808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=24506807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVSgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2014&pages=57-63&author=D.+Burgerauthor=T.+L.+Reudelhuberauthor=A.+Mahajanauthor=K.+Chibaleauthor=E.+D.+Sturrockauthor=R.+M.+Touyz&title=Effects+of+a+domain-selective+ACE+inhibitor+in+a+mouse+model+of+chronic+angiotensin+II-dependent+hypertension&doi=10.1042%2FCS20130808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension</span></div><div class="casAuthors">Burger, Dylan; Reudelhuber, Timothy L.; Mahajan, Aman; Chibale, Kelly; Sturrock, Edward D.; Touyz, Rhian M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-63</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The somatic isoenzyme of ACE (angiotensin I-converting enzyme) comprises two distinct zinc-dependent catalytic domains with different substrate specificities for angiotensin I (cleaved selectively by the C-domain) and bradykinin (cleaved equally efficiently by both the N- and C-domains).  Classical ACEIs (ACE inhibitors) target both domains, with side effects such as cough and angio-edema being attributed, in part, to N-domain inhibition, probably through bradykinin accumulation.  We questioned whether a novel C-domain-selective ACEI (lisW-S) has anti-hypertensive effects without influencing bradykinin status.  AngII (angiotensin II)-dependent hypertension was studied in mice that express active human renin in the liver (TtRhRen).  Compared with wild-type littermates, TtRhRen mice displayed cardiac hypertrophy and had significantly elevated SBP [systolic BP (blood pressure)] as detd. by tail cuff sphygmomanometry (150±3 compared with 112±5 mmHg; P<0.05) and telemetry (163±3 compared with 112±2 mmHg; P<0.01).  Treatment with the non-selective ACEI lisinopril (1 mg/kg of body wt. per day via an osmotic mini-pump for 2 wk) reduced SBP (127±3 compared with. 154±6; P<0.05).  Similarly, treatment with the C-domain selective ACEI lisW-S (lisinopril-tryptophan; 3.6 mg/kg of body wt. per day via an osmotic mini-pump for 2 wk) reduced BP.  Treatment with lisinopril or lisW-S significantly reduced levels of AngII in kidneys (~ 4-fold; P<0.001).  Ang-(2-8) [angiotensin-2-8)] was significantly reduced by lisinopril, but not by lisW-S.  Plasma bradykinin levels were significantly increased only in the lisinopril group.  These data suggest that C-domain-selective ACEIs reduce BP and AngII levels similarly to classical ACEIs.  C-domain-selective ACEIs have the potential to avoid undesirable effects on the bradykinin system common to classic ACEIs and may represent a novel approach to the treatment of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhycqW23ZEE7Vg90H21EOLACvtfcHk0lib8z9ZvbtN7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVSgt7o%253D&md5=8bfc8db2df8a753cba417fc6504dc23c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1042%2FCS20130808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20130808%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DD.%26aulast%3DReudelhuber%26aufirst%3DT.%2BL.%26aulast%3DMahajan%26aufirst%3DA.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DTouyz%26aufirst%3DR.%2BM.%26atitle%3DEffects%2520of%2520a%2520domain-selective%2520ACE%2520inhibitor%2520in%2520a%2520mouse%2520model%2520of%2520chronic%2520angiotensin%2520II-dependent%2520hypertension%26jtitle%3DClin.%2520Sci.%26date%3D2014%26volume%3D127%26spage%3D57%26epage%3D63%26doi%3D10.1042%2FCS20130808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deddish, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skidgel, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdos, E. G.</span></span> <span> </span><span class="NLM_article-title">N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.31.4.912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1161%2F01.HYP.31.4.912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=9535414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK1cXisFWqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1998&pages=912-917&author=P.+A.+Deddishauthor=B.+Marcicauthor=H.+L.+Jackmanauthor=H.+Z.+Wangauthor=R.+A.+Skidgelauthor=E.+G.+Erdos&title=N-domain-specific+substrate+and+C-domain+inhibitors+of+angiotensin-converting+enzyme%3A+angiotensin-%281-7%29+and+keto-ACE&doi=10.1161%2F01.HYP.31.4.912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme. Angiotensin-(1-7) and keto-ACE</span></div><div class="casAuthors">Deddish, Peter A.; Marcic, Branislav; Jackman, Herbert L.; Wang, Huan-Zhu; Skidgel, Randal A.; Erdos, Ervin G.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">912-917</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The authors used the isolated N- and C-domains of the angiotensin I-converting enzyme (N-ACE and C-ACE; ACE; kininase II) to investigate the hydrolysis of the active 1-7 deriv. of angiotensin (Ang) II and inhibition by 5-S-5-benzamido-4-oxo-6-phenylhexanoyl-L-proline (keto-ACE).  Ang-(1-7) is both a substrate and an inhibitor; it is cleaved by N-ACE at approx. one half the rate of bradykinin but negligibly by C-ACE.  It inhibits C-ACE, however, at an order of magnitude lower concn. than N-ACE; the IC50 of C-ACE with 100 μM Ang I substrate was 1.2 μM and the Ki was 0.13.  While searching for a specific inhibitor of a single active site of ACE, the authors found that keto-ACE inhibited bradykinin and Ang I hydrolysis by C-ACE in approx. a 38- to 47-times lower concn. than by N-ACE; IC50 values with C-ACE were 0.5 and 0.04 μM.  Furthermore, the authors investigated how Ang-(1-7) acts via bradykinin and the involvement of its B2 receptor.  Ang-(1-7) was ineffective directly on the human bradykinin B2 receptor transfected and expressed in Chinese hamster ovary cells.  However, Ang-(1-7) potentiated arachidonic acid release by an ACE-resistant bradykinin analog (1 μM), acting on the B2 receptor when the cells were cotransfected with cDNA of both B2 receptor and ACE and the proteins were expressed on the plasma membrane were cotransfected with cDNA of both B2 receptor and ACE and the proteins were expressed on the plasma membrane of Chinese hamster ovary cells.  Thus like other ACE inhibitors, Ang-(1-7) can potentiate the actions of a ligand of the B2 receptor indirectly by binding to the active site of ACE and independent of blocking ligand hydrolysis.  This potentiation of kinins at the receptor level can explain some of the well-documented kinin like actions of Ang-(1-7).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsz053b09bnrVg90H21EOLACvtfcHk0lib8z9ZvbtN7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFWqtb8%253D&md5=5ff623c87fbd3083895520524ce4f6e2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.31.4.912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.31.4.912%26sid%3Dliteratum%253Aachs%26aulast%3DDeddish%26aufirst%3DP.%2BA.%26aulast%3DMarcic%26aufirst%3DB.%26aulast%3DJackman%26aufirst%3DH.%2BL.%26aulast%3DWang%26aufirst%3DH.%2BZ.%26aulast%3DSkidgel%26aufirst%3DR.%2BA.%26aulast%3DErdos%26aufirst%3DE.%2BG.%26atitle%3DN-domain-specific%2520substrate%2520and%2520C-domain%2520inhibitors%2520of%2520angiotensin-converting%2520enzyme%253A%2520angiotensin-%25281-7%2529%2520and%2520keto-ACE%26jtitle%3DHypertension%26date%3D1998%26volume%3D31%26spage%3D912%26epage%3D917%26doi%3D10.1161%2F01.HYP.31.4.912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poglitsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats</span>. <i>J. Renin-Angiotensin-Aldosterone Syst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1149</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1177/1470320314568438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1177%2F1470320314568438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=25757657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVOhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1149-1158&author=S.+Sharpauthor=M.+Poglitschauthor=P.+Zillaauthor=N.+H.+Daviesauthor=E.+D.+Sturrock&title=Pharmacodynamic+effects+of+C-domain-specific+ACE+inhibitors+on+the+renin-angiotensin+system+in+myocardial+infarcted+rats&doi=10.1177%2F1470320314568438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats</span></div><div class="casAuthors">Sharp, Sarah; Poglitsch, Marko; Zilla, Peter; Davies, Neil H.; Sturrock, Edward D.</div><div class="citationInfo"><span class="NLM_cas:title">JRAAS</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1149-1158</span>CODEN:
                <span class="NLM_cas:coden">JRAAAG</span>;
        ISSN:<span class="NLM_cas:issn">1470-3203</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Introduction: The renin-angiotensin system (RAS) is a dynamic network that plays a crit. role in blood pressure regulation and fluid and electrolyte homeostasis.  Modulators of the RAS, such as angiotensin-converting enzyme (ACE) inhibitors, are widely used to treat hypertension, heart failure and myocardial infarction.  Methods: The effect of ACE inhibitors (lisinopril and C-domain-selective LisW-S) on the constituent peptides of the RAS following myocardial infarction was examd. in rats.  Ten angiotensin peptides were analyzed using a sensitive LC-MS/MS-based assay to examine both the circulating and equil. levels of these peptides.  Results: Administration of lisinopril or LisW-S caused a significant decrease in Ang 1-8/Ang 1-10 ratios as detd. by circulating and equil. peptide level anal.  Furthermore, Ang 1-7 levels were elevated by both ACE inhibitors, but only lisinopril decreased the Ang 1-5/Ang 1-7 ratio.  This indicates LisW-S C-domain specificity as Ang 1-5 is generated by hydrolysis of Ang 1-7 by the N-domain.  Further corroboration of LisW-S C-domain specificity is that only lisinopril increased the circulating levels of the N-domain ACE substrate Ac-SDKP.  Conclusion: LisW-S is able to effectively block ACE in vivo by C-domain-selective inhibition.  The LC-MS/MS-based assay allows the evaluation of the pharmacol. impact of RAS inhibitors in different pathophysiol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrZekUQeLdirVg90H21EOLACvtfcHk0lib8z9ZvbtN7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVOhsL0%253D&md5=502923ff663bc51727c9161dee9bf020</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F1470320314568438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1470320314568438%26sid%3Dliteratum%253Aachs%26aulast%3DSharp%26aufirst%3DS.%26aulast%3DPoglitsch%26aufirst%3DM.%26aulast%3DZilla%26aufirst%3DP.%26aulast%3DDavies%26aufirst%3DN.%2BH.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26atitle%3DPharmacodynamic%2520effects%2520of%2520C-domain-specific%2520ACE%2520inhibitors%2520on%2520the%2520renin-angiotensin%2520system%2520in%2520myocardial%2520infarcted%2520rats%26jtitle%3DJ.%2520Renin-Angiotensin-Aldosterone%2520Syst.%26date%3D2015%26volume%3D16%26spage%3D1149%26epage%3D1158%26doi%3D10.1177%2F1470320314568438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cozier, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwager, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">1477</span>– <span class="NLM_lpage">1490</span>, <span class="refDoi"> DOI: 10.1111/febs.14421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1111%2Ffebs.14421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=29476645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktV2nur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2018&pages=1477-1490&author=G.+E.+Cozierauthor=S.+L.+Schwagerauthor=R.+K.+Sharmaauthor=K.+Chibaleauthor=E.+D.+Sturrockauthor=K.+R.+Acharya&title=Crystal+structures+of+sampatrilat+and+sampatrilat-Asp+in+complex+with+human+ACE+-+a+molecular+basis+for+domain+selectivity&doi=10.1111%2Ffebs.14421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity</span></div><div class="casAuthors">Cozier, Gyles E.; Schwager, Sylva L.; Sharma, Rajni K.; Chibale, Kelly; Sturrock, Edward D.; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1477-1490</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Angiotensin-1-converting enzyme (ACE) is a zinc metallopeptidase that consists of two homologous catalytic domains (known as nACE and cACE) with different substrate specificities.  Based on kinetic studies it was previously reported that sampatrilat, a tight-binding inhibitor of ACE, Ki = 13.8 nM and 171.9 nM for cACE and nACE resp. [Sharma et al., Journal of Chem. Information and Modeling (2016), 56, 2486-2494], was 12.4-fold more selective for cACE.  In addn., sampatrilat-Asp (samAsp), in which an aspartate group replaces the sampatrilat lysine, was found to be a nonspecific and lower micromolar affinity inhibitor.  Here, we report a detailed three-dimensional structural anal. of sampatrilat and samAsp binding to ACE using high-resoln. crystal structures elucidated by X-ray crystallog., which provides a mol. basis for differences in inhibitor affinity and selectivity for nACE and cACE.  The structures show that the specificity of sampatrilat can be explained by increased hydrophobic interactions and a H-bond from Glu403 of cACE with the lysine side chain of sampatrilat that are not obsd. in nACE.  In addn., the structures clearly show a significantly greater no. of hydrophilic and hydrophobic interactions with sampatrilat compared to samAsp in both cACE and nACE consistent with the difference in affinities.  Our findings provide new exptl. insights into ligand binding at the active site pockets that are important for the design of highly specific domain selective inhibitors of ACE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgO5eB50LzpbVg90H21EOLACvtfcHk0lgWe41Ttyx6Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktV2nur8%253D&md5=407be458962d79e4fa0e512e01bb7e04</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Ffebs.14421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.14421%26sid%3Dliteratum%253Aachs%26aulast%3DCozier%26aufirst%3DG.%2BE.%26aulast%3DSchwager%26aufirst%3DS.%2BL.%26aulast%3DSharma%26aufirst%3DR.%2BK.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DCrystal%2520structures%2520of%2520sampatrilat%2520and%2520sampatrilat-Asp%2520in%2520complex%2520with%2520human%2520ACE%2520-%2520a%2520molecular%2520basis%2520for%2520domain%2520selectivity%26jtitle%3DFEBS%2520J.%26date%3D2018%26volume%3D285%26spage%3D1477%26epage%3D1490%26doi%3D10.1111%2Ffebs.14421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Labiuk, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sygusch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grochulski, P.</span></span> <span> </span><span class="NLM_article-title">Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiorphan</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1107/S2053230X19006046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS2053230X19006046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=31204686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFyisLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=405-411&author=S.+L.+Labiukauthor=J.+Syguschauthor=P.+Grochulski&title=Structures+of+soluble+rabbit+neprilysin+complexed+with+phosphoramidon+or+thiorphan&doi=10.1107%2FS2053230X19006046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiorphan</span></div><div class="casAuthors">Labiuk, Shaunivan L.; Sygusch, Jurgen; Grochulski, Pawel</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">405-411</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Neutral endopeptidase (neprilysin; NEP) is a proteinase that cleaves a wide variety of peptides and has been implicated in Alzheimer's disease, cardiovascular conditions, arthritis and other inflammatory diseases.  The structure of the sol. extracellular domain (residues 55-750) of rabbit neprilysin was solved both in its native form at 2.1 Å resoln., and bound to the inhibitors phosphoramidon and thiorphan at 2.8 and 3.0 Å resoln., resp.  Consistent with the extracellular domain of human neprilysin, the structure reveals a large central cavity which contains the active site and the location for inhibitor binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-pU4K_8fu4LVg90H21EOLACvtfcHk0lgWe41Ttyx6Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFyisLbE&md5=c4f8f74d7cd835fe6642d74ee09b31e6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1107%2FS2053230X19006046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X19006046%26sid%3Dliteratum%253Aachs%26aulast%3DLabiuk%26aufirst%3DS.%2BL.%26aulast%3DSygusch%26aufirst%3DJ.%26aulast%3DGrochulski%26aufirst%3DP.%26atitle%3DStructures%2520of%2520soluble%2520rabbit%2520neprilysin%2520complexed%2520with%2520phosphoramidon%2520or%2520thiorphan%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2019%26volume%3D75%26spage%3D405%26epage%3D411%26doi%3D10.1107%2FS2053230X19006046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oefner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arcy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, G. E.</span></span> <span> </span><span class="NLM_article-title">Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1999.3492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1006%2Fjmbi.1999.3492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10669592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD3cXps1GqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2000&pages=341-349&author=C.+Oefnerauthor=A.+D%E2%80%99Arcyauthor=M.+Hennigauthor=F.+K.+Winklerauthor=G.+E.+Dale&title=Structure+of+human+neutral+endopeptidase+%28Neprilysin%29+complexed+with+phosphoramidon&doi=10.1006%2Fjmbi.1999.3492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon</span></div><div class="casAuthors">Oefner, Christian; D'Arcy, Allan; Hennig, Michael; Winkler, Fritz K.; Dale, Glenn E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-349</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Neprilysin (EC 3.4.24.11; neutral endopeptidase) (I) is a mammalian type II integral membrane Zn-contg. endopeptidase, which degrades and inactivates a no. of bioactive peptides.  The range of substrates cleaved by I in vitro includes the enkephalins, substance P, endothelin, bradykinin, and atrial natriuretic factor.  Due to the physiol. importance of I in the modulation of nociceptive and pressor responses there is considerable interest in inhibitors of this enzyme as novel analgesics and anti-hypertensive agents.  Here, the authors describe the crystal structure of the extracellular domain (residues 52-749) of human I complexed with the generic metalloproteinase inhibitor, phosphoramidon (II), at 2.1 Å resoln.  The structure revealed 2 multiply connected folding domains which embraced a large central cavity contg. the active site.  II was bound to one side of this cavity and its binding mode provided a detailed understanding of the ligand-binding and specificity determinants.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCc0rfNE03ULVg90H21EOLACvtfcHk0lgWe41Ttyx6Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXps1GqsA%253D%253D&md5=82d113a6b2e0349fd738bd62e6e59f9a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1999.3492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1999.3492%26sid%3Dliteratum%253Aachs%26aulast%3DOefner%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DA.%26aulast%3DHennig%26aufirst%3DM.%26aulast%3DWinkler%26aufirst%3DF.%2BK.%26aulast%3DDale%26aufirst%3DG.%2BE.%26atitle%3DStructure%2520of%2520human%2520neutral%2520endopeptidase%2520%2528Neprilysin%2529%2520complexed%2520with%2520phosphoramidon%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2000%26volume%3D296%26spage%3D341%26epage%3D349%26doi%3D10.1006%2Fjmbi.1999.3492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiering, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arcy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, M.</span></span> <span> </span><span class="NLM_article-title">Structure of neprilysin in complex with the active metabolite of sacubitril</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">27909</span> <span class="refDoi"> DOI: 10.1038/srep27909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1038%2Fsrep27909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=27302413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWnsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=N.+Schieringauthor=A.+D%E2%80%99Arcyauthor=F.+Villardauthor=P.+Ramageauthor=C.+Logelauthor=F.+Cuminauthor=G.+M.+Ksanderauthor=C.+Wiesmannauthor=R.+G.+Karkiauthor=M.+Mogi&title=Structure+of+neprilysin+in+complex+with+the+active+metabolite+of+sacubitril&doi=10.1038%2Fsrep27909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of neprilysin in complex with the active metabolite of sacubitril</span></div><div class="casAuthors">Schiering, Nikolaus; D'Arcy, Allan; Villard, Frederic; Ramage, Paul; Logel, Claude; Cumin, Frederic; Ksander, Gary M.; Wiesmann, Christian; Karki, Rajeshri G.; Mogi, Muneto</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27909</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sacubitril is an Et ester prodrug of LBQ657, the active neprilysin (NEP) inhibitor, and a component of LCZ696 (sacubitril/valsartan).  We report herein the three-dimensional structure of LBQ657 in complex with human NEP at 2 Å resoln.  The crystal structure unravels the binding mode of the compd. occupying the S1, S1' and S2' sub-pockets of the active site, consistent with a competitive inhibition mode.  An induced fit conformational change upon binding of the P1'-biphenyl moiety of the inhibitor suggests an explanation for its selectivity against structurally homologous zinc metallopeptidases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp01sPJaXPD2rVg90H21EOLACvtfcHk0lj534ESfZ6azg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWnsrvJ&md5=145b5c3201d621f289a12e43f461d28a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fsrep27909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep27909%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DA.%26aulast%3DVillard%26aufirst%3DF.%26aulast%3DRamage%26aufirst%3DP.%26aulast%3DLogel%26aufirst%3DC.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DKarki%26aufirst%3DR.%2BG.%26aulast%3DMogi%26aufirst%3DM.%26atitle%3DStructure%2520of%2520neprilysin%2520in%2520complex%2520with%2520the%2520active%2520metabolite%2520of%2520sacubitril%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26doi%3D10.1038%2Fsrep27909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinsen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajfirouz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruminski, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Hostos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, M. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrhea</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.231167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1124%2Fjpet.115.231167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=26907621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWhtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2016&pages=423-431&author=D.+W.+Griggsauthor=M.+J.+Prinsenauthor=J.+Olivaauthor=M.+A.+Campbellauthor=S.+D.+Arnettauthor=D.+Tajfirouzauthor=P.+G.+Ruminskiauthor=Y.+Yuauthor=B.+R.+Bondauthor=Y.+Jiauthor=G.+Neckermannauthor=R.+K.+Choyauthor=E.+de+Hostosauthor=M.+J.+Meyers&title=Pharmacologic+comparison+of+clinical+neutral+endopeptidase+inhibitors+in+a+rat+model+of+acute+secretory+diarrhea&doi=10.1124%2Fjpet.115.231167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrhea</span></div><div class="casAuthors">Griggs, David W.; Prinsen, Michael J.; Oliva, Jonathan; Campbell, Mary A.; Arnett, Stacy D.; Tajfirouz, Deena; Ruminski, Peter G.; Yu, Ying; Bond, Brian R.; Ji, Yuhua; Neckermann, Georg; Choy, Robert K. M.; de Hostos, Eugenio; Meyers, Marvin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">423-431</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Racecadotril (acetorphan) is a neutral endopeptidase (NEP) inhibitor with known antidiarrheal activity in animals and humans; however, in humans, it suffers from shortcomings that might be improved with newer drugs in this class that have progressed to the clinic for nonenteric disease indications.  To identify potentially superior NEP inhibitors with immediate clin. utility for diarrhea treatment, we compared their efficacy and pharmacol. properties in a rat intestinal hypersecretion model.  Racecadotril and seven other clin.-stage inhibitors of NEP were obtained or synthesized.  Enzyme potency and specificity were compared using purified peptidases.  Compds. were orally administered to rats before administration of castor oil to induce diarrhea.  Stool wt. was recorded over 4 h.  To assess other pharmacol. properties, select compds. were orally administered to normal or castor oil-treated rats, blood and tissue samples collected at multiple time points, and active compd. concns. detd. by mass spectroscopy.  NEP enzyme activity was measured in tissue homogenates.  Three previously untested clin. NEP inhibitors delayed diarrhea onset and reduced total stool output, with little or no effect on intestinal motility assessed by the charcoal meal test.  Each was shown to be a potent, highly specific inhibitor of NEP.  Each exhibited greater suppression of NEP activity in intestinal and nonintestinal tissues than did racecadotril and sustained this inhibition longer.  These results suggest that newer clin.-stage NEP inhibitors originally developed for other indications may be directly repositioned for treatment of acute secretory diarrhea and offer advantages over racecadotril, such as less frequent dosing and potentially improved efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbmMeM1b6li7Vg90H21EOLACvtfcHk0lj534ESfZ6azg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWhtbvL&md5=5d6358c680375427cb3fd23e9a135f47</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.231167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.231167%26sid%3Dliteratum%253Aachs%26aulast%3DGriggs%26aufirst%3DD.%2BW.%26aulast%3DPrinsen%26aufirst%3DM.%2BJ.%26aulast%3DOliva%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DM.%2BA.%26aulast%3DArnett%26aufirst%3DS.%2BD.%26aulast%3DTajfirouz%26aufirst%3DD.%26aulast%3DRuminski%26aufirst%3DP.%2BG.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DBond%26aufirst%3DB.%2BR.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DNeckermann%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%2BK.%26aulast%3Dde%2BHostos%26aufirst%3DE.%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26atitle%3DPharmacologic%2520comparison%2520of%2520clinical%2520neutral%2520endopeptidase%2520inhibitors%2520in%2520a%2520rat%2520model%2520of%2520acute%2520secretory%2520diarrhea%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D357%26spage%3D423%26epage%3D431%26doi%3D10.1124%2Fjpet.115.231167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kukkola, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakane, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilci, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghai, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeng, A. Y.</span></span> <span> </span><span class="NLM_article-title">Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">S65</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1097/00005344-199506263-00021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1097%2F00005344-199506263-00021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=8587470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK2MXps1KiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1995&pages=S65-568&author=P.+J.+Kukkolaauthor=P.+Savageauthor=Y.+Sakaneauthor=J.+C.+Berryauthor=N.+A.+Bilciauthor=R.+D.+Ghaiauthor=A.+Y.+Jeng&title=Differential+structure-activity+relationships+of+phosphoramidon+analogues+for+inhibition+of+three+metalloproteases%3A+endothelin-converting+enzyme%2C+neutral+endopeptidase%2C+and+angiotensin-converting+enzyme&doi=10.1097%2F00005344-199506263-00021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Differential structure-activity relationships of phosphoramidon analogs for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme</span></div><div class="casAuthors">Kukkola, Paivi J.; Savage, Paula; Sakane, Yumi; Berry, J. Carol; Bilci, Natalie A.; Ghai, Rajendra D.; Jeng, Arco Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">S65-S68</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">The structure-activity relationships of phosphoramidon analogs for inhibition of endothelin-converting enzyme (ECE), neutral endopeptidase 24.11 (NEP), and angiotensin-converting enzyme (ACE) were compared.  Phosphoramidon inhibited ECE, NEP, and ACE activities with IC50 values of 3.5, 0.034, and 78 μM, resp.  Removal of the rhamnose moiety of phosphoramidon (dipeptide 3) reduced the potency for ECE (IC50 = 70 μM), whereas the potencies for NEP (0.002 μM) and ACE (0.20 μM) were increased.  Addn. of 2-(2-naphthyl)ethyl to dipeptide 3 improved the potency for ECE (0.55 μM) but weakened the potency for NEP (0.02 μM), and had no significant change for ACE.  Interchange between Leu and Trp abolished the inhibitory activities for ECE and NEP, but the compd. remained active for ACE.  These results suggest that a hydrophobic group in the P1 position of phosphoramidon analogs increases the potency for ECE significantly, whereas compds. contg. a free phosphonic acid are optimal for inhibition of NEP and ACE.  Furthermore, an arom. group in the P'2 position is essential for the inhibition of ECE and NEP, but not ACE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp82VFZCm3gE7Vg90H21EOLACvtfcHk0lg4N2i4IzxZNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXps1KiurY%253D&md5=4740a47c33fe7e7efc824cc2bcc81a48</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1097%2F00005344-199506263-00021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199506263-00021%26sid%3Dliteratum%253Aachs%26aulast%3DKukkola%26aufirst%3DP.%2BJ.%26aulast%3DSavage%26aufirst%3DP.%26aulast%3DSakane%26aufirst%3DY.%26aulast%3DBerry%26aufirst%3DJ.%2BC.%26aulast%3DBilci%26aufirst%3DN.%2BA.%26aulast%3DGhai%26aufirst%3DR.%2BD.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26atitle%3DDifferential%2520structure-activity%2520relationships%2520of%2520phosphoramidon%2520analogues%2520for%2520inhibition%2520of%2520three%2520metalloproteases%253A%2520endothelin-converting%2520enzyme%252C%2520neutral%2520endopeptidase%252C%2520and%2520angiotensin-converting%2520enzyme%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1995%26volume%3D26%26spage%3DS65%26epage%3D568%26doi%3D10.1097%2F00005344-199506263-00021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaucher, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiraboschi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prange, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournie-Zaluski, M. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of alpha-mercaptoacyldipeptides in the thermolysin active site: structural parameters for a Zn monodentation or bidentation in metalloendopeptidases</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">12569</span>– <span class="NLM_lpage">12576</span>, <span class="refDoi"> DOI: 10.1021/bi991043z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi991043z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK1MXls1ajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=12569-12576&author=J.+F.+Gaucherauthor=M.+Selktiauthor=G.+Tiraboschiauthor=T.+Prangeauthor=B.+P.+Roquesauthor=A.+Tomasauthor=M.+C.+Fournie-Zaluski&title=Crystal+structures+of+alpha-mercaptoacyldipeptides+in+the+thermolysin+active+site%3A+structural+parameters+for+a+Zn+monodentation+or+bidentation+in+metalloendopeptidases&doi=10.1021%2Fbi991043z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of α-Mercaptoacyldipeptides in the Thermolysin Active Site: Structural Parameters for a Zn Monodentation or Bidentation in Metalloendopeptidases</span></div><div class="casAuthors">Gaucher, J. F.; Selkti, M.; Tiraboschi, G.; Prange, T.; Roques, B. P.; Tomas, A.; Fournie-Zaluski, M. C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">12569-12576</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three α-mercaptoacyldipeptides differing essentially in the size of their C-terminal residues have been crystd. in the thermolysin active site.  A new mode of binding was obsd. for 3 [HS-CH(CH2Ph)CO-Phe-Tyr] and 4 [HS-CH((CH2)4CH3)CO-Phe-Ala], in which the mercaptoacyl moieties act as bidentates with Zn-S and Zn-O distances of 2.3 and 2.4 Å, resp., the side chains fitting the S1, S1', and S2' pockets.  Moreover, a distance of 3.1 Å between the sulfur atom and the OE1 of Glu143 suggests that they are H-bonded and that one of these atoms is protonated.  This H-bond network involving Glu143, the mercaptoacyl group of the inhibitor, and the Zn ion could be considered a "modified" transition state mimic of the peptide bond hydrolysis.  Due to the presence of the hindering (5-phenyl)proline, the inhibitor HS-CH(CH2Ph)CO-Gly-(5-Ph)Pro (2) interacts through the usual Zn monodentation via the thiol group and occupancy of S1' and S2' subsites by the arom. moieties, the proline ring being outside the active site.  The inhibitory potencies are consistent with these structural data, with higher affinities for 3 (4.2 × 10-8 M) and 4 (4.8 × 10-8 M) than for 2 (1.2 × 10-6 M).  The extension of the results, obtained with thermolysin being considered as the model of physiol. zinc metallopeptidases, allows inhibitor-recognition modes for other peptidases, such as angiotensin converting enzyme and neutral endopeptidase, to be proposed and opens interesting possibilities for the design of new classes of inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS0RBz62580rVg90H21EOLACvtfcHk0lg4N2i4IzxZNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXls1ajtrY%253D&md5=92d076d0ba415a404eed4d22ef3c9d7d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fbi991043z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi991043z%26sid%3Dliteratum%253Aachs%26aulast%3DGaucher%26aufirst%3DJ.%2BF.%26aulast%3DSelkti%26aufirst%3DM.%26aulast%3DTiraboschi%26aufirst%3DG.%26aulast%3DPrange%26aufirst%3DT.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26aulast%3DTomas%26aufirst%3DA.%26aulast%3DFournie-Zaluski%26aufirst%3DM.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520alpha-mercaptoacyldipeptides%2520in%2520the%2520thermolysin%2520active%2520site%253A%2520structural%2520parameters%2520for%2520a%2520Zn%2520monodentation%2520or%2520bidentation%2520in%2520metalloendopeptidases%26jtitle%3DBiochemistry%26date%3D1999%26volume%3D38%26spage%3D12569%26epage%3D12576%26doi%3D10.1021%2Fbi991043z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghai, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMartin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohacek, R.</span></span> <span> </span><span class="NLM_article-title">Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1021/jm960583g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960583g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVSksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=506-514&author=G.+M.+Ksanderauthor=R.+de+Jesusauthor=A.+Yuanauthor=R.+D.+Ghaiauthor=C.+McMartinauthor=R.+Bohacek&title=Meta-substituted+benzofused+macrocyclic+lactams+as+zinc+metalloprotease+inhibitors&doi=10.1021%2Fjm960583g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Meta-Substituted Benzofused Macrocyclic Lactams as Zinc Metalloprotease Inhibitors</span></div><div class="casAuthors">Ksander, Gary M.; de Jesus, Reynalda; Yuan, Andrew; Ghai, Raj D.; McMartin, Colin; Bohacek, Regine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">506-514</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and biochem. profile of meta-substituted benzofused macrocyclic lactams are described.  The meta-substituted benzofused macrocyclic lactams were designed to have a degree of flexibility allowing the amide bond to occupy two completely different conformations while maintaining sufficient rigidity to allow for strong interaction between enzyme and inhibitor.  Using TFIT, a novel mol. superimposition program, it was shown that the meta analogs could be readily superimposed onto our ACE inhibitor template whereas no low-energy superimpositions of the ortho-substituted macrocycles could be found.  Unlike the ortho-substituted benzofused macrocyclic lactams described in a previous paper which are selective NEP inhibitors, the meta-substituted compds. are dual inhibitors of both NEP and ACE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzRsksrVMvXrVg90H21EOLACvtfcHk0lg4N2i4IzxZNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVSksr0%253D&md5=f74c5dbf907c905f15ce359f7817ad21</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm960583g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960583g%26sid%3Dliteratum%253Aachs%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3Dde%2BJesus%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DA.%26aulast%3DGhai%26aufirst%3DR.%2BD.%26aulast%3DMcMartin%26aufirst%3DC.%26aulast%3DBohacek%26aufirst%3DR.%26atitle%3DMeta-substituted%2520benzofused%2520macrocyclic%2520lactams%2520as%2520zinc%2520metalloprotease%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D506%26epage%3D514%26doi%3D10.1021%2Fjm960583g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghai, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMartin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohacek, R.</span></span> <span> </span><span class="NLM_article-title">Ortho-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1021/jm960582o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960582o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVSksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=495-505&author=G.+M.+Ksanderauthor=R.+de+Jesusauthor=A.+Yuanauthor=R.+D.+Ghaiauthor=A.+Trapaniauthor=C.+McMartinauthor=R.+Bohacek&title=Ortho-substituted+benzofused+macrocyclic+lactams+as+zinc+metalloprotease+inhibitors&doi=10.1021%2Fjm960582o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Ortho-Substituted Benzofused Macrocyclic Lactams as Zinc Metalloprotease Inhibitors</span></div><div class="casAuthors">Ksander, Gary M.; de Jesus, Reynalda; Yuan, Andrew; Ghai, R. D.; Trapani, A.; McMartin, Colin; Bohacek, Regine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">495-505</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design and prepn. of ortho-substituted benzofused macrocyclic lactams are described.  The benzofused macrocyclic lactams were designed as neutral endopeptidase 24.11 (NEP) inhibitors.  Docking studies were carried out in a model of thermolysin (TLN) using the MACROMODEL and QXP modeling programs to select suitable ring sizes.  These studies predicted that the 11-, 12-, and 13-membered ring macrocyclic lactams would be active in both enzymes TLN and NEP.  Good predictability of exptl. results, within this series, of binding to thermolysin and to a lesser extent to NEP was obsd.  A visual comparison, docked at the active site of TLN, is presented for thiorphan, a 10-membered ring macrocycle and an 11-membered ring benzofused macrocyclic lactam.  Potent inhibition of both NEP and thermolysin was obtained.  The 11-membered ring macrocycle, 2,3,4,5,6,7,8,9-octahydro-2(S)-mercapto-3-oxo-1H-4-benzazacycloundecine-5(S)-carboxylic acid, is the most potent inhibitor from this series of compds. (TLN IC50 = 68 nM; NEP IC50 = 0.9 nM).  The effects of prodrug benzyl 2(R)-[(acetylthio)methyl]-2,3,4,5,6,7,8,9,10,11-decahydro-2-ox-1H-4-benzazacyclotridecine-5(S)-carboxylate administered at 10 mg/kg po on plasma atrial natriuretic peptide (ANP) levels in conscious rats was greater than 200% over a 4 h period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKuBNgiRCKeLVg90H21EOLACvtfcHk0ljOsS9R3Hw2tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVSksrw%253D&md5=bf9bddcbf267a128645d8c1f3a1e155b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm960582o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960582o%26sid%3Dliteratum%253Aachs%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3Dde%2BJesus%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DA.%26aulast%3DGhai%26aufirst%3DR.%2BD.%26aulast%3DTrapani%26aufirst%3DA.%26aulast%3DMcMartin%26aufirst%3DC.%26aulast%3DBohacek%26aufirst%3DR.%26atitle%3DOrtho-substituted%2520benzofused%2520macrocyclic%2520lactams%2520as%2520zinc%2520metalloprotease%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D495%26epage%3D505%26doi%3D10.1021%2Fjm960582o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiraboschi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jullian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thery, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonczak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournie-Zaluski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span> <span> </span><span class="NLM_article-title">A three-dimensional construction of the active site (region 507-749) of human neutral endopeptidase (EC.3.4.24.11)</span>. <i>Protein Eng., Des. Sel.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1093/protein/12.2.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1093%2Fprotein%2F12.2.141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1999&pages=141-149&author=G.+Tiraboschiauthor=N.+Jullianauthor=V.+Theryauthor=S.+Antonczakauthor=M.+C.+Fournie-Zaluskiauthor=B.+P.+Roques&title=A+three-dimensional+construction+of+the+active+site+%28region+507-749%29+of+human+neutral+endopeptidase+%28EC.3.4.24.11%29&doi=10.1093%2Fprotein%2F12.2.141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2F12.2.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252F12.2.141%26sid%3Dliteratum%253Aachs%26aulast%3DTiraboschi%26aufirst%3DG.%26aulast%3DJullian%26aufirst%3DN.%26aulast%3DThery%26aufirst%3DV.%26aulast%3DAntonczak%26aufirst%3DS.%26aulast%3DFournie-Zaluski%26aufirst%3DM.%2BC.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26atitle%3DA%2520three-dimensional%2520construction%2520of%2520the%2520active%2520site%2520%2528region%2520507-749%2529%2520of%2520human%2520neutral%2520endopeptidase%2520%2528EC.3.4.24.11%2529%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D1999%26volume%3D12%26spage%3D141%26epage%3D149%26doi%3D10.1093%2Fprotein%2F12.2.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaspard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhenc-Gelas, F.</span></span> <span> </span><span class="NLM_article-title">Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">9496</span>– <span class="NLM_lpage">9503</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=7683654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK3sXktVekt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=9496-9503&author=E.+Jaspardauthor=L.+Weiauthor=F.+Alhenc-Gelas&title=Differences+in+the+properties+and+enzymatic+specificities+of+the+two+active+sites+of+angiotensin+I-converting+enzyme+%28kininase+II%29.+Studies+with+bradykinin+and+other+natural+peptides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Differences in the properties and enzymic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides</span></div><div class="casAuthors">Jaspard, Emmanuel; Wei, Lei; Alhenc-Gelas, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9496-503</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Angiotensin I-converting enzyme (ACE, E.C.3.4.15.1) has been recently shown to contain two very similar domains, each of which bears a functional active site hydrolyzing Hip-His-Leu or angiotensin I (AI).  The substrate specificity of the two active sites of ACE was compared using wild-type recombinant ACE and mutants, where one active site is suppressed by deletion or inactivated by mutations of 2 histidines coordinating an essential zinc atom.  Both active sites converted bradykinin (BK) to BK1-7 and BK1-5 with similar kinetics and with Kmapp at least 30 times lower and kcat/Kmapp 10 times higher than for AI.  The carboxyl-terminal active site, but not the amino-terminal site, was activated by chloride; however, chloride activation was minimal compared with AI.  Both domains also hydrolyzed substance P and cleaved a carboxyl-terminal protected dipeptide and tripeptide.  The carboxyl-terminal active site was more readily activated by chloride and hydrolyzed substance P faster.  Luteinizing-hormone releasing hormone was hydrolyzed by both active sites, but hydrolysis by the amino-terminal active site was faster.  It performed the endoproteolytic amino-terminal cleavage of this peptide at least 30 times faster than the carboxyl-terminal active site.  Both active sites cleaved a carboxyl-terminal tripeptide from LH-releasing hormone.  Thus, both active sites of ACE possess dipeptidyl carboxypeptidase and endopeptidase activities.  However, only the carboxyl-terminal active site can undergo a chloride-induced alteration that greatly enhances the hydrolysis of AI or substance P, and the amino-terminal active site possesses an unusual amino-terminal endoproteolytic specificity for a natural peptide.  This suggests physiol. important differences between the subsites of the two active centers, and different substrate specificity, despite the high degree of sequence homol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDfIaBdRuIgLVg90H21EOLACvtfcHk0ljOsS9R3Hw2tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVekt7Y%253D&md5=472186440cc10fbf168a059ef314462c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJaspard%26aufirst%3DE.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DAlhenc-Gelas%26aufirst%3DF.%26atitle%3DDifferences%2520in%2520the%2520properties%2520and%2520enzymatic%2520specificities%2520of%2520the%2520two%2520active%2520sites%2520of%2520angiotensin%2520I-converting%2520enzyme%2520%2528kininase%2520II%2529.%2520Studies%2520with%2520bradykinin%2520and%2520other%2520natural%2520peptides%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D9496%26epage%3D9503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corradi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitapi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">The structure of testis angiotensin-converting enzyme in complex with the C-domain specific inhibitor RXPA380</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5473</span>– <span class="NLM_lpage">5478</span>, <span class="refDoi"> DOI: 10.1021/bi700275e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi700275e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1Kntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=5473-5478&author=H.+R.+Corradiauthor=I.+Chitapiauthor=B.+T.+Sewellauthor=D.+Georgiadisauthor=V.+Diveauthor=E.+D.+Sturrockauthor=K.+R.+Acharya&title=The+structure+of+testis+angiotensin-converting+enzyme+in+complex+with+the+C-domain+specific+inhibitor+RXPA380&doi=10.1021%2Fbi700275e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The Structure of Testis Angiotensin-Converting Enzyme in Complex with the C Domain-Specific Inhibitor RXPA380</span></div><div class="casAuthors">Corradi, Hazel R.; Chitapi, Itai; Sewell, B. Trevor; Georgiadis, Dimitris; Dive, Vincent; Sturrock, Edward D.; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5473-5478</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Angiotensin I-converting enzyme (ACE) is central to the regulation of the renin-angiotensin system and is a key therapeutic target for combating hypertension and related cardiovascular diseases.  Currently available drugs bind both active sites of its two homologous domains, although it is now understood that these domains function differently in vivo.  The recently solved crystal structures of both domains (N and C) open the door to new domain-specific inhibitor design, taking advantage of the differences between these two large active sites.  Here we present the first crystal structure at a resoln. of 2.25 Å of testis ACE (identical to the C domain of somatic ACE) with the highly C-domain-specific phosphinic inhibitor, RXPA380.  Testis ACE retains the same conformation as seen in previously detd. inhibitor complexes, but the RXPA380 central backbone conformation is more similar to that seen for the inhibitor captopril than enalaprilat.  The RXPA380 mol. occupies more subsites of the testis ACE active site than the previously detd. inhibitors and possesses bulky moieties that extend into the S2' and S2 subsites.  Thus the high affinity of RXPA380 for the testis ACE/somatic ACE C domain is explained by the interaction of these bulky moieties with residues unique to these domains, specifically Phe391, Val379, and Val380, that are not found in the N domain.  The characterization of the extended active site and the binding of a potent C-domain-selective inhibitor provide the first structural data for the design of truly domain-specific pharmacophores.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorNz6kJtEO_7Vg90H21EOLACvtfcHk0ljOsS9R3Hw2tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1Kntb8%253D&md5=804714644ac98552f2f877a37a2ed371</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fbi700275e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi700275e%26sid%3Dliteratum%253Aachs%26aulast%3DCorradi%26aufirst%3DH.%2BR.%26aulast%3DChitapi%26aufirst%3DI.%26aulast%3DSewell%26aufirst%3DB.%2BT.%26aulast%3DGeorgiadis%26aufirst%3DD.%26aulast%3DDive%26aufirst%3DV.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DThe%2520structure%2520of%2520testis%2520angiotensin-converting%2520enzyme%2520in%2520complex%2520with%2520the%2520C-domain%2520specific%2520inhibitor%2520RXPA380%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D5473%26epage%3D5478%26doi%3D10.1021%2Fbi700275e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jullien, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makritis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yiotakis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, V.</span></span> <span> </span><span class="NLM_article-title">Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1021/jm9010803</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9010803" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlymtbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=208-220&author=N.+Jullienauthor=A.+Makritisauthor=D.+Georgiadisauthor=F.+Beauauthor=A.+Yiotakisauthor=V.+Dive&title=Phosphinic+tripeptides+as+dual+angiotensin-converting+enzyme+C-domain+and+endothelin-converting+enzyme-1+inhibitors&doi=10.1021%2Fjm9010803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphinic Tripeptides as Dual Angiotensin-Converting Enzyme C-Domain and Endothelin-Converting Enzyme-1 Inhibitors</span></div><div class="casAuthors">Jullien, Nicolas; Makritis, Anastasios; Georgiadis, Dimitris; Beau, Fabrice; Yiotakis, Athanasios; Dive, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">208-220</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of phosphinic inhibitors able to interact with both angiotensin-converting enzyme (ACE) C-domain and endothelin-converting enzyme-1 (ECE-1), while sparing neprilysin (NEP), has been developed.  The most potent and selective inhibitor in this series (compd. 8F2) displays Ki values of 0.65 nM, 150 nM, 14 nM and 6.7 μM toward somatic ACE C-domain, ACE N-domain, ECE-1, and NEP, resp.  Remarkably, in this series, the inhibitor's ability to discriminate between ECE-1 and NEP was obsd. to depend on the stereochem. of the residue present in the inhibitor's P1' position.  After iv administration, compd. 8F2 (10 mg/kg) lowered mean arterial blood pressure by 24 ± 2 mmHg in spontaneously hypertensive rats, as compared with controls.  Mixed ACE/ECE-1 inhibitor may lead to a new generation of vasopeptide inhibitors that should reduce the levels of angiotensin-II and endothelin-1, without interfering with bradykinin cleavage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hR7yZw_SuLVg90H21EOLACvtfcHk0ljJggsozy7SSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlymtbrE&md5=8669922da99511db6fdbb67b7660aa5c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm9010803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9010803%26sid%3Dliteratum%253Aachs%26aulast%3DJullien%26aufirst%3DN.%26aulast%3DMakritis%26aufirst%3DA.%26aulast%3DGeorgiadis%26aufirst%3DD.%26aulast%3DBeau%26aufirst%3DF.%26aulast%3DYiotakis%26aufirst%3DA.%26aulast%3DDive%26aufirst%3DV.%26atitle%3DPhosphinic%2520tripeptides%2520as%2520dual%2520angiotensin-converting%2520enzyme%2520C-domain%2520and%2520endothelin-converting%2520enzyme-1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D208%26epage%3D220%26doi%3D10.1021%2Fjm9010803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">High resolution crystal structure of substrate-free human neprilysin</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2018.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2Fj.jsb.2018.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=29906506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2jsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2018&pages=19-25&author=S.+Mossauthor=V.+Subramanianauthor=K.+R.+Acharya&title=High+resolution+crystal+structure+of+substrate-free+human+neprilysin&doi=10.1016%2Fj.jsb.2018.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">High resolution crystal structure of substrate-free human neprilysin</span></div><div class="casAuthors">Moss, Stephen; Subramanian, Vasanta; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Neprilysin is a transmembrane M13 zinc metalloprotease responsible for the degrdn. of several biol. active peptides including insulin, enkephalin, substance P, bradykinin, endothelin-1, neurotensin and amyloid-β.  The protein has received attention for its role in modulating blood pressure responses with its inhibition producing an antihypertensive response.  To date, several inhibitor bound crystal structures of the human neprilysin extracellular domain have been detd., but, a structure free of bound inhibitor or substrate has yet to be reported.  Here, we report the first crystal structure free of substrate or inhibitor for the extracellular catalytic domain of human neprilysin at 1.9 Å resoln.  This structure will provide a ref. point for comparisons to future inhibitor or substrate bound structures.  The neprilysin structure also reveals that a closed protein conformation can be adopted in protein crystals absent of bound substrate or inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUuVQEv0Psg7Vg90H21EOLACvtfcHk0ljJggsozy7SSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2jsr7M&md5=6f1c9c2b31964684decb80bb4c2eea32</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2018.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2018.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DV.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DHigh%2520resolution%2520crystal%2520structure%2520of%2520substrate-free%2520human%2520neprilysin%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2018%26volume%3D204%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.jsb.2018.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waterman, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildea, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkhurst, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewster, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauter, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, G.</span></span> <span> </span><span class="NLM_article-title">Diffraction-geometry refinement in the DIALS framework</span>. <i>Acta Crystallogr., Sect. D: Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1107/S2059798316002187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS2059798316002187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFSkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=558-575&author=D.+G.+Watermanauthor=G.+Winterauthor=R.+J.+Gildeaauthor=J.+M.+Parkhurstauthor=A.+S.+Brewsterauthor=N.+K.+Sauterauthor=G.+Evans&title=Diffraction-geometry+refinement+in+the+DIALS+framework&doi=10.1107%2FS2059798316002187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Diffraction-geometry refinement in the DIALS framework</span></div><div class="casAuthors">Waterman, David G.; Winter, Graeme; Gildea, Richard J.; Parkhurst, James M.; Brewster, Aaron S.; Sauter, Nicholas K.; Evans, Gwyndaf</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Structural Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">558-575</span>CODEN:
                <span class="NLM_cas:coden">ACSDAD</span>;
        ISSN:<span class="NLM_cas:issn">2059-7983</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Rapid data collection and modern computing resources provide the opportunity to revisit the task of optimizing the model of diffraction geometry prior to integration.  A comprehensive description is given of new software that builds upon established methods by performing a single global refinement procedure, utilizing a smoothly varying model of the crystal lattice where appropriate.  This global refinement technique extends to multiple data sets, providing useful constraints to handle the problem of correlated parameters, particularly for small wedges of data.  Examples of advanced uses of the software are given and the design is explained in detail, with particular emphasis on the flexibility and extensibility it entails.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmCZHkbbl6bVg90H21EOLACvtfcHk0ljJggsozy7SSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFSkurs%253D&md5=0041260941cd2e0581c8a1db0b5add97</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1107%2FS2059798316002187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2059798316002187%26sid%3Dliteratum%253Aachs%26aulast%3DWaterman%26aufirst%3DD.%2BG.%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DGildea%26aufirst%3DR.%2BJ.%26aulast%3DParkhurst%26aufirst%3DJ.%2BM.%26aulast%3DBrewster%26aufirst%3DA.%2BS.%26aulast%3DSauter%26aufirst%3DN.%2BK.%26aulast%3DEvans%26aufirst%3DG.%26atitle%3DDiffraction-geometry%2520refinement%2520in%2520the%2520DIALS%2520framework%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Struct.%2520Biol.%26date%3D2016%26volume%3D72%26spage%3D558%26epage%3D575%26doi%3D10.1107%2FS2059798316002187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span> <span> </span><span class="NLM_article-title">How good are my data and what is the resolution?</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1204</span>– <span class="NLM_lpage">1214</span>, <span class="refDoi"> DOI: 10.1107/S0907444913000061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444913000061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=23793146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVejsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=1204-1214&author=P.+R.+Evansauthor=G.+N.+Murshudov&title=How+good+are+my+data+and+what+is+the+resolution%3F&doi=10.1107%2FS0907444913000061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">How good are my data and what is the resolution?</span></div><div class="casAuthors">Evans, Philip R.; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1204-1214</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Following integration of the obsd. diffraction spots, the process of  data redn.' initially aims to det. the point-group symmetry of the data and the likely space group.  This can be performed with the program POINTLESS.  The scaling program then puts all the measurements on a common scale, avs. measurements of symmetry-related reflections (using the symmetry detd. previously) and produces many statistics that provide the first important measures of data quality.  A new scaling program, AIMLESS, implements scaling models similar to those in SCALA but adds some addnl. analyses.  From the analyses, a no. of decisions can be made about the quality of the data and whether some measurements should be discarded.  The effective  resoln.' of a data set is a difficult and possibly contentious question (particularly with referees of papers) and this is discussed in the light of tests comparing the data-processing statistics with trials of refinement against obsd. and simulated data, and automated model-building and comparison of maps calcd. with different resoln. limits.  These trials show that adding weak high-resoln. data beyond the commonly used limits may make some improvement and does no harm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreOyPAR8GLBrVg90H21EOLACvtfcHk0lgdnPuqePsgOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVejsL8%253D&md5=3f649426c21e9d423f94ef8d7c568233</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1107%2FS0907444913000061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444913000061%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DHow%2520good%2520are%2520my%2520data%2520and%2520what%2520is%2520the%2520resolution%253F%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2013%26volume%3D69%26spage%3D1204%26epage%3D1214%26doi%3D10.1107%2FS0907444913000061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Collaborative
Computational Project Number 4</span> <span> </span><span class="NLM_article-title">The CCP4 suite: programs for protein crystallography</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1107/S0907444994003112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=15299374" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=760-763&author=Collaborative%0AComputational+Project+Number+4&title=The+CCP4+suite%3A+programs+for+protein+crystallography&doi=10.1107%2FS0907444994003112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520CCP4%2520suite%253A%2520programs%2520for%2520protein%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2FS0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lgdnPuqePsgOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span> <span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lgdnPuqePsgOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkoczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0liPvld2D7L-pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0liPvld2D7L-pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immormino, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom structure validation for macromolecular crystallography</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1107/S0907444909042073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444909042073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=20057044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=12-21&author=V.+B.+Chenauthor=W.+B.+Arendallauthor=J.+J.+Headdauthor=D.+A.+Keedyauthor=R.+M.+Immorminoauthor=G.+J.+Kapralauthor=L.+W.+Murrayauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+structure+validation+for+macromolecular+crystallography&doi=10.1107%2FS0907444909042073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom structure validation for macromolecular crystallography</span></div><div class="casAuthors">Chen, Vincent B.; Arendall, W. Bryan, III; Headd, Jeffrey J.; Keedy, Daniel A.; Immormino, Robert M.; Kapral, Gary J.; Murray, Laura W.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MolProbity is a structure-validation web service that provides broad-spectrum solidly based evaluation of model quality at both the global and local levels for both proteins and nucleic acids.  It relies heavily on the power and sensitivity provided by optimized hydrogen placement and all-atom contact anal., complemented by updated versions of covalent-geometry and torsion-angle criteria.  Some of the local corrections can be performed automatically in MolProbity and all of the diagnostics are presented in chart and graphical forms that help guide manual rebuilding.  X-ray crystallog. provides a wealth of biol. important mol. data in the form of at. three-dimensional structures of proteins, nucleic acids and increasingly large complexes in multiple forms and states.  Advances in automation, in everything from crystn. to data collection to phasing to model building to refinement, have made solving a structure using crystallog. easier than ever.  However, despite these improvements, local errors that can affect biol. interpretation are widespread at low resoln. and even high-resoln. structures nearly all contain at least a few local errors such as Ramachandran outliers, flipped branched protein side chains and incorrect sugar puckers.  It is crit. both for the crystallographer and for the end user that there are easy and reliable methods to diagnose and correct these sorts of errors in structures.  MolProbity is the authors' contribution to helping solve this problem and this article reviews its general capabilities, reports on recent enhancements and usage, and presents evidence that the resulting improvements are now beneficially affecting the global database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIjgsh59dO-7Vg90H21EOLACvtfcHk0liPvld2D7L-pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D&md5=b5fc7574f43f01dd6e43c3663ca4f779</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444909042073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909042073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520structure%2520validation%2520for%2520macromolecular%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D12%26epage%3D21%26doi%3D10.1107%2FS0907444909042073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Presenting your structures: the CCP4mg molecular-graphics software</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">386</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1107/S0907444911007281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444911007281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=21460457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=386-394&author=S.+McNicholasauthor=E.+Pottertonauthor=K.+S.+Wilsonauthor=M.+E.+Noble&title=Presenting+your+structures%3A+the+CCP4mg+molecular-graphics+software&doi=10.1107%2FS0907444911007281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Presenting your structures: The CCP4mg molecular-graphics software</span></div><div class="casAuthors">McNicholas, S.; Potterton, E.; Wilson, K. S.; Noble, M. E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">386-394</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">CCP4mg is a mol.-graphics program that is designed to give rapid access to both straightforward and complex static and dynamic representations of macromol. structures.  It has recently been updated with a new interface that provides more sophisticated atom-selection options and a wizard to facilitate the generation of complex scenes.  These scenes may contain a mixt. of coordinate-derived and abstr. graphical objects, including text objects, arbitrary vectors, geometric objects and imported images, which can enhance a picture and eliminate the need for subsequent editing.  Scene descriptions can be saved to file and transferred to other mols.  Here, the substantially enhanced version 2 of the program, with a new underlying GUI toolkit, is described.  A built-in rendering module produces publication-quality images.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdtflrxrILlbVg90H21EOLACvtfcHk0ljcxmdBlknuLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqurw%253D&md5=d96403a39bc723a66f11a730f81f76c3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007281%26sid%3Dliteratum%253Aachs%26aulast%3DMcNicholas%26aufirst%3DS.%26aulast%3DPotterton%26aufirst%3DE.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DPresenting%2520your%2520structures%253A%2520the%2520CCP4mg%2520molecular-graphics%2520software%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D386%26epage%3D394%26doi%3D10.1107%2FS0907444911007281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laskowski, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swindells, M. B.</span></span> <span> </span><span class="NLM_article-title">LigPlot+: multiple ligand-protein interaction diagrams for drug discovery</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2778</span>– <span class="NLM_lpage">2786</span>, <span class="refDoi"> DOI: 10.1021/ci200227u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200227u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1KjtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2778-2786&author=R.+A.+Laskowskiauthor=M.+B.+Swindells&title=LigPlot%2B%3A+multiple+ligand-protein+interaction+diagrams+for+drug+discovery&doi=10.1021%2Fci200227u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery</span></div><div class="casAuthors">Laskowski, Roman A.; Swindells, Mark B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2778-2786</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe a graphical system for automatically generating multiple 2D diagrams of ligand-protein interactions from 3D coordinates.  The diagrams portray the hydrogen-bond interaction patterns and hydrophobic contacts between the ligand(s) and the main-chain or side-chain elements of the protein.  The system is able to plot, in the same orientation, related sets of ligand-protein interactions.  This facilitates popular research tasks, such as analyzing a series of small mols. binding to the same protein target, a single ligand binding to homologous proteins, or the completely general case where both protein and ligand change.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYuWvYH7Nel7Vg90H21EOLACvtfcHk0ljcxmdBlknuLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1KjtrzP&md5=576e59ad4f0c4304d01c6c80301ecf39</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fci200227u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200227u%26sid%3Dliteratum%253Aachs%26aulast%3DLaskowski%26aufirst%3DR.%2BA.%26aulast%3DSwindells%26aufirst%3DM.%2BB.%26atitle%3DLigPlot%252B%253A%2520multiple%2520ligand-protein%2520interaction%2520diagrams%2520for%2520drug%2520discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2778%26epage%3D2786%26doi%3D10.1021%2Fci200227u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rene M.  Koenigs</span>. </span><span class="cited-content_cbyCitation_article-title">7-Membered rings made easy. </span><span class="cited-content_cbyCitation_journal-name">Chem Catalysis</span><span> <strong>2021,</strong> <em>1 </em>
                                    (1)
                                     , 18-19. <a href="https://doi.org/10.1016/j.checat.2021.03.009" title="DOI URL">https://doi.org/10.1016/j.checat.2021.03.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.checat.2021.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.checat.2021.03.009%26sid%3Dliteratum%253Aachs%26jtitle%3DChem%2520Catalysis%26atitle%3D7-Membered%252Brings%252Bmade%252Beasy%26aulast%3DKoenigs%26aufirst%3DRene%2BM.%26date%3D2021%26volume%3D1%26issue%3D1%26spage%3D18%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jayanti B.  Hirani</span>, <span class="hlFld-ContribAuthor ">Mayank  Pandya</span>, <span class="hlFld-ContribAuthor ">Suresh B.  Koradiya</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Spectral Analysis and Antibacterial Screening of Tetracyclic Thiazepine Based
Pyrazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>5 </em>
                                    (4)
                                     , 283-288. <a href="https://doi.org/10.14233/ajomc.2020.AJOMC-P281" title="DOI URL">https://doi.org/10.14233/ajomc.2020.AJOMC-P281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.14233/ajomc.2020.AJOMC-P281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.14233%2Fajomc.2020.AJOMC-P281%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252BSpectral%252BAnalysis%252Band%252BAntibacterial%252BScreening%252Bof%252BTetracyclic%252BThiazepine%252BBased%252BPyrazole%252BDerivatives%26aulast%3DHirani%26aufirst%3DJayanti%2BB.%26date%3D2021%26date%3D2020%26volume%3D5%26issue%3D4%26spage%3D283%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">François  Marceau</span>, <span class="hlFld-ContribAuthor ">Hélène  Bachelard</span>, <span class="hlFld-ContribAuthor ">Xavier  Charest-Morin</span>, <span class="hlFld-ContribAuthor ">Jacques  Hébert</span>, <span class="hlFld-ContribAuthor ">Georges E.  Rivard</span>. </span><span class="cited-content_cbyCitation_article-title">In Vitro Modeling of Bradykinin-Mediated Angioedema States. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (9)
                                     , 201. <a href="https://doi.org/10.3390/ph13090201" title="DOI URL">https://doi.org/10.3390/ph13090201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13090201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13090201%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DIn%252BVitro%252BModeling%252Bof%252BBradykinin-Mediated%252BAngioedema%252BStates%26aulast%3DMarceau%26aufirst%3DFran%25C3%25A7ois%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D9%26spage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edward D.  Sturrock</span>, <span class="hlFld-ContribAuthor ">K. Ravi  Acharya</span>. </span><span class="cited-content_cbyCitation_article-title">ACE Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-11. <a href="https://doi.org/10.1007/978-3-030-21573-6_1-1" title="DOI URL">https://doi.org/10.1007/978-3-030-21573-6_1-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-21573-6_1-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-21573-6_1-1%26sid%3Dliteratum%253Aachs%26atitle%3DACE%252BInhibitors%26aulast%3DSturrock%26aufirst%3DEdward%2BD.%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D11%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DEncyclopedia%252Bof%252BMolecular%252BPharmacology%26aulast%3DOffermanns%26aufirst%3DStefan%26date%3D2020%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic overlay representation showing the subdomain arrangement of the omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>), and samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>) complex structures colored in green, blue, and orange, respectively. Active site zinc ions are depicted as spheres, inhibitor molecules as sticks, and the glycosylation sites as glycoblocks (labeled with the corresponding asparagine residue number). Loop regions have been shortened for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic representation of inhibitors bound to NEP overlayed with the final 2mFo–DFc (blue, contoured at 1σ level) electron density map and the mFo–DFc (green, contoured at 3σ level) electron density omit map for (A) omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), (B) sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>), and (C) samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>) complexes. The zinc ion is shown as a lilac sphere with the inhibitors shown as sticks. α-Helices and β-strands are shown in rose and dark cyan, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. LigPlot representation of the binding site interactions of (A) omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), (B) sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>), and (C) samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>) complexes. Hydrogen-bond/electrostatic interactions are shown in green, hydrophobic interactions in red, and water molecules as red spheres. Residues solely involved in hydrophobic interactions are represented by red, semicircular symbols. The inhibitor moieties are given their “P” number based on the enzyme S-subsite to which they bind.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Close-up views of (A) omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), (B) sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>), and (C) samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVY">6XVY</a>) binding sites showing hydrogen-bond/electrostatic interactions (dashed lines). The inhibitor molecules are depicted as fat sticks, protein chain as a cartoon with α-helices and β-strands in rose and dark cyan, respectively, zinc ion as lilac sphere, and water molecules as red spheres. The inhibitor moieties are given their P number based on the enzyme S-subsite to which they bind.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>), and samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>) binding sites colored green, blue, and orange, respectively. Inhibitors are depicted as sticks and zinc ions as spheres. (A) Overlay of inhibitors from the crystal structures with the subsite binding pockets indicated. (B) Close-up overlay view of the S<sub>1</sub>′ pocket. (C) Close-up overlay view of the S<sub>2</sub>′ pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison of omapatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), sampatrilat–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVP">6SVP</a>), and samASP–NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>) binding sites with native NEP and previous inhibitor–NEP complex structures. Structures of native NEP, LBQ657–NEP, thiorphan–NEP, and phosphoramidon–NEP used PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GID">6GID</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JMY">5JMY</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V48">5V48</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1DMT">1DMT</a>, respectively. (A, B) Two views of the S<sub>1</sub>′ and S<sub>2</sub>′ subsites with residues from these subsites involved in interacting with the ligands shown in only one of the views for clarity. Omapatrilat–NEP, sampatrilat–NEP, samASP–NEP, native NEP, phosphoramidon–NEP, thiorphan–NEP, and LBQ657–NEP are shown in green, blue, orange, gray, brown, magenta, and yellow, respectively. (C) Chemical structures of phosphoramidon, thiorphan, and LBQ657. (D–F) LigPlot representation of the binding site interactions of phosphoramidon–NEP, thiorphan–NEP, and LBQ657–NEP complexes. Hydrogen-bond/electrostatic interactions are shown in green, hydrophobic interactions in red, and water molecules as red spheres. Residues solely involved in hydrophobic interactions are represented by red, semicircular symbols. The inhibitor moieties are given their P number based on the enzyme S-subsite to which they bind. Note that the structure of thiorphan is in complex with rabbit NEP with residues having a slightly different numbering.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. LigPlot representation of the binding site interactions of omapatrilat–nACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5X">6H5X</a>), omapatrilat–cACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5W">6H5W</a>), sampatrilat–nACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9V">6F9V</a>), sampatrilat–cACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9T">6F9T</a>), samASP–nACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9R">6F9R</a>), and samASP–cACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9U">6F9U</a>) complexes. Hydrogen-bond/electrostatic interactions are shown in green, hydrophobic interactions in red, and water molecules as red spheres. Residues solely involved in hydrophobic interactions are represented by red, semicircular symbols. The inhibitor moieties are given their P number based on the enzyme S-subsite to which they bind.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/medium/jm0c00441_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Comparison of inhibitor binding sites between NEP and ACE domains. The zinc ion and its binding residues were used to overlay the structures. (A) Omapatrilat binding site with NEP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>), nACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5X">6H5X</a>), and cACE (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5W">6H5W</a>) structures shown in green, magenta, and gray, respectively. NEP, nACE, and cACE binding sites for (B) sampatrilat (blue PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>, magenta PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9V">6F9V</a>, and gray PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9T">6F9T</a>) and (C) samASP (orange PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>, brown PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9R">6F9R</a>, and yellow PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9U">6F9U</a>). The subsite pockets for NEP and ACE domains are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00441/20200520/images/large/jm0c00441_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00441&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egan, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjeldsen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancia, G.</span></span> <span> </span><span class="NLM_article-title">The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard?</span>. <i>J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1148</span>– <span class="NLM_lpage">1153</span>, <span class="refDoi"> DOI: 10.1097/HJH.0000000000002021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1097%2FHJH.0000000000002021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=30624370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1Shu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=1148-1153&author=B.+M.+Eganauthor=S.+E.+Kjeldsenauthor=G.+Grassiauthor=M.+Eslerauthor=G.+Mancia&title=The+global+burden+of+hypertension+exceeds+1.4+billion+people%3A+should+a+systolic+blood+pressure+target+below+130+become+the+universal+standard%3F&doi=10.1097%2FHJH.0000000000002021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard?</span></div><div class="casAuthors">Egan, Brent M.; Kjeldsen, Sverre E.; Grassi, Guido; Esler, Murray; Mancia, Guiseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1148-1153</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">: In 2010, 1.4 billion people globally had hypertension, with 14% controlled to systolic blood pressure (SBP, mmHg) below 140, which contributes to 18 million cardiovascular deaths annually.  Recent hypertension guidelines endorsed SBP targets below 130 or lower for all or some hypertensive patients to reduce cardiovascular events (CVEs) more than the prior SBP target less than 140.  In 2016, the Australian Guideline strongly recommended target SBP below 120 for adults at very high risk for CVE or aged above 75 years.  In 2017 and 2018, the Canadian Guideline recommended automated office SBP (AOSBP) below 120 in adults at high risk and aged above 75 years (grade B).  In 2017, the US Guideline recommended SBP below 130 for all adults (moderate-to-high risk class I; lower-risk grade IIb).  In 2018, the European Guideline recommended SBP below 140 for all adults, and, if tolerated, a SBP range of 120-129 for adults aged below 65 years and 130-139 for adults aged at least 65 years (class I).  The guidelines were variably influenced by Systolic blood PRessure INTervention trial and meta-analyses indicating fewer CVE when mean in-trial SBP was below 130 vs. above 130.  Clinicians considering lower SBP targets should be aware that: AOSBP preceded by 5-min rest is approx. 10-15mmHg lower than usual office SBP; hypertensive patients with office SBP consistently vs. intermittently below 140 have fewer CVE; benefits of mean office SBP or AOSBP below 120 remain unproven and could increase adverse events.  Clinicians worldwide will do well to control SBP to below 140 in most hypertensive patients on most visits, which should lead to mean in-clinic SBP of 120-129.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrha8SRcuzFo7Vg90H21EOLACvtfcHk0liog8oSSt0f0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1Shu7Y%253D&md5=a7dace6b4ca10c90a545ec3e87c5ef0a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1097%2FHJH.0000000000002021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHJH.0000000000002021%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DB.%2BM.%26aulast%3DKjeldsen%26aufirst%3DS.%2BE.%26aulast%3DGrassi%26aufirst%3DG.%26aulast%3DEsler%26aufirst%3DM.%26aulast%3DMancia%26aufirst%3DG.%26atitle%3DThe%2520global%2520burden%2520of%2520hypertension%2520exceeds%25201.4%2520billion%2520people%253A%2520should%2520a%2520systolic%2520blood%2520pressure%2520target%2520below%2520130%2520become%2520the%2520universal%2520standard%253F%26jtitle%3DJ.%2520Hypertens.%26date%3D2019%26volume%3D37%26spage%3D1148%26epage%3D1153%26doi%3D10.1097%2FHJH.0000000000002021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nussberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cugno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amstutz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicardi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellacani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agostoni, A.</span></span> <span> </span><span class="NLM_article-title">Plasma bradykinin in angio-oedema</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(97)09137-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2FS0140-6736%2897%2909137-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=9734886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK1cXkt1Sls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=1998&pages=1693-1697&author=J.+Nussbergerauthor=M.+Cugnoauthor=C.+Amstutzauthor=M.+Cicardiauthor=A.+Pellacaniauthor=A.+Agostoni&title=Plasma+bradykinin+in+angio-oedema&doi=10.1016%2FS0140-6736%2897%2909137-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma bradykinin in angio-edema</span></div><div class="casAuthors">Nussberger, Juerg; Cugno, Massimo; Amstutz, Catherine; Cicardi, Marco; Pellacani, Andrea; Agostoni, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">9117</span>),
    <span class="NLM_cas:pages">1693-1697</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">Bradykinin is believed to be the main mediator of symptoms in hereditary (HA) and acquired (AA) angio-edema due to C1 esterase inhibitor deficiency, as well as in angio-edema that complicates treatment with inhibitors of angiotensin-converting enzyme (ACE).  Difficulties in the measurement of kinin concns., however, have so far precluded the demonstration of an incontrovertible change in plasma bradykinin concns. in these disorders.  By developing a reliable assay we have been able to follow bradykinin concns. during attacks and during remission in HA and in AA, and also in a patient treated with an ACE-inhibitor.  Liq.-phase extn., high-performance liq. chromatog., and RIA were used for specific measurement of plasma bradykinin concns. in 22 patients with HA and in 22 healthy volunteers of similar age and sex distribution.  Four patients with AA and one hypertensive patient treated with the ACE inhibitor captopril were also studied.  Among the healthy volunteers plasma bradykinin concn. was inversely proportional to age.  The geometric mean plasma bradykinin concn. in the healthy volunteers was 2.2 fmol/mL (SD 2.2), compared with 3.9 fmol/mL (3.7) among patients with HA during remission (p=0.095).  Bradykinin was also high in the patients with AA (10.4 fmol/mL [1.6]).  During acute attacks of edema, in both HA and AA, plasma bradykinin rose to two to 12 times the upper limit of normal.  Infusion of C1-esterase inhibitor (the deficient factor in both HA and AA) immediately lowered bradykinin concns.  In the patient receiving the ACE-inhibitor captopril, bradykinin concn. was very high at 47 fmol/mL during an acute attack of angio-edema, but normal at 3.2 fmol/mL in remission after withdrawal of the drug.  A sensitive method for measurement of plasma bradykinin provided the means to show that concns. of this peptide decrease with age in healthy people.  Although the differences between patients in remission and healthy controls did not reach statistical significance, there were substantial rises in bradykinin during acute attacks of hereditary, acquired, or captopril-induced angio-edema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb4Tr2-3qhp7Vg90H21EOLACvtfcHk0liog8oSSt0f0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt1Sls74%253D&md5=16a3faac0fdb640549c75e1b93e2c3be</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2897%2909137-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252897%252909137-X%26sid%3Dliteratum%253Aachs%26aulast%3DNussberger%26aufirst%3DJ.%26aulast%3DCugno%26aufirst%3DM.%26aulast%3DAmstutz%26aufirst%3DC.%26aulast%3DCicardi%26aufirst%3DM.%26aulast%3DPellacani%26aufirst%3DA.%26aulast%3DAgostoni%26aufirst%3DA.%26atitle%3DPlasma%2520bradykinin%2520in%2520angio-oedema%26jtitle%3DLancet%26date%3D1998%26volume%3D351%26spage%3D1693%26epage%3D1697%26doi%3D10.1016%2FS0140-6736%2897%2909137-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steckelings, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artuc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiehstutz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henz, B. M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions</span>. <i>Acta Derm.-Venereol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1080/000155501317140007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1080%2F000155501317140007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=11800136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlCjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2001&pages=321-325&author=U.+M.+Steckelingsauthor=M.+Artucauthor=T.+Wollschlagerauthor=S.+Wiehstutzauthor=B.+M.+Henz&title=Angiotensin-converting+enzyme+inhibitors+as+inducers+of+adverse+cutaneous+reactions&doi=10.1080%2F000155501317140007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions</span></div><div class="casAuthors">Steckelings, U. M.; Artuc, M.; Wollschlager, T.; Wiehstutz, S.; Henz, B. M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Dermato-Venereologica</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">321-325</span>CODEN:
                <span class="NLM_cas:coden">ADVEA4</span>;
        ISSN:<span class="NLM_cas:issn">0001-5555</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Since adverse effects due to angiotensin-converting enzyme (ACE) inhibitors frequently occur in cutaneous locations, this review summarizes the spectrum of expected and unexpected adverse effects of these drugs, possible assocd. mechanisms, and their basic functions for dermatologists.  ACE inhibitors block the activity of the metalloproteinase ACE by binding to its active site, thus displacing angiotensin I and preventing its conversion to vasopressive angiotensin II.  Furthermore, ACE degrades bradykinin, substance P, enkephalins, and some of the reproductive peptide hormones.  The overall incidence of adverse effects to ACE inhibitors is estd. at 28%, approx. half of which occurs in the skin.  General reactions are 1st-dose hypotension, hyperkalemia, and renal failure.  Cutaneous reactions comprise life-threatening angioedema, pruritus, bullous eruptions, urticaria, other generalized rashes, photosensitivity, and hair loss.  ACE inhibitors thus mimic a broad variety of skin diseases, why these drugs should be thought of when sudden, unexplainable skin eruptions are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGIU4lVFQTD7Vg90H21EOLACvtfcHk0liog8oSSt0f0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlCjsw%253D%253D&md5=cca6e609e38c73f45a66d7861962952e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F000155501317140007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F000155501317140007%26sid%3Dliteratum%253Aachs%26aulast%3DSteckelings%26aufirst%3DU.%2BM.%26aulast%3DArtuc%26aufirst%3DM.%26aulast%3DWollschlager%26aufirst%3DT.%26aulast%3DWiehstutz%26aufirst%3DS.%26aulast%3DHenz%26aufirst%3DB.%2BM.%26atitle%3DAngiotensin-converting%2520enzyme%2520inhibitors%2520as%2520inducers%2520of%2520adverse%2520cutaneous%2520reactions%26jtitle%3DActa%2520Derm.-Venereol.%26date%3D2001%26volume%3D81%26spage%3D321%26epage%3D325%26doi%3D10.1080%2F000155501317140007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messerli, F. H.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1467</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.108.111393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1161%2FHYPERTENSIONAHA.108.111393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=18413486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVahurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1465-1467&author=M.+A.+Weberauthor=F.+H.+Messerli&title=Angiotensin-converting+enzyme+inhibitors+and+angioedema%3A+estimating+the+risk&doi=10.1161%2FHYPERTENSIONAHA.108.111393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk</span></div><div class="casAuthors">Weber, Michael A.; Messerli, Franz H.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1465-1467</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvGFGj7rAMm7Vg90H21EOLACvtfcHk0lh7IwrRxCmdGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVahurg%253D&md5=9c00260a5a4f6db0f679058a5db727e2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.108.111393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.108.111393%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DM.%2BA.%26aulast%3DMesserli%26aufirst%3DF.%2BH.%26atitle%3DAngiotensin-converting%2520enzyme%2520inhibitors%2520and%2520angioedema%253A%2520estimating%2520the%2520risk%26jtitle%3DHypertension%26date%3D2008%26volume%3D51%26spage%3D1465%26epage%3D1467%26doi%3D10.1161%2FHYPERTENSIONAHA.108.111393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arendse, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danser, A. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poglitsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touyz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, J. C.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Cortes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlers, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span> <span> </span><span class="NLM_article-title">Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1124/pr.118.017129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1124%2Fpr.118.017129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=31537750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A280%3ADC%252BB3MngsVamtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=539-570&author=L.+B.+Arendseauthor=A.+H.+J.+Danserauthor=M.+Poglitschauthor=R.+M.+Touyzauthor=J.+C.+Burnettauthor=C.+Llorens-Cortesauthor=M.+R.+Ehlersauthor=E.+D.+Sturrock&title=Novel+therapeutic+approaches+targeting+the+renin-angiotensin+system+and+associated+peptides+in+hypertension+and+heart+failure&doi=10.1124%2Fpr.118.017129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure</span></div><div class="casAuthors">Arendse Lauren B; Danser A H Jan; Poglitsch Marko; Touyz Rhian M; Burnett John C Jr; Llorens-Cortes Catherine; Ehlers Mario R; Sturrock Edward D</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">539-570</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite the success of renin-angiotensin system (RAS) blockade by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT1R) blockers, current therapies for hypertension and related cardiovascular diseases are still inadequate.  Identification of additional components of the RAS and associated vasoactive pathways, as well as new structural and functional insights into established targets, have led to novel therapeutic approaches with the potential to provide improved cardiovascular protection and better blood pressure control and/or reduced adverse side effects.  The simultaneous modulation of several neurohumoral mediators in key interconnected blood pressure-regulating pathways has been an attractive approach to improve treatment efficacy, and several novel approaches involve combination therapy or dual-acting agents.  In addition, increased understanding of the complexity of the RAS has led to novel approaches aimed at upregulating the ACE2/angiotensin-(1-7)/Mas axis to counter-regulate the harmful effects of the ACE/angiotensin II/angiotensin III/AT1R axis.  These advances have opened new avenues for the development of novel drugs targeting the RAS to better treat hypertension and heart failure.  Here we focus on new therapies in preclinical and early clinical stages of development, including novel small molecule inhibitors and receptor agonists/antagonists, less conventional strategies such as gene therapy to suppress angiotensinogen at the RNA level, recombinant ACE2 protein, and novel bispecific designer peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAI0aDOrgWeMERNNga7KD-fW6udTcc2eZkGkFOoNPYnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MngsVamtQ%253D%253D&md5=13d62a245da308da55a0ac09e2ae8d90</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fpr.118.017129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.118.017129%26sid%3Dliteratum%253Aachs%26aulast%3DArendse%26aufirst%3DL.%2BB.%26aulast%3DDanser%26aufirst%3DA.%2BH.%2BJ.%26aulast%3DPoglitsch%26aufirst%3DM.%26aulast%3DTouyz%26aufirst%3DR.%2BM.%26aulast%3DBurnett%26aufirst%3DJ.%2BC.%26aulast%3DLlorens-Cortes%26aufirst%3DC.%26aulast%3DEhlers%26aufirst%3DM.%2BR.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26atitle%3DNovel%2520therapeutic%2520approaches%2520targeting%2520the%2520renin-angiotensin%2520system%2520and%2520associated%2520peptides%2520in%2520hypertension%2520and%2520heart%2520failure%26jtitle%3DPharmacol.%2520Rev.%26date%3D2019%26volume%3D71%26spage%3D539%26epage%3D570%26doi%3D10.1124%2Fpr.118.017129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathisuwan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbert, R. L.</span></span> <span> </span><span class="NLM_article-title">A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1592/phco.22.1.27.33502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1592%2Fphco.22.1.27.33502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=11794428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvVKksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=27-42&author=S.+Nathisuwanauthor=R.+L.+Talbert&title=A+review+of+vasopeptidase+inhibitors%3A+a+new+modality+in+the+treatment+of+hypertension+and+chronic+heart+failure&doi=10.1592%2Fphco.22.1.27.33502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A review of vasopeptidase inhibitors: A new modality in the treatment of hypertension and chronic heart failure</span></div><div class="casAuthors">Nathisuwan, Surakit; Talbert, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-42</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Pharmacotherapy Publications</span>)
        </div><div class="casAbstract">A review.  Vasopeptidase inhibitors are a group of agents capable of inhibiting neutral endopeptidase and angiotensin-converting enzymes, which leads to potentiation of natriuretic peptide actions and suppression of the reninangiotensin-aldosterone system.  With this distinctively characteristic mechanism, these agents have emerged as a new drug class for management of hypertension and heart failure.  Several vasopeptidase inhibitors are under clin. investigation.  Omapatrilat is the most studied agent in this class.  Clin. studies of omapatrilat in hypertension have consistently shown the agent's effectiveness in a variety of patient populations.  In patients with heart failure, omapatrilat significantly improved neurohormonal and hemodynamic status.  Long-term effects of omapatrilat in patients with heart failure recently were compared with those of conventional therapy in a large phase II trial.  Results of the study appear promising.  Large clin. trials are ongoing, and addnl. information regarding safety and efficacy from these studies may help define the place in therapy for this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdG44q7150ybVg90H21EOLACvtfcHk0lh7IwrRxCmdGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvVKksw%253D%253D&md5=1cecd58c809de787d03181d29e65169c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1592%2Fphco.22.1.27.33502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1592%252Fphco.22.1.27.33502%26sid%3Dliteratum%253Aachs%26aulast%3DNathisuwan%26aufirst%3DS.%26aulast%3DTalbert%26aufirst%3DR.%2BL.%26atitle%3DA%2520review%2520of%2520vasopeptidase%2520inhibitors%253A%2520a%2520new%2520modality%2520in%2520the%2520treatment%2520of%2520hypertension%2520and%2520chronic%2520heart%2520failure%26jtitle%3DPharmacotherapy%26date%3D2002%26volume%3D22%26spage%3D27%26epage%3D42%26doi%3D10.1592%2Fphco.22.1.27.33502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trindade, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouleau, J. L.</span></span> <span> </span><span class="NLM_article-title">Vasopeptidase inhibitors: potential role in the treatment of heart failure</span>. <i>Heart Failure Monit.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=12634892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD3MXns1Gqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=2-7&author=P.+T.+Trindadeauthor=J.+L.+Rouleau&title=Vasopeptidase+inhibitors%3A+potential+role+in+the+treatment+of+heart+failure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Vasopeptidase inhibitors: Potential role in the treatment of heart failure</span></div><div class="casAuthors">Trindade, Pedro T.; Rouleau, Jean L.</div><div class="citationInfo"><span class="NLM_cas:title">Heart Failure Monitor</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-7</span>CODEN:
                <span class="NLM_cas:coden">HFMEAG</span>;
        ISSN:<span class="NLM_cas:issn">1470-8590</span>.
    
            (<span class="NLM_cas:orgname">ReMEDICA Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Current thinking views the progression of heart failure as the result of sustained activation of vasoconstrictor neurohormones.  In this model, the sustained synthesis of vasoconstrictor neurohormones leads to disease progression through alterations in cardiomyocyte structure and function, which affects myocardial contractility, cardiac metab., and cellular growth.  Ultimately, these events induce irreversible adverse ventricular remodeling through myocyte cell loss and progressive myocardial fibrosis.  In the past decade, several landmark clin. trials tested the neurohormonal hypothesis, by targeting the activation of both the β-adrenergic and the renin-angiotensin-aldosterone systems.  Although the obsd. decrease in mortality using this strategy in heart failure populations was encouraging, morbidity and mortality levels remained elevated, and it has now been shown that several other humoral interactions are at play and potentially deserve antagonizing, or in the case of vasodilator neurohormones, deserve stimulation.  It is known that a family of vasodilator neurohormones, the natriuretic peptides, that have natriuretic, vasodilatory, and antiproliferative effects, endogenously inhibit the renin-angiotensin system.  These peptides are degraded primarily by a neutral endopeptidase (NEP), an endothelial cell-surface zinc metallopeptidase, which shares a similar structure and catalytic site with the angiotensin converting enzyme (ACE).  NEPs have broad substrate specificity, encompassing atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide, but also bradykinin and adrenomedullin.  The recognition that ACE and NEP enzymes had related structures, led to the design and development of a new class of mols. with a dual inhibitory effect on ACE and NEP, referred to as vasopeptidase inhibitors.  Preliminary clin. trials in heart failure with vasopeptidase inhibitors have become available and show promising results.  Thus, the combined inhibition of ACE and NEP, by attenuating excessive vasoconstriction and enhancing vasodilator substances, holds promise as a valuable option in heart failure treatment for the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ-LfqhBLlArVg90H21EOLACvtfcHk0lh7IwrRxCmdGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXns1Gqtrg%253D&md5=1e17a1559d9af49c1014ce92333bfc7e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrindade%26aufirst%3DP.%2BT.%26aulast%3DRouleau%26aufirst%3DJ.%2BL.%26atitle%3DVasopeptidase%2520inhibitors%253A%2520potential%2520role%2520in%2520the%2520treatment%2520of%2520heart%2520failure%26jtitle%3DHeart%2520Failure%2520Monit.%26date%3D2001%26volume%3D2%26spage%3D2%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. A.</span></span> <span> </span><span class="NLM_article-title">Vasopeptidase inhibitors</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">1525</span>– <span class="NLM_lpage">1532</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(01)06584-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2FS0140-6736%2801%2906584-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=11705582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A280%3ADC%252BD3MnltFOisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2001&pages=1525-1532&author=M.+A.+Weber&title=Vasopeptidase+inhibitors&doi=10.1016%2FS0140-6736%2801%2906584-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Vasopeptidase inhibitors</span></div><div class="casAuthors">Weber M A</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">9292</span>),
    <span class="NLM_cas:pages">1525-32</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">Vasopeptidase inhibitors are a new class of cardiovascular drug that simultaneously inhibit both neutral endopeptidase and angiotensin-converting enzyme (ACE).  They increase the availability of peptides that have vasodilatory and other vascular effects; they also inhibit production of angiotensin II.  In animal models vasopeptidase inhibitors decrease blood pressure in low, medium, and high renin forms of hypertension, and they also appear to confer benefits in models of heart failure and ischaemic heart disease.  Studies in human hypertension show that these agents are effective in decreasing blood pressure regardless of race or age.  Experience with omapatrilat, the most clinically advanced of these drugs, has shown it to be more effective than currently available ACE inhibitors or other widely used antihypertensive agents.  Studies with omapatrilat in congestive heart failure have shown beneficial effects on haemodynamics and symptoms.  The vasopeptidase inhibitors appear to have safety profiles similar to ACE inhibitors, though the frequency of side-effects such as angio-oedema and cough remains to be established.  Large trials with clinical endpoints, some already in progress, are needed to establish the place of this class of drug beside that of established therapies in conditions such as hypertension, heart failure, ischaemic heart disease, and nephropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNUjLeVs7MGT0O18WR3iAofW6udTcc2eb-HAXygbzCtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnltFOisA%253D%253D&md5=ed69ac5d07ea379e550a651e6c222121</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2801%2906584-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252801%252906584-9%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DM.%2BA.%26atitle%3DVasopeptidase%2520inhibitors%26jtitle%3DLancet%26date%3D2001%26volume%3D358%26spage%3D1525%26epage%3D1532%26doi%3D10.1016%2FS0140-6736%2801%2906584-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cozier, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendse, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwager, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for multiple omapatrilat binding sites within the ACE C-domain: Implications for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10141</span>– <span class="NLM_lpage">10154</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCisb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10141-10154&author=G.+E.+Cozierauthor=L.+B.+Arendseauthor=S.+L.+Schwagerauthor=E.+D.+Sturrockauthor=K.+R.+Acharya&title=Molecular+basis+for+multiple+omapatrilat+binding+sites+within+the+ACE+C-domain%3A+Implications+for+drug+design&doi=10.1021%2Facs.jmedchem.8b01309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain: Implications for Drug Design</span></div><div class="casAuthors">Cozier, Gyles E.; Arendse, Lauren B.; Schwager, Sylva L.; Sturrock, Edward D.; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10141-10154</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Omapatrilat was designed as a vasopeptidase inhibitor with dual activity against the zinc metallopeptidases angiotensin-1 converting enzyme (ACE) and neprilysin (NEP).  ACE has two homologous catalytic domains (nACE and cACE), which exhibit different substrate specificities.  Here, the authors report high-resoln. crystal structures of omapatrilat in complex with nACE and cACE and show omapatrilat has subnanomolar affinity for both domains.  The structures show nearly identical binding interactions for omapatrilat in each domain, explaining the lack of domain selectivity.  The cACE complex structure revealed an omapatrilat dimer occupying the cavity beyond the S2 subsite, and this dimer had low micromolar inhibition of nACE and cACE.  These results highlight residues beyond the S2 subsite that could be exploited for domain selective inhibition.  In addn., it suggests the possibility of either domain specific allosteric inhibitors that bind exclusively to the nonprime cavity or the potential for targeting specific substrates rather than completely inhibiting the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4n5G90jRNyrVg90H21EOLACvtfcHk0lhFd_jM-VGMHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCisb7J&md5=a71906277e73b0818845e3253ec9ef33</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01309%26sid%3Dliteratum%253Aachs%26aulast%3DCozier%26aufirst%3DG.%2BE.%26aulast%3DArendse%26aufirst%3DL.%2BB.%26aulast%3DSchwager%26aufirst%3DS.%2BL.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DMolecular%2520basis%2520for%2520multiple%2520omapatrilat%2520binding%2520sites%2520within%2520the%2520ACE%2520C-domain%253A%2520Implications%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10141%26epage%3D10154%26doi%3D10.1021%2Facs.jmedchem.8b01309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryono, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpkins, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimarusti, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejneka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarchyk, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarz, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboa-Offei, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathers, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trippodo, N. C.</span></span> <span> </span><span class="NLM_article-title">Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1570</span>– <span class="NLM_lpage">1577</span>, <span class="refDoi"> DOI: 10.1021/jm970041e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970041e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK2sXjtFSjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1570-1577&author=J.+A.+Roblauthor=C.+Q.+Sunauthor=J.+Stevensonauthor=D.+E.+Ryonoauthor=L.+M.+Simpkinsauthor=M.+P.+Cimarustiauthor=T.+Dejnekaauthor=W.+A.+Slusarchykauthor=S.+Chaoauthor=L.+Strattonauthor=R.+N.+Misraauthor=M.+S.+Bednarzauthor=M.+M.+Asaadauthor=H.+S.+Cheungauthor=B.+E.+Abboa-Offeiauthor=P.+L.+Smithauthor=P.+D.+Mathersauthor=M.+Foxauthor=T.+R.+Schaefferauthor=A.+A.+Seymourauthor=N.+C.+Trippodo&title=Dual+metalloprotease+inhibitors%3A+mercaptoacetyl-based+fused+heterocyclic+dipeptide+mimetics+as+inhibitors+of+angiotensin-converting+enzyme+and+neutral+endopeptidase&doi=10.1021%2Fjm970041e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Metalloprotease Inhibitors: Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase</span></div><div class="casAuthors">Robl, Jeffrey A.; Sun, Chong-Qing; Stevenson, Jay; Ryono, Denis E.; Simpkins, Ligaya M.; Cimarusti, Maria P.; Dejneka, Tamara; Slusarchyk, William A.; Chao, Sam; Stratton, Leslie; Misra, Raj N.; Bednarz, Mark S.; Asaad, Magdi M.; Cheung, Hong Son; Abboa-Offei, Benoni E.; Smith, Patricia L.; Mathers, Parker D.; Fox, Maxine; Schaeffer, Thomas R.; Seymour, Andrea A.; Trippodo, Nick C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1570-1577</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 7,6- and 7,5-fused bicyclic thiazepinones and oxazepinones were generated and incorporated as conformationally restricted dipeptide surrogates in mercaptoacyl dipeptides.  These compds. are potent inhibitors of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) both in vitro and in vivo.  Compd. 1a, a 7,6-fused bicyclic thiazepinone, demonstrated excellent blood pressure lowering in a variety of animal models characterized by various levels of plasma renin activity and significantly potentiated urinary sodium, ANP, and cGMP excretion in a cynomolgus monkey assay.  On the basis of its potency and duration of action, compd. 1a (BMS-186716) was advanced into clin. development for the treatment of hypertension and congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA1AhNVtyuOrVg90H21EOLACvtfcHk0lhFd_jM-VGMHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtFSjtbY%253D&md5=e255086829b24dd59c25c1991ba04264</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm970041e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970041e%26sid%3Dliteratum%253Aachs%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DSun%26aufirst%3DC.%2BQ.%26aulast%3DStevenson%26aufirst%3DJ.%26aulast%3DRyono%26aufirst%3DD.%2BE.%26aulast%3DSimpkins%26aufirst%3DL.%2BM.%26aulast%3DCimarusti%26aufirst%3DM.%2BP.%26aulast%3DDejneka%26aufirst%3DT.%26aulast%3DSlusarchyk%26aufirst%3DW.%2BA.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DStratton%26aufirst%3DL.%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DAsaad%26aufirst%3DM.%2BM.%26aulast%3DCheung%26aufirst%3DH.%2BS.%26aulast%3DAbboa-Offei%26aufirst%3DB.%2BE.%26aulast%3DSmith%26aufirst%3DP.%2BL.%26aulast%3DMathers%26aufirst%3DP.%2BD.%26aulast%3DFox%26aufirst%3DM.%26aulast%3DSchaeffer%26aufirst%3DT.%2BR.%26aulast%3DSeymour%26aufirst%3DA.%2BA.%26aulast%3DTrippodo%26aufirst%3DN.%2BC.%26atitle%3DDual%2520metalloprotease%2520inhibitors%253A%2520mercaptoacetyl-based%2520fused%2520heterocyclic%2520dipeptide%2520mimetics%2520as%2520inhibitors%2520of%2520angiotensin-converting%2520enzyme%2520and%2520neutral%2520endopeptidase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1570%26epage%3D1577%26doi%3D10.1021%2Fjm970041e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azizi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvol, P.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1226</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.35.6.1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1161%2F01.HYP.35.6.1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10856268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVCntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=1226-1231&author=M.+Aziziauthor=C.+Massienauthor=A.+Michaudauthor=P.+Corvol&title=In+vitro+and+in+vivo+inhibition+of+the+2+active+sites+of+ACE+by+omapatrilat%2C+a+vasopeptidase+inhibitor&doi=10.1161%2F01.HYP.35.6.1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor</span></div><div class="casAuthors">Azizi, Michel; Massien, Christine; Michaud, Annie; Corvol, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1226-1231</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The vasopeptidase inhibitor omapatrilat inhibits both neutral endopeptidase and angiotensin-converting enzyme (ACE).  The in vitro and in vivo inhibitory potency of omapatrilat and the specific ACE inhibitor fosinopril toward the 2 active sites of ACE (called N- and C-domains) was investigated with the use of 3 substrates: angiotensin I, which is equally cleaved by the 2 ACE domains; hippuryl-histidyl-leucine, specific synthetic substrate of the C-domain in high-salt conditions; and a newly synthesized specific substrate of the N-domain designed by acetylating the lysine residue of AcSDKP.  In vitro, omapatrilat was 5 times more potent than fosinoprilat in inhibiting angiotensin I hydrolysis.  Omapatrilat inhibited similarly both N- and C-domain hydrolysis, whereas fosinoprilat was slightly more specific for the N-domain.  The in vivo selective inhibitory potency of single oral doses of 10 mg omapatrilat and 20 mg fosinopril were investigated in a double-blind, placebo-controlled, cross-over study in 9 mildly sodium-depleted normotensive subjects.  In accordance with the in vitro results, fosinopril appeared to be more specific for the N-domain than the C-domain in vivo, since plasma and urine AcSDKP concns. were significantly higher than those obsd. with omapatrilat.  This study shows that it is possible to assess sep. in vitro and in vivo the selectivity of ACE or ACE/neutral endopeptidase inhibitors.  A differential selectivity may explain some peculiar properties obsd. with some ACE inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpEX7zuaqkurVg90H21EOLACvtfcHk0limmB2iBfT12A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVCntr0%253D&md5=961802b4e2984e1d80acb5e49dbac749</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.35.6.1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.35.6.1226%26sid%3Dliteratum%253Aachs%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DMassien%26aufirst%3DC.%26aulast%3DMichaud%26aufirst%3DA.%26aulast%3DCorvol%26aufirst%3DP.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520inhibition%2520of%2520the%25202%2520active%2520sites%2520of%2520ACE%2520by%2520omapatrilat%252C%2520a%2520vasopeptidase%2520inhibitor%26jtitle%3DHypertension%26date%3D2000%26volume%3D35%26spage%3D1226%26epage%3D1231%26doi%3D10.1161%2F01.HYP.35.6.1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostis, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmieder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, E.</span></span> <span> </span><span class="NLM_article-title">Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial</span>. <i>Am. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.amjhyper.2003.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2Fj.amjhyper.2003.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=14751650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvF2gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=103-111&author=J.+B.+Kostisauthor=M.+Packerauthor=H.+R.+Blackauthor=R.+Schmiederauthor=D.+Henryauthor=E.+Levy&title=Omapatrilat+and+enalapril+in+patients+with+hypertension%3A+the+Omapatrilat+Cardiovascular+Treatment+vs.+Enalapril+%28OCTAVE%29+trial&doi=10.1016%2Fj.amjhyper.2003.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial</span></div><div class="casAuthors">Kostis, John B.; Packer, Milton; Black, Henry R.; Schmieder, Roland; Henry, David; Levy, Elliott</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hypertension</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-111</span>CODEN:
                <span class="NLM_cas:coden">AJHYE6</span>;
        ISSN:<span class="NLM_cas:issn">0895-7061</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Recent reports suggest that existing antihypertensive agents may not have sufficient efficacy to control blood pressure (BP) in many patients.  Omapatrilat, an agent under development, has been shown to have significantly greater antihypertensive efficacy than existing agents, but may also carry increased risk of angioedema.  We compared the efficacy and safety of omapatrilat to a representative angiotensin-converting enzyme (ACE) inhibitor, enalapril.  The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial is a multicenter, randomized, double-blind, active-controlled, 24-wk trial in 25,302 patients with untreated or uncontrolled hypertension conducted in 3298 office-based sites in 12 countries.  Subjects were randomized to omapatrilat 10 mg or enalapril 5 mg as initial therapy for hypertension (group 1, n = 9292), replacement for existing antihypertensive therapy (group 2, n = 11,224), or in addn. to existing antihypertensive therapy (group 3, n = 4751).  Study drug was force-titrated at week 2 and electively titrated at weeks 4 and 6 to a max. of omapatrilat 80 mg or enalapril 40 mg once daily.  At weeks 8 and 16, adjunctive antihypertensive medications were added electively to achieve target BP.  Omapatrilat reduced systolic BP 3.6 mm Hg more than enalapril at week 8, and was assocd. with less use of adjunctive antihypertensive therapy by week 24 (19% v 27%; P < 0.001 for both comparisons).  Subjects randomized to omapatrilat were more likely to reach BP target, regardless of demographics or comorbid conditions and whether omapatrilat was used as initial therapy, replacement for existing therapy, or in addn. to existing therapy.  Angioedema was more frequent with omapatrilat than enalapril (2.17% v 0.68%).  Two omapatrilat-treated subjects experienced angioedema with airway compromise, which was successfully treated.  Omapatrilat provided broadly superior antihypertensive efficacy when used in a setting resembling clin. practice.  Angioedema was more common than with enalapril but life-threatening angioedema was rare.  The risk-benefit profile for omapatrilat in clin. use therefore appears likely to be favorable in appropriate patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPTjmO9Y1hr7Vg90H21EOLACvtfcHk0limmB2iBfT12A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvF2gtw%253D%253D&md5=a783f9aa5c8d243ac3c077b601918535</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.amjhyper.2003.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjhyper.2003.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DKostis%26aufirst%3DJ.%2BB.%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DBlack%26aufirst%3DH.%2BR.%26aulast%3DSchmieder%26aufirst%3DR.%26aulast%3DHenry%26aufirst%3DD.%26aulast%3DLevy%26aufirst%3DE.%26atitle%3DOmapatrilat%2520and%2520enalapril%2520in%2520patients%2520with%2520hypertension%253A%2520the%2520Omapatrilat%2520Cardiovascular%2520Treatment%2520vs.%2520Enalapril%2520%2528OCTAVE%2529%2520trial%26jtitle%3DAm.%2520J.%2520Hypertens.%26date%3D2004%26volume%3D17%26spage%3D103%26epage%3D111%26doi%3D10.1016%2Fj.amjhyper.2003.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fryer, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segreti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfor, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widomski, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backes, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballaron, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevillyan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Geldern, T. W.</span></span> <span> </span><span class="NLM_article-title">Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1038%2Fsj.bjp.0707641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=18084312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislWis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2008&pages=947-955&author=R.+M.+Fryerauthor=J.+Segretiauthor=P.+N.+Banforauthor=D.+L.+Widomskiauthor=B.+J.+Backesauthor=C.+W.+Linauthor=S.+J.+Ballaronauthor=B.+F.+Coxauthor=J.+M.+Trevillyanauthor=G.+A.+Reinhartauthor=T.+W.+von+Geldern&title=Effect+of+bradykinin+metabolism+inhibitors+on+evoked+hypotension+in+rats%3A+rank+efficacy+of+enzymes+associated+with+bradykinin-mediated+angioedema&doi=10.1038%2Fsj.bjp.0707641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema</span></div><div class="casAuthors">Fryer, R. M.; Segreti, J.; Banfor, P. N.; Widomski, D. L.; Backes, B. J.; Lin, C. W.; Ballaron, S. J.; Cox, B. F.; Trevillyan, J. M.; Reinhart, G. A.; von Geldern, T. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">947-955</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of bradykinin metabolizing enzymes (BMEs) can cause acute angioedema, as demonstrated in a recent clin. trial in patients administered the antihypertensive, omapatrilat.  However, the relative contribution of specific BMEs to this effect is unclear and confounded by the lack of a predictive pre-clin. model of angioedema.  Rats were instrumented to record blood pressure and heart rate; inhibitors were infused for 35 min and bradykinin was infused during the last 5 min to elicit hypotension, as a functional marker of circulating bradykinin and relative angioedema risk.  In the presence of omapatrilat, bradykinin produced dose-dependent hypotension, an effect abolished by B2 blockade.  In the presence of lisinopril (ACE inhibitor), but not candoxatril (NEP inhibitor) or apstatin (APP inhibitor), bradykinin also elicited hypotension.  Lisinopril-mediated hypotension was unchanged with concomitant blockade of NEP or NEP/DPPIV (candoxatril + A-899301).  However, hypotension was enhanced upon concomitant blockade of APP and further intensified in the presence of NEP inhibition to values not different from omapatrilat alone.  We demonstrated that bradykinin is degraded in vivo with an enzyme rank-efficacy of ACE>APP»NEP or DPPIV.  These results suggest the effects of omapatrilat are mediated by inhibition of three BMEs, ACE/APP/NEP.  However, dual inhibition of ACE/NEP or ACE/NEP/DPPIV elicits no increased risk of angioedema compared to ACE inhibition alone.  Thus, novel BME inhibitors must display no activity against APP to avoid angioedema risk due to high prevalence of ACE inhibitor therapy in patients with diabetes and cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHe-dQxhoWF7Vg90H21EOLACvtfcHk0limmB2iBfT12A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislWis7Y%253D&md5=e3067cd71575b8f32a623ef6a0303569</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707641%26sid%3Dliteratum%253Aachs%26aulast%3DFryer%26aufirst%3DR.%2BM.%26aulast%3DSegreti%26aufirst%3DJ.%26aulast%3DBanfor%26aufirst%3DP.%2BN.%26aulast%3DWidomski%26aufirst%3DD.%2BL.%26aulast%3DBackes%26aufirst%3DB.%2BJ.%26aulast%3DLin%26aufirst%3DC.%2BW.%26aulast%3DBallaron%26aufirst%3DS.%2BJ.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DTrevillyan%26aufirst%3DJ.%2BM.%26aulast%3DReinhart%26aufirst%3DG.%2BA.%26aulast%3Dvon%2BGeldern%26aufirst%3DT.%2BW.%26atitle%3DEffect%2520of%2520bradykinin%2520metabolism%2520inhibitors%2520on%2520evoked%2520hypotension%2520in%2520rats%253A%2520rank%2520efficacy%2520of%2520enzymes%2520associated%2520with%2520bradykinin-mediated%2520angioedema%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D153%26spage%3D947%26epage%3D955%26doi%3D10.1038%2Fsj.bjp.0707641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span> <span> </span><span class="NLM_article-title">Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">948</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1996.tb15763.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1111%2Fj.1476-5381.1996.tb15763.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=8922744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK28XmvVSmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=1996&pages=943-948&author=J.+E.+Kirkauthor=M.+R.+Wilkins&title=Renal+effects+of+concurrent+E-24.11+and+ACE+inhibition+in+the+aorto-venocaval+fistula+rat&doi=10.1111%2Fj.1476-5381.1996.tb15763.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat</span></div><div class="casAuthors">Kirk, Jane E.; Wilkins, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">943-948</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The present studies compare the early renal response to (a) an endopeptidase-24.11 (E-24.11) inhibitor (candoxatrilat) (b) an angiotensin-converting enzyme (ACE) inhibitor (lisinopril) and (c) the combination of endopeptidase-24.11 and ACE inhibition in the rat A-V fistula model of chronic vol. overload.  Candoxatrilat (3 and 10 mg kg-1) i.v. produced a prompt 3 fold increase in urinary sodium and cGMP excretion without affecting significantly blood pressure or glomerular filtration rate (GFR).  Lisinopril (0.03 mg kg-1) alone inhibited the pressor response to angiotensin I but had no significant effect on urinary sodium excretion or blood pressure.  Lisinopril (0.03 mg kg-1) attenuated significantly the early natriuretic response to candoxatrilat (3 mg kg-1) and the assocd. rise in urinary cGMP, but sodium excretion eventually reached levels assocd. with acute E-24.11 inhibition.  Doses of the dual E-24.11/ACE inhibitor, sampatrilat, that inhibited the pressor response to angiotensin I reduced mean arterial blood pressure and produced a delayed natriuresis and rise in urinary cGMP excretion when compared to candoxatrilat alone.  Concurrent administration of an ACE inhibitor reduces the early renal response to E-24.11 inhibition in the A-V fistula rat, an effect attributable to the hypotensive action of this combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrza9Wz_KQUtbVg90H21EOLACvtfcHk0ljAiDaTUNNKAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmvVSmsb0%253D&md5=c2c774afa874ee4e8e89cb73812ee932</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1996.tb15763.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1996.tb15763.x%26sid%3Dliteratum%253Aachs%26aulast%3DKirk%26aufirst%3DJ.%2BE.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26atitle%3DRenal%2520effects%2520of%2520concurrent%2520E-24.11%2520and%2520ACE%2520inhibition%2520in%2520the%2520aorto-venocaval%2520fistula%2520rat%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D119%26spage%3D943%26epage%3D948%26doi%3D10.1111%2Fj.1476-5381.1996.tb15763.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinoza-Moraga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poblete, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">The dynamic nonprime binding of sampatrilat to the C-domain of angiotensin-converting enzyme</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2486</span>– <span class="NLM_lpage">2494</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGrtb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=2486-2494&author=R.+K.+Sharmaauthor=M.+Espinoza-Moragaauthor=H.+Pobleteauthor=R.+G.+Douglasauthor=E.+D.+Sturrockauthor=J.+Caballeroauthor=K.+Chibale&title=The+dynamic+nonprime+binding+of+sampatrilat+to+the+C-domain+of+angiotensin-converting+enzyme&doi=10.1021%2Facs.jcim.6b00524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme</span></div><div class="casAuthors">Sharma, Rajni K.; Espinoza-Moraga, Marlene; Poblete, Horacio; Douglas, Ross G.; Sturrock, Edward D.; Caballero, Julio; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2486-2494</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sampatrilat is a vasopeptidase inhibitor that inhibits both angiotensin I-converting enzyme (ACE) and neutral endopeptidase (NEP).  ACE is a zinc dipeptidyl carboxypeptidase that contains two extracellular domains (nACE and cACE).  In this study the mol. basis for the selectivity of sampatrilat for nACE and cACE was investigated.  Enzyme inhibition assays were performed to evaluate the in vitro ACE domain selectivity of sampatrilat.  The inhibition of the C-domain (Ki 13.8 nM) by sampatrilat was 12.4-fold more potent than that for the N-domain (171.9 nM) indicating differences in affinities for the resp. ACE domain binding sites.  Interestingly, replacement of the P2 group of sampatrilat with an aspartate abrogated its C-selectivity, and lowered the potency of the inhibitor with activities in the micromolar range.  The mol. basis for this selective profile was evaluated using mol. modeling methods.  The authors found that the C-domain selectivity of sampatrilat is due to occupation of the lysine side chain in the S1 and S2 subsites and interactions with Glu 748 and Glu 1008, resp.  This study provides new insights into ligand interactions with the non-prime binding site that can be exploited for the design of domain-selective ACE inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnJlhUEhuTprVg90H21EOLACvtfcHk0ljAiDaTUNNKAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGrtb3K&md5=bc40414bf5b79a1d921c275457f9c6e7</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00524%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DR.%2BK.%26aulast%3DEspinoza-Moraga%26aufirst%3DM.%26aulast%3DPoblete%26aufirst%3DH.%26aulast%3DDouglas%26aufirst%3DR.%2BG.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DCaballero%26aufirst%3DJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DThe%2520dynamic%2520nonprime%2520binding%2520of%2520sampatrilat%2520to%2520the%2520C-domain%2520of%2520angiotensin-converting%2520enzyme%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26spage%3D2486%26epage%3D2494%26doi%3D10.1021%2Facs.jcim.6b00524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venn, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, K. C.</span></span> <span> </span><span class="NLM_article-title">Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA)</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1016/S0731-7085(97)00127-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2FS0731-7085%2897%2900127-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=9535200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK1cXhsVKhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=883-892&author=R.+F.+Vennauthor=G.+Barnardauthor=B.+Kayeauthor=P.+V.+Macraeauthor=K.+C.+Saunders&title=Clinical+analysis+of+sampatrilat%2C+a+combined+renal+endopeptidase+and+angiotensin-converting+enzyme+inhibitor+II%3A+assay+in+the+plasma+and+urine+of+human+volunteers+by+dissociation+enhanced+lanthanide+fluorescence+immunoassay+%28DELFIA%29&doi=10.1016%2FS0731-7085%2897%2900127-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor. II: Assay in the plasma and urine of human volunteers by dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA)</span></div><div class="casAuthors">Venn, Richard F.; Barnard, Geoff; Kaye, Barry; Macrae, Paul V.; Saunders, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">An immunoassay for sampatrilat was developed which uses time-resolved fluorescence as an end-point and which has lower limits of quantification of 0.2 ng/mL plasma assay and 5 ng/mL urine.  This assay is a 96-well-plate-based competitive immunoassay; the end-point is the detn. of a (nonradioactive) europium label by time-resolved fluorimetry.  Sampatrilat is labeled with chelated europium via isothiocyanate chem.  The advantage of this assay is its extremely high throughput, allowing rapid anal. of many thousands of samples.  The DELFIA method was successfully cross-validated with the previously described HPLC-atm.-pressure chem. ionization mass-spectrometric method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI9iRZ2RsM-LVg90H21EOLACvtfcHk0ljAiDaTUNNKAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsVKhu7Y%253D&md5=fbdf57f0398d3c14e9abcb9f05d69d24</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0731-7085%2897%2900127-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0731-7085%252897%252900127-1%26sid%3Dliteratum%253Aachs%26aulast%3DVenn%26aufirst%3DR.%2BF.%26aulast%3DBarnard%26aufirst%3DG.%26aulast%3DKaye%26aufirst%3DB.%26aulast%3DMacrae%26aufirst%3DP.%2BV.%26aulast%3DSaunders%26aufirst%3DK.%2BC.%26atitle%3DClinical%2520analysis%2520of%2520sampatrilat%252C%2520a%2520combined%2520renal%2520endopeptidase%2520and%2520angiotensin-converting%2520enzyme%2520inhibitor%2520II%253A%2520assay%2520in%2520the%2520plasma%2520and%2520urine%2520of%2520human%2520volunteers%2520by%2520dissociation%2520enhanced%2520lanthanide%2520fluorescence%2520immunoassay%2520%2528DELFIA%2529%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D1998%26volume%3D16%26spage%3D883%26epage%3D892%26doi%3D10.1016%2FS0731-7085%2897%2900127-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venn, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, K. C.</span></span> <span> </span><span class="NLM_article-title">Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1016/S0731-7085(97)00126-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2FS0731-7085%2897%2900126-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=9535199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK1cXhsVKhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=875-881&author=R.+F.+Vennauthor=B.+Kayeauthor=P.+V.+Macraeauthor=K.+C.+Saunders&title=Clinical+analysis+of+sampatrilat%2C+a+combined+renal+endopeptidase+and+angiotensin-converting+enzyme+inhibitor+I%3A+assay+in+plasma+of+human+volunteers+by+atmospheric-pressure+ionisation+mass-spectrometry+following+derivatisation+with+BF3-methanol&doi=10.1016%2FS0731-7085%2897%2900126-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor. I: Assay in plasma of human volunteers by atmospheric-pressure ionization mass spectrometry following derivatization with BF3-methanol</span></div><div class="casAuthors">Venn, Richard F.; Kaye, Barry; Macrae, Paul V.; Saunders, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">875-881</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A selective and sensitive method for detg. sampatrilat in plasma, employing HPLC and atm.-pressure ionization mass spectrometry (APCI-MS-MS), was developed.  The plasma samples were extd. on solid-phase extn. cartridges, derivatized with BF3-MeOH, dild., extd. again and then subjected to HPLC-APCI-MS-MS.  Derivatization was necessary because the two COOH groups in the mol. prevented efficient ionization in the heated nebulizer source.  The calibration range was 0.5-20 ng/mL and the lower limit of quantification was 0.5 ng/mL.  Imprecision and inaccuracy were detd. on 3 sep. occasions at 3 concns. (0.5, 5 and 20 ng/mL) and were <10% in every case.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptAzuhofkmxrVg90H21EOLACvtfcHk0ljE9tAs8GXRWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsVKhu7k%253D&md5=d4e689de04d4ff213d3030693e487bb6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0731-7085%2897%2900126-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0731-7085%252897%252900126-X%26sid%3Dliteratum%253Aachs%26aulast%3DVenn%26aufirst%3DR.%2BF.%26aulast%3DKaye%26aufirst%3DB.%26aulast%3DMacrae%26aufirst%3DP.%2BV.%26aulast%3DSaunders%26aufirst%3DK.%2BC.%26atitle%3DClinical%2520analysis%2520of%2520sampatrilat%252C%2520a%2520combined%2520renal%2520endopeptidase%2520and%2520angiotensin-converting%2520enzyme%2520inhibitor%2520I%253A%2520assay%2520in%2520plasma%2520of%2520human%2520volunteers%2520by%2520atmospheric-pressure%2520ionisation%2520mass-spectrometry%2520following%2520derivatisation%2520with%2520BF3-methanol%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D1998%26volume%3D16%26spage%3D875%26epage%3D881%26doi%3D10.1016%2FS0731-7085%2897%2900126-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hettiarachchi, J.</span></span> <span> </span><span class="NLM_article-title">Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1016/S0009-9236(98)90075-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2FS0009-9236%2898%2990075-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=9797801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A280%3ADyaK1M%252FhsVGgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1998&pages=439-449&author=E.+J.+Wallisauthor=L.+E.+Ramsayauthor=J.+Hettiarachchi&title=Combined+inhibition+of+neutral+endopeptidase+and+angiotensin-converting+enzyme+by+sampatrilat+in+essential+hypertension&doi=10.1016%2FS0009-9236%2898%2990075-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension</span></div><div class="casAuthors">Wallis E J; Ramsay L E; Hettiarachchi J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-49</span>
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">BACKGROUND:  The antihypertensive response to angiotensin-converting enzyme (ACE) inhibitors may be attenuated by a compensatory decrease in atrial natriuretic factor production.  If so, inhibition of atrial natriuretic factor breakdown by neutral endopeptidase (NEP) may enhance the antihypertensive effects of ACE inhibition.  We compared effects of the combined ACE-NEP inhibitor sampatrilat, lisinopril, and placebo on blood pressure, plasma ACE, and renin activity and urinary cyclic guanosine monophosphate (cGMP) of patients with hypertension.  METHODS AND RESULTS:  After a 4-week placebo run-in period, 124 patients with a mean blood pressure of 162/102 mm Hg were randomized in a double-blind parallel-group design to 1 of 5 treatments, given once daily for 10 days: 50 mg, 100 mg, or 200 mg sampatrilat; 20 mg lisinopril; or placebo.  The first dose of sampatrilat did not lower clinic or ambulatory blood pressure.  Lisinopril had an immediate antihypertensive effect that differed significantly from all doses of sampatrilat.  After 10 days of treatment, sampatrilat lowered clinic and ambulatory blood pressure significantly at all doses, with a trend toward a dose response for systolic ambulatory blood pressure.  Sampatrilat inhibited plasma ACE in a dose-dependent fashion but significantly less so than lisinopril on days 1 and 10 of treatment.  Lisinopril but not sampatrilat significantly increased plasma renin activity, whereas sampatrilat but not lisinopril significantly increased urinary cGMP excretion.  CONCLUSION:  The increasing efficacy of sampatrilat compared with lisinopril over 10 days could not be attributed to an increase in plasma ACE inhibition, suggesting that the NEP inhibitor activity of sampatrilat may have contributed to its antihypertensive action.  NEP inhibition may enhance the antihypertensive effect of ACE inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjVN-vZ51TwsrRqEXsZufAfW6udTcc2eYySxVflZDCkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FhsVGgtw%253D%253D&md5=a1e186848d1983dddd5cfc69d1b1585f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0009-9236%2898%2990075-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-9236%252898%252990075-3%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DE.%2BJ.%26aulast%3DRamsay%26aufirst%3DL.%2BE.%26aulast%3DHettiarachchi%26aufirst%3DJ.%26atitle%3DCombined%2520inhibition%2520of%2520neutral%2520endopeptidase%2520and%2520angiotensin-converting%2520enzyme%2520by%2520sampatrilat%2520in%2520essential%2520hypertension%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1998%26volume%3D64%26spage%3D439%26epage%3D449%26doi%3D10.1016%2FS0009-9236%2898%2990075-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watermeyer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroger, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span> <span> </span><span class="NLM_article-title">Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1042/BJ20100056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1042%2FBJ20100056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=20233165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1Cmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2010&pages=67-74&author=J.+M.+Watermeyerauthor=W.+L.+Krogerauthor=H.+G.+O%E2%80%99Neillauthor=B.+T.+Sewellauthor=E.+D.+Sturrock&title=Characterization+of+domain-selective+inhibitor+binding+in+angiotensin-converting+enzyme+using+a+novel+derivative+of+lisinopril&doi=10.1042%2FBJ20100056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril</span></div><div class="casAuthors">Watermeyer, Jean M.; Kroeger, Wendy L.; O'Neill, Hester G.; Sewell, B. Trevor; Sturrock, Edward D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-74</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Human ACE (angiotensin-converting enzyme) (EC 3.4.15.1) is an important drug target because of its role in the regulation of blood pressure via the renin-angiotensin-aldosterone system.  Somatic ACE comprises two homologous domains, the differing substrate preferences of which present a new avenue for domain-selective inhibitor design.  LisW-S, a C-domain-selective deriv. of the drug lisinopril, was co-crystd. with human testis ACE and a crystal structure was detd. using X-ray crystallog. to a resoln. of 2.30 Å (1 Å=0.1 nm).  In this structure, lisW-S is seen to have a similar binding mode to its parent compd. lisinopril, but the P2' tryptophan moiety takes a different conformation to that seen in other inhibitors having a tryptophan residue in this position.  The domain-specific interactions of this inhibitor was examd. further by mutating C-domain-specific active-site residues to their N domain equiv., then assessing the effect of the mutation on inhibition by lisW-S using a fluorescence-based assay.  Kinetics anal. shows a 258-fold domain-selectivity that is largely due to the co-operative effect of C-domain-specific residues in the S2' subsite.  The high affinity and selectivity of this inhibitor make it a good lead candidate for cardiovascular drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV_1gE3mSs_LVg90H21EOLACvtfcHk0ljE9tAs8GXRWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1Cmtr8%253D&md5=1957d1bed6004296c886e8a8088c256c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1042%2FBJ20100056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100056%26sid%3Dliteratum%253Aachs%26aulast%3DWatermeyer%26aufirst%3DJ.%2BM.%26aulast%3DKroger%26aufirst%3DW.%2BL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DH.%2BG.%26aulast%3DSewell%26aufirst%3DB.%2BT.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26atitle%3DCharacterization%2520of%2520domain-selective%2520inhibitor%2520binding%2520in%2520angiotensin-converting%2520enzyme%2520using%2520a%2520novel%2520derivative%2520of%2520lisinopril%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D428%26spage%3D67%26epage%3D74%26doi%3D10.1042%2FBJ20100056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reudelhuber, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touyz, R. M.</span></span> <span> </span><span class="NLM_article-title">Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1042/CS20130808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1042%2FCS20130808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=24506807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVSgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2014&pages=57-63&author=D.+Burgerauthor=T.+L.+Reudelhuberauthor=A.+Mahajanauthor=K.+Chibaleauthor=E.+D.+Sturrockauthor=R.+M.+Touyz&title=Effects+of+a+domain-selective+ACE+inhibitor+in+a+mouse+model+of+chronic+angiotensin+II-dependent+hypertension&doi=10.1042%2FCS20130808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension</span></div><div class="casAuthors">Burger, Dylan; Reudelhuber, Timothy L.; Mahajan, Aman; Chibale, Kelly; Sturrock, Edward D.; Touyz, Rhian M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-63</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The somatic isoenzyme of ACE (angiotensin I-converting enzyme) comprises two distinct zinc-dependent catalytic domains with different substrate specificities for angiotensin I (cleaved selectively by the C-domain) and bradykinin (cleaved equally efficiently by both the N- and C-domains).  Classical ACEIs (ACE inhibitors) target both domains, with side effects such as cough and angio-edema being attributed, in part, to N-domain inhibition, probably through bradykinin accumulation.  We questioned whether a novel C-domain-selective ACEI (lisW-S) has anti-hypertensive effects without influencing bradykinin status.  AngII (angiotensin II)-dependent hypertension was studied in mice that express active human renin in the liver (TtRhRen).  Compared with wild-type littermates, TtRhRen mice displayed cardiac hypertrophy and had significantly elevated SBP [systolic BP (blood pressure)] as detd. by tail cuff sphygmomanometry (150±3 compared with 112±5 mmHg; P<0.05) and telemetry (163±3 compared with 112±2 mmHg; P<0.01).  Treatment with the non-selective ACEI lisinopril (1 mg/kg of body wt. per day via an osmotic mini-pump for 2 wk) reduced SBP (127±3 compared with. 154±6; P<0.05).  Similarly, treatment with the C-domain selective ACEI lisW-S (lisinopril-tryptophan; 3.6 mg/kg of body wt. per day via an osmotic mini-pump for 2 wk) reduced BP.  Treatment with lisinopril or lisW-S significantly reduced levels of AngII in kidneys (~ 4-fold; P<0.001).  Ang-(2-8) [angiotensin-2-8)] was significantly reduced by lisinopril, but not by lisW-S.  Plasma bradykinin levels were significantly increased only in the lisinopril group.  These data suggest that C-domain-selective ACEIs reduce BP and AngII levels similarly to classical ACEIs.  C-domain-selective ACEIs have the potential to avoid undesirable effects on the bradykinin system common to classic ACEIs and may represent a novel approach to the treatment of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhycqW23ZEE7Vg90H21EOLACvtfcHk0liCBcSgvo3Zsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVSgt7o%253D&md5=8bfc8db2df8a753cba417fc6504dc23c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1042%2FCS20130808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20130808%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DD.%26aulast%3DReudelhuber%26aufirst%3DT.%2BL.%26aulast%3DMahajan%26aufirst%3DA.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DTouyz%26aufirst%3DR.%2BM.%26atitle%3DEffects%2520of%2520a%2520domain-selective%2520ACE%2520inhibitor%2520in%2520a%2520mouse%2520model%2520of%2520chronic%2520angiotensin%2520II-dependent%2520hypertension%26jtitle%3DClin.%2520Sci.%26date%3D2014%26volume%3D127%26spage%3D57%26epage%3D63%26doi%3D10.1042%2FCS20130808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deddish, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skidgel, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdos, E. G.</span></span> <span> </span><span class="NLM_article-title">N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.31.4.912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1161%2F01.HYP.31.4.912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=9535414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK1cXisFWqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1998&pages=912-917&author=P.+A.+Deddishauthor=B.+Marcicauthor=H.+L.+Jackmanauthor=H.+Z.+Wangauthor=R.+A.+Skidgelauthor=E.+G.+Erdos&title=N-domain-specific+substrate+and+C-domain+inhibitors+of+angiotensin-converting+enzyme%3A+angiotensin-%281-7%29+and+keto-ACE&doi=10.1161%2F01.HYP.31.4.912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme. Angiotensin-(1-7) and keto-ACE</span></div><div class="casAuthors">Deddish, Peter A.; Marcic, Branislav; Jackman, Herbert L.; Wang, Huan-Zhu; Skidgel, Randal A.; Erdos, Ervin G.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">912-917</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The authors used the isolated N- and C-domains of the angiotensin I-converting enzyme (N-ACE and C-ACE; ACE; kininase II) to investigate the hydrolysis of the active 1-7 deriv. of angiotensin (Ang) II and inhibition by 5-S-5-benzamido-4-oxo-6-phenylhexanoyl-L-proline (keto-ACE).  Ang-(1-7) is both a substrate and an inhibitor; it is cleaved by N-ACE at approx. one half the rate of bradykinin but negligibly by C-ACE.  It inhibits C-ACE, however, at an order of magnitude lower concn. than N-ACE; the IC50 of C-ACE with 100 μM Ang I substrate was 1.2 μM and the Ki was 0.13.  While searching for a specific inhibitor of a single active site of ACE, the authors found that keto-ACE inhibited bradykinin and Ang I hydrolysis by C-ACE in approx. a 38- to 47-times lower concn. than by N-ACE; IC50 values with C-ACE were 0.5 and 0.04 μM.  Furthermore, the authors investigated how Ang-(1-7) acts via bradykinin and the involvement of its B2 receptor.  Ang-(1-7) was ineffective directly on the human bradykinin B2 receptor transfected and expressed in Chinese hamster ovary cells.  However, Ang-(1-7) potentiated arachidonic acid release by an ACE-resistant bradykinin analog (1 μM), acting on the B2 receptor when the cells were cotransfected with cDNA of both B2 receptor and ACE and the proteins were expressed on the plasma membrane were cotransfected with cDNA of both B2 receptor and ACE and the proteins were expressed on the plasma membrane of Chinese hamster ovary cells.  Thus like other ACE inhibitors, Ang-(1-7) can potentiate the actions of a ligand of the B2 receptor indirectly by binding to the active site of ACE and independent of blocking ligand hydrolysis.  This potentiation of kinins at the receptor level can explain some of the well-documented kinin like actions of Ang-(1-7).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsz053b09bnrVg90H21EOLACvtfcHk0liCBcSgvo3Zsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFWqtb8%253D&md5=5ff623c87fbd3083895520524ce4f6e2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.31.4.912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.31.4.912%26sid%3Dliteratum%253Aachs%26aulast%3DDeddish%26aufirst%3DP.%2BA.%26aulast%3DMarcic%26aufirst%3DB.%26aulast%3DJackman%26aufirst%3DH.%2BL.%26aulast%3DWang%26aufirst%3DH.%2BZ.%26aulast%3DSkidgel%26aufirst%3DR.%2BA.%26aulast%3DErdos%26aufirst%3DE.%2BG.%26atitle%3DN-domain-specific%2520substrate%2520and%2520C-domain%2520inhibitors%2520of%2520angiotensin-converting%2520enzyme%253A%2520angiotensin-%25281-7%2529%2520and%2520keto-ACE%26jtitle%3DHypertension%26date%3D1998%26volume%3D31%26spage%3D912%26epage%3D917%26doi%3D10.1161%2F01.HYP.31.4.912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poglitsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats</span>. <i>J. Renin-Angiotensin-Aldosterone Syst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1149</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1177/1470320314568438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1177%2F1470320314568438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=25757657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVOhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1149-1158&author=S.+Sharpauthor=M.+Poglitschauthor=P.+Zillaauthor=N.+H.+Daviesauthor=E.+D.+Sturrock&title=Pharmacodynamic+effects+of+C-domain-specific+ACE+inhibitors+on+the+renin-angiotensin+system+in+myocardial+infarcted+rats&doi=10.1177%2F1470320314568438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats</span></div><div class="casAuthors">Sharp, Sarah; Poglitsch, Marko; Zilla, Peter; Davies, Neil H.; Sturrock, Edward D.</div><div class="citationInfo"><span class="NLM_cas:title">JRAAS</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1149-1158</span>CODEN:
                <span class="NLM_cas:coden">JRAAAG</span>;
        ISSN:<span class="NLM_cas:issn">1470-3203</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Introduction: The renin-angiotensin system (RAS) is a dynamic network that plays a crit. role in blood pressure regulation and fluid and electrolyte homeostasis.  Modulators of the RAS, such as angiotensin-converting enzyme (ACE) inhibitors, are widely used to treat hypertension, heart failure and myocardial infarction.  Methods: The effect of ACE inhibitors (lisinopril and C-domain-selective LisW-S) on the constituent peptides of the RAS following myocardial infarction was examd. in rats.  Ten angiotensin peptides were analyzed using a sensitive LC-MS/MS-based assay to examine both the circulating and equil. levels of these peptides.  Results: Administration of lisinopril or LisW-S caused a significant decrease in Ang 1-8/Ang 1-10 ratios as detd. by circulating and equil. peptide level anal.  Furthermore, Ang 1-7 levels were elevated by both ACE inhibitors, but only lisinopril decreased the Ang 1-5/Ang 1-7 ratio.  This indicates LisW-S C-domain specificity as Ang 1-5 is generated by hydrolysis of Ang 1-7 by the N-domain.  Further corroboration of LisW-S C-domain specificity is that only lisinopril increased the circulating levels of the N-domain ACE substrate Ac-SDKP.  Conclusion: LisW-S is able to effectively block ACE in vivo by C-domain-selective inhibition.  The LC-MS/MS-based assay allows the evaluation of the pharmacol. impact of RAS inhibitors in different pathophysiol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrZekUQeLdirVg90H21EOLACvtfcHk0liCBcSgvo3Zsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVOhsL0%253D&md5=502923ff663bc51727c9161dee9bf020</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F1470320314568438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1470320314568438%26sid%3Dliteratum%253Aachs%26aulast%3DSharp%26aufirst%3DS.%26aulast%3DPoglitsch%26aufirst%3DM.%26aulast%3DZilla%26aufirst%3DP.%26aulast%3DDavies%26aufirst%3DN.%2BH.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26atitle%3DPharmacodynamic%2520effects%2520of%2520C-domain-specific%2520ACE%2520inhibitors%2520on%2520the%2520renin-angiotensin%2520system%2520in%2520myocardial%2520infarcted%2520rats%26jtitle%3DJ.%2520Renin-Angiotensin-Aldosterone%2520Syst.%26date%3D2015%26volume%3D16%26spage%3D1149%26epage%3D1158%26doi%3D10.1177%2F1470320314568438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cozier, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwager, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">1477</span>– <span class="NLM_lpage">1490</span>, <span class="refDoi"> DOI: 10.1111/febs.14421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1111%2Ffebs.14421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=29476645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktV2nur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2018&pages=1477-1490&author=G.+E.+Cozierauthor=S.+L.+Schwagerauthor=R.+K.+Sharmaauthor=K.+Chibaleauthor=E.+D.+Sturrockauthor=K.+R.+Acharya&title=Crystal+structures+of+sampatrilat+and+sampatrilat-Asp+in+complex+with+human+ACE+-+a+molecular+basis+for+domain+selectivity&doi=10.1111%2Ffebs.14421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity</span></div><div class="casAuthors">Cozier, Gyles E.; Schwager, Sylva L.; Sharma, Rajni K.; Chibale, Kelly; Sturrock, Edward D.; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1477-1490</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Angiotensin-1-converting enzyme (ACE) is a zinc metallopeptidase that consists of two homologous catalytic domains (known as nACE and cACE) with different substrate specificities.  Based on kinetic studies it was previously reported that sampatrilat, a tight-binding inhibitor of ACE, Ki = 13.8 nM and 171.9 nM for cACE and nACE resp. [Sharma et al., Journal of Chem. Information and Modeling (2016), 56, 2486-2494], was 12.4-fold more selective for cACE.  In addn., sampatrilat-Asp (samAsp), in which an aspartate group replaces the sampatrilat lysine, was found to be a nonspecific and lower micromolar affinity inhibitor.  Here, we report a detailed three-dimensional structural anal. of sampatrilat and samAsp binding to ACE using high-resoln. crystal structures elucidated by X-ray crystallog., which provides a mol. basis for differences in inhibitor affinity and selectivity for nACE and cACE.  The structures show that the specificity of sampatrilat can be explained by increased hydrophobic interactions and a H-bond from Glu403 of cACE with the lysine side chain of sampatrilat that are not obsd. in nACE.  In addn., the structures clearly show a significantly greater no. of hydrophilic and hydrophobic interactions with sampatrilat compared to samAsp in both cACE and nACE consistent with the difference in affinities.  Our findings provide new exptl. insights into ligand binding at the active site pockets that are important for the design of highly specific domain selective inhibitors of ACE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgO5eB50LzpbVg90H21EOLACvtfcHk0lgd9vanGQAcsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktV2nur8%253D&md5=407be458962d79e4fa0e512e01bb7e04</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Ffebs.14421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.14421%26sid%3Dliteratum%253Aachs%26aulast%3DCozier%26aufirst%3DG.%2BE.%26aulast%3DSchwager%26aufirst%3DS.%2BL.%26aulast%3DSharma%26aufirst%3DR.%2BK.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DCrystal%2520structures%2520of%2520sampatrilat%2520and%2520sampatrilat-Asp%2520in%2520complex%2520with%2520human%2520ACE%2520-%2520a%2520molecular%2520basis%2520for%2520domain%2520selectivity%26jtitle%3DFEBS%2520J.%26date%3D2018%26volume%3D285%26spage%3D1477%26epage%3D1490%26doi%3D10.1111%2Ffebs.14421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Labiuk, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sygusch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grochulski, P.</span></span> <span> </span><span class="NLM_article-title">Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiorphan</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1107/S2053230X19006046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS2053230X19006046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=31204686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFyisLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=405-411&author=S.+L.+Labiukauthor=J.+Syguschauthor=P.+Grochulski&title=Structures+of+soluble+rabbit+neprilysin+complexed+with+phosphoramidon+or+thiorphan&doi=10.1107%2FS2053230X19006046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiorphan</span></div><div class="casAuthors">Labiuk, Shaunivan L.; Sygusch, Jurgen; Grochulski, Pawel</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">405-411</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Neutral endopeptidase (neprilysin; NEP) is a proteinase that cleaves a wide variety of peptides and has been implicated in Alzheimer's disease, cardiovascular conditions, arthritis and other inflammatory diseases.  The structure of the sol. extracellular domain (residues 55-750) of rabbit neprilysin was solved both in its native form at 2.1 Å resoln., and bound to the inhibitors phosphoramidon and thiorphan at 2.8 and 3.0 Å resoln., resp.  Consistent with the extracellular domain of human neprilysin, the structure reveals a large central cavity which contains the active site and the location for inhibitor binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-pU4K_8fu4LVg90H21EOLACvtfcHk0lgd9vanGQAcsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFyisLbE&md5=c4f8f74d7cd835fe6642d74ee09b31e6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1107%2FS2053230X19006046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X19006046%26sid%3Dliteratum%253Aachs%26aulast%3DLabiuk%26aufirst%3DS.%2BL.%26aulast%3DSygusch%26aufirst%3DJ.%26aulast%3DGrochulski%26aufirst%3DP.%26atitle%3DStructures%2520of%2520soluble%2520rabbit%2520neprilysin%2520complexed%2520with%2520phosphoramidon%2520or%2520thiorphan%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2019%26volume%3D75%26spage%3D405%26epage%3D411%26doi%3D10.1107%2FS2053230X19006046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oefner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arcy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, G. E.</span></span> <span> </span><span class="NLM_article-title">Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1999.3492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1006%2Fjmbi.1999.3492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10669592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD3cXps1GqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2000&pages=341-349&author=C.+Oefnerauthor=A.+D%E2%80%99Arcyauthor=M.+Hennigauthor=F.+K.+Winklerauthor=G.+E.+Dale&title=Structure+of+human+neutral+endopeptidase+%28Neprilysin%29+complexed+with+phosphoramidon&doi=10.1006%2Fjmbi.1999.3492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon</span></div><div class="casAuthors">Oefner, Christian; D'Arcy, Allan; Hennig, Michael; Winkler, Fritz K.; Dale, Glenn E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-349</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Neprilysin (EC 3.4.24.11; neutral endopeptidase) (I) is a mammalian type II integral membrane Zn-contg. endopeptidase, which degrades and inactivates a no. of bioactive peptides.  The range of substrates cleaved by I in vitro includes the enkephalins, substance P, endothelin, bradykinin, and atrial natriuretic factor.  Due to the physiol. importance of I in the modulation of nociceptive and pressor responses there is considerable interest in inhibitors of this enzyme as novel analgesics and anti-hypertensive agents.  Here, the authors describe the crystal structure of the extracellular domain (residues 52-749) of human I complexed with the generic metalloproteinase inhibitor, phosphoramidon (II), at 2.1 Å resoln.  The structure revealed 2 multiply connected folding domains which embraced a large central cavity contg. the active site.  II was bound to one side of this cavity and its binding mode provided a detailed understanding of the ligand-binding and specificity determinants.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCc0rfNE03ULVg90H21EOLACvtfcHk0lhXeniR0nQB9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXps1GqsA%253D%253D&md5=82d113a6b2e0349fd738bd62e6e59f9a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1999.3492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1999.3492%26sid%3Dliteratum%253Aachs%26aulast%3DOefner%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DA.%26aulast%3DHennig%26aufirst%3DM.%26aulast%3DWinkler%26aufirst%3DF.%2BK.%26aulast%3DDale%26aufirst%3DG.%2BE.%26atitle%3DStructure%2520of%2520human%2520neutral%2520endopeptidase%2520%2528Neprilysin%2529%2520complexed%2520with%2520phosphoramidon%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2000%26volume%3D296%26spage%3D341%26epage%3D349%26doi%3D10.1006%2Fjmbi.1999.3492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiering, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arcy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, M.</span></span> <span> </span><span class="NLM_article-title">Structure of neprilysin in complex with the active metabolite of sacubitril</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">27909</span> <span class="refDoi"> DOI: 10.1038/srep27909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1038%2Fsrep27909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=27302413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWnsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=N.+Schieringauthor=A.+D%E2%80%99Arcyauthor=F.+Villardauthor=P.+Ramageauthor=C.+Logelauthor=F.+Cuminauthor=G.+M.+Ksanderauthor=C.+Wiesmannauthor=R.+G.+Karkiauthor=M.+Mogi&title=Structure+of+neprilysin+in+complex+with+the+active+metabolite+of+sacubitril&doi=10.1038%2Fsrep27909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of neprilysin in complex with the active metabolite of sacubitril</span></div><div class="casAuthors">Schiering, Nikolaus; D'Arcy, Allan; Villard, Frederic; Ramage, Paul; Logel, Claude; Cumin, Frederic; Ksander, Gary M.; Wiesmann, Christian; Karki, Rajeshri G.; Mogi, Muneto</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27909</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sacubitril is an Et ester prodrug of LBQ657, the active neprilysin (NEP) inhibitor, and a component of LCZ696 (sacubitril/valsartan).  We report herein the three-dimensional structure of LBQ657 in complex with human NEP at 2 Å resoln.  The crystal structure unravels the binding mode of the compd. occupying the S1, S1' and S2' sub-pockets of the active site, consistent with a competitive inhibition mode.  An induced fit conformational change upon binding of the P1'-biphenyl moiety of the inhibitor suggests an explanation for its selectivity against structurally homologous zinc metallopeptidases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp01sPJaXPD2rVg90H21EOLACvtfcHk0lhXeniR0nQB9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWnsrvJ&md5=145b5c3201d621f289a12e43f461d28a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fsrep27909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep27909%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DA.%26aulast%3DVillard%26aufirst%3DF.%26aulast%3DRamage%26aufirst%3DP.%26aulast%3DLogel%26aufirst%3DC.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DKarki%26aufirst%3DR.%2BG.%26aulast%3DMogi%26aufirst%3DM.%26atitle%3DStructure%2520of%2520neprilysin%2520in%2520complex%2520with%2520the%2520active%2520metabolite%2520of%2520sacubitril%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26doi%3D10.1038%2Fsrep27909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinsen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajfirouz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruminski, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Hostos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, M. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrhea</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.231167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1124%2Fjpet.115.231167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=26907621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWhtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2016&pages=423-431&author=D.+W.+Griggsauthor=M.+J.+Prinsenauthor=J.+Olivaauthor=M.+A.+Campbellauthor=S.+D.+Arnettauthor=D.+Tajfirouzauthor=P.+G.+Ruminskiauthor=Y.+Yuauthor=B.+R.+Bondauthor=Y.+Jiauthor=G.+Neckermannauthor=R.+K.+Choyauthor=E.+de+Hostosauthor=M.+J.+Meyers&title=Pharmacologic+comparison+of+clinical+neutral+endopeptidase+inhibitors+in+a+rat+model+of+acute+secretory+diarrhea&doi=10.1124%2Fjpet.115.231167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrhea</span></div><div class="casAuthors">Griggs, David W.; Prinsen, Michael J.; Oliva, Jonathan; Campbell, Mary A.; Arnett, Stacy D.; Tajfirouz, Deena; Ruminski, Peter G.; Yu, Ying; Bond, Brian R.; Ji, Yuhua; Neckermann, Georg; Choy, Robert K. M.; de Hostos, Eugenio; Meyers, Marvin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">423-431</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Racecadotril (acetorphan) is a neutral endopeptidase (NEP) inhibitor with known antidiarrheal activity in animals and humans; however, in humans, it suffers from shortcomings that might be improved with newer drugs in this class that have progressed to the clinic for nonenteric disease indications.  To identify potentially superior NEP inhibitors with immediate clin. utility for diarrhea treatment, we compared their efficacy and pharmacol. properties in a rat intestinal hypersecretion model.  Racecadotril and seven other clin.-stage inhibitors of NEP were obtained or synthesized.  Enzyme potency and specificity were compared using purified peptidases.  Compds. were orally administered to rats before administration of castor oil to induce diarrhea.  Stool wt. was recorded over 4 h.  To assess other pharmacol. properties, select compds. were orally administered to normal or castor oil-treated rats, blood and tissue samples collected at multiple time points, and active compd. concns. detd. by mass spectroscopy.  NEP enzyme activity was measured in tissue homogenates.  Three previously untested clin. NEP inhibitors delayed diarrhea onset and reduced total stool output, with little or no effect on intestinal motility assessed by the charcoal meal test.  Each was shown to be a potent, highly specific inhibitor of NEP.  Each exhibited greater suppression of NEP activity in intestinal and nonintestinal tissues than did racecadotril and sustained this inhibition longer.  These results suggest that newer clin.-stage NEP inhibitors originally developed for other indications may be directly repositioned for treatment of acute secretory diarrhea and offer advantages over racecadotril, such as less frequent dosing and potentially improved efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbmMeM1b6li7Vg90H21EOLACvtfcHk0lgO0jochB71wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWhtbvL&md5=5d6358c680375427cb3fd23e9a135f47</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.231167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.231167%26sid%3Dliteratum%253Aachs%26aulast%3DGriggs%26aufirst%3DD.%2BW.%26aulast%3DPrinsen%26aufirst%3DM.%2BJ.%26aulast%3DOliva%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DM.%2BA.%26aulast%3DArnett%26aufirst%3DS.%2BD.%26aulast%3DTajfirouz%26aufirst%3DD.%26aulast%3DRuminski%26aufirst%3DP.%2BG.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DBond%26aufirst%3DB.%2BR.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DNeckermann%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%2BK.%26aulast%3Dde%2BHostos%26aufirst%3DE.%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26atitle%3DPharmacologic%2520comparison%2520of%2520clinical%2520neutral%2520endopeptidase%2520inhibitors%2520in%2520a%2520rat%2520model%2520of%2520acute%2520secretory%2520diarrhea%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D357%26spage%3D423%26epage%3D431%26doi%3D10.1124%2Fjpet.115.231167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kukkola, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakane, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilci, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghai, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeng, A. Y.</span></span> <span> </span><span class="NLM_article-title">Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">S65</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1097/00005344-199506263-00021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1097%2F00005344-199506263-00021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=8587470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK2MXps1KiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1995&pages=S65-568&author=P.+J.+Kukkolaauthor=P.+Savageauthor=Y.+Sakaneauthor=J.+C.+Berryauthor=N.+A.+Bilciauthor=R.+D.+Ghaiauthor=A.+Y.+Jeng&title=Differential+structure-activity+relationships+of+phosphoramidon+analogues+for+inhibition+of+three+metalloproteases%3A+endothelin-converting+enzyme%2C+neutral+endopeptidase%2C+and+angiotensin-converting+enzyme&doi=10.1097%2F00005344-199506263-00021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Differential structure-activity relationships of phosphoramidon analogs for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme</span></div><div class="casAuthors">Kukkola, Paivi J.; Savage, Paula; Sakane, Yumi; Berry, J. Carol; Bilci, Natalie A.; Ghai, Rajendra D.; Jeng, Arco Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">S65-S68</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">The structure-activity relationships of phosphoramidon analogs for inhibition of endothelin-converting enzyme (ECE), neutral endopeptidase 24.11 (NEP), and angiotensin-converting enzyme (ACE) were compared.  Phosphoramidon inhibited ECE, NEP, and ACE activities with IC50 values of 3.5, 0.034, and 78 μM, resp.  Removal of the rhamnose moiety of phosphoramidon (dipeptide 3) reduced the potency for ECE (IC50 = 70 μM), whereas the potencies for NEP (0.002 μM) and ACE (0.20 μM) were increased.  Addn. of 2-(2-naphthyl)ethyl to dipeptide 3 improved the potency for ECE (0.55 μM) but weakened the potency for NEP (0.02 μM), and had no significant change for ACE.  Interchange between Leu and Trp abolished the inhibitory activities for ECE and NEP, but the compd. remained active for ACE.  These results suggest that a hydrophobic group in the P1 position of phosphoramidon analogs increases the potency for ECE significantly, whereas compds. contg. a free phosphonic acid are optimal for inhibition of NEP and ACE.  Furthermore, an arom. group in the P'2 position is essential for the inhibition of ECE and NEP, but not ACE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp82VFZCm3gE7Vg90H21EOLACvtfcHk0lgO0jochB71wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXps1KiurY%253D&md5=4740a47c33fe7e7efc824cc2bcc81a48</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1097%2F00005344-199506263-00021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199506263-00021%26sid%3Dliteratum%253Aachs%26aulast%3DKukkola%26aufirst%3DP.%2BJ.%26aulast%3DSavage%26aufirst%3DP.%26aulast%3DSakane%26aufirst%3DY.%26aulast%3DBerry%26aufirst%3DJ.%2BC.%26aulast%3DBilci%26aufirst%3DN.%2BA.%26aulast%3DGhai%26aufirst%3DR.%2BD.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26atitle%3DDifferential%2520structure-activity%2520relationships%2520of%2520phosphoramidon%2520analogues%2520for%2520inhibition%2520of%2520three%2520metalloproteases%253A%2520endothelin-converting%2520enzyme%252C%2520neutral%2520endopeptidase%252C%2520and%2520angiotensin-converting%2520enzyme%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1995%26volume%3D26%26spage%3DS65%26epage%3D568%26doi%3D10.1097%2F00005344-199506263-00021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaucher, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiraboschi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prange, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournie-Zaluski, M. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of alpha-mercaptoacyldipeptides in the thermolysin active site: structural parameters for a Zn monodentation or bidentation in metalloendopeptidases</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">12569</span>– <span class="NLM_lpage">12576</span>, <span class="refDoi"> DOI: 10.1021/bi991043z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi991043z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK1MXls1ajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=12569-12576&author=J.+F.+Gaucherauthor=M.+Selktiauthor=G.+Tiraboschiauthor=T.+Prangeauthor=B.+P.+Roquesauthor=A.+Tomasauthor=M.+C.+Fournie-Zaluski&title=Crystal+structures+of+alpha-mercaptoacyldipeptides+in+the+thermolysin+active+site%3A+structural+parameters+for+a+Zn+monodentation+or+bidentation+in+metalloendopeptidases&doi=10.1021%2Fbi991043z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of α-Mercaptoacyldipeptides in the Thermolysin Active Site: Structural Parameters for a Zn Monodentation or Bidentation in Metalloendopeptidases</span></div><div class="casAuthors">Gaucher, J. F.; Selkti, M.; Tiraboschi, G.; Prange, T.; Roques, B. P.; Tomas, A.; Fournie-Zaluski, M. C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">12569-12576</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three α-mercaptoacyldipeptides differing essentially in the size of their C-terminal residues have been crystd. in the thermolysin active site.  A new mode of binding was obsd. for 3 [HS-CH(CH2Ph)CO-Phe-Tyr] and 4 [HS-CH((CH2)4CH3)CO-Phe-Ala], in which the mercaptoacyl moieties act as bidentates with Zn-S and Zn-O distances of 2.3 and 2.4 Å, resp., the side chains fitting the S1, S1', and S2' pockets.  Moreover, a distance of 3.1 Å between the sulfur atom and the OE1 of Glu143 suggests that they are H-bonded and that one of these atoms is protonated.  This H-bond network involving Glu143, the mercaptoacyl group of the inhibitor, and the Zn ion could be considered a "modified" transition state mimic of the peptide bond hydrolysis.  Due to the presence of the hindering (5-phenyl)proline, the inhibitor HS-CH(CH2Ph)CO-Gly-(5-Ph)Pro (2) interacts through the usual Zn monodentation via the thiol group and occupancy of S1' and S2' subsites by the arom. moieties, the proline ring being outside the active site.  The inhibitory potencies are consistent with these structural data, with higher affinities for 3 (4.2 × 10-8 M) and 4 (4.8 × 10-8 M) than for 2 (1.2 × 10-6 M).  The extension of the results, obtained with thermolysin being considered as the model of physiol. zinc metallopeptidases, allows inhibitor-recognition modes for other peptidases, such as angiotensin converting enzyme and neutral endopeptidase, to be proposed and opens interesting possibilities for the design of new classes of inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS0RBz62580rVg90H21EOLACvtfcHk0lgO0jochB71wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXls1ajtrY%253D&md5=92d076d0ba415a404eed4d22ef3c9d7d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fbi991043z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi991043z%26sid%3Dliteratum%253Aachs%26aulast%3DGaucher%26aufirst%3DJ.%2BF.%26aulast%3DSelkti%26aufirst%3DM.%26aulast%3DTiraboschi%26aufirst%3DG.%26aulast%3DPrange%26aufirst%3DT.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26aulast%3DTomas%26aufirst%3DA.%26aulast%3DFournie-Zaluski%26aufirst%3DM.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520alpha-mercaptoacyldipeptides%2520in%2520the%2520thermolysin%2520active%2520site%253A%2520structural%2520parameters%2520for%2520a%2520Zn%2520monodentation%2520or%2520bidentation%2520in%2520metalloendopeptidases%26jtitle%3DBiochemistry%26date%3D1999%26volume%3D38%26spage%3D12569%26epage%3D12576%26doi%3D10.1021%2Fbi991043z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghai, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMartin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohacek, R.</span></span> <span> </span><span class="NLM_article-title">Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1021/jm960583g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960583g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVSksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=506-514&author=G.+M.+Ksanderauthor=R.+de+Jesusauthor=A.+Yuanauthor=R.+D.+Ghaiauthor=C.+McMartinauthor=R.+Bohacek&title=Meta-substituted+benzofused+macrocyclic+lactams+as+zinc+metalloprotease+inhibitors&doi=10.1021%2Fjm960583g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Meta-Substituted Benzofused Macrocyclic Lactams as Zinc Metalloprotease Inhibitors</span></div><div class="casAuthors">Ksander, Gary M.; de Jesus, Reynalda; Yuan, Andrew; Ghai, Raj D.; McMartin, Colin; Bohacek, Regine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">506-514</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and biochem. profile of meta-substituted benzofused macrocyclic lactams are described.  The meta-substituted benzofused macrocyclic lactams were designed to have a degree of flexibility allowing the amide bond to occupy two completely different conformations while maintaining sufficient rigidity to allow for strong interaction between enzyme and inhibitor.  Using TFIT, a novel mol. superimposition program, it was shown that the meta analogs could be readily superimposed onto our ACE inhibitor template whereas no low-energy superimpositions of the ortho-substituted macrocycles could be found.  Unlike the ortho-substituted benzofused macrocyclic lactams described in a previous paper which are selective NEP inhibitors, the meta-substituted compds. are dual inhibitors of both NEP and ACE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzRsksrVMvXrVg90H21EOLACvtfcHk0liAiYgxTiyvNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVSksr0%253D&md5=f74c5dbf907c905f15ce359f7817ad21</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm960583g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960583g%26sid%3Dliteratum%253Aachs%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3Dde%2BJesus%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DA.%26aulast%3DGhai%26aufirst%3DR.%2BD.%26aulast%3DMcMartin%26aufirst%3DC.%26aulast%3DBohacek%26aufirst%3DR.%26atitle%3DMeta-substituted%2520benzofused%2520macrocyclic%2520lactams%2520as%2520zinc%2520metalloprotease%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D506%26epage%3D514%26doi%3D10.1021%2Fjm960583g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghai, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMartin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohacek, R.</span></span> <span> </span><span class="NLM_article-title">Ortho-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1021/jm960582o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960582o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVSksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=495-505&author=G.+M.+Ksanderauthor=R.+de+Jesusauthor=A.+Yuanauthor=R.+D.+Ghaiauthor=A.+Trapaniauthor=C.+McMartinauthor=R.+Bohacek&title=Ortho-substituted+benzofused+macrocyclic+lactams+as+zinc+metalloprotease+inhibitors&doi=10.1021%2Fjm960582o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Ortho-Substituted Benzofused Macrocyclic Lactams as Zinc Metalloprotease Inhibitors</span></div><div class="casAuthors">Ksander, Gary M.; de Jesus, Reynalda; Yuan, Andrew; Ghai, R. D.; Trapani, A.; McMartin, Colin; Bohacek, Regine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">495-505</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design and prepn. of ortho-substituted benzofused macrocyclic lactams are described.  The benzofused macrocyclic lactams were designed as neutral endopeptidase 24.11 (NEP) inhibitors.  Docking studies were carried out in a model of thermolysin (TLN) using the MACROMODEL and QXP modeling programs to select suitable ring sizes.  These studies predicted that the 11-, 12-, and 13-membered ring macrocyclic lactams would be active in both enzymes TLN and NEP.  Good predictability of exptl. results, within this series, of binding to thermolysin and to a lesser extent to NEP was obsd.  A visual comparison, docked at the active site of TLN, is presented for thiorphan, a 10-membered ring macrocycle and an 11-membered ring benzofused macrocyclic lactam.  Potent inhibition of both NEP and thermolysin was obtained.  The 11-membered ring macrocycle, 2,3,4,5,6,7,8,9-octahydro-2(S)-mercapto-3-oxo-1H-4-benzazacycloundecine-5(S)-carboxylic acid, is the most potent inhibitor from this series of compds. (TLN IC50 = 68 nM; NEP IC50 = 0.9 nM).  The effects of prodrug benzyl 2(R)-[(acetylthio)methyl]-2,3,4,5,6,7,8,9,10,11-decahydro-2-ox-1H-4-benzazacyclotridecine-5(S)-carboxylate administered at 10 mg/kg po on plasma atrial natriuretic peptide (ANP) levels in conscious rats was greater than 200% over a 4 h period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKuBNgiRCKeLVg90H21EOLACvtfcHk0liAiYgxTiyvNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVSksrw%253D&md5=bf9bddcbf267a128645d8c1f3a1e155b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm960582o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960582o%26sid%3Dliteratum%253Aachs%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3Dde%2BJesus%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DA.%26aulast%3DGhai%26aufirst%3DR.%2BD.%26aulast%3DTrapani%26aufirst%3DA.%26aulast%3DMcMartin%26aufirst%3DC.%26aulast%3DBohacek%26aufirst%3DR.%26atitle%3DOrtho-substituted%2520benzofused%2520macrocyclic%2520lactams%2520as%2520zinc%2520metalloprotease%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D495%26epage%3D505%26doi%3D10.1021%2Fjm960582o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiraboschi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jullian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thery, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonczak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournie-Zaluski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span> <span> </span><span class="NLM_article-title">A three-dimensional construction of the active site (region 507-749) of human neutral endopeptidase (EC.3.4.24.11)</span>. <i>Protein Eng., Des. Sel.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1093/protein/12.2.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1093%2Fprotein%2F12.2.141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1999&pages=141-149&author=G.+Tiraboschiauthor=N.+Jullianauthor=V.+Theryauthor=S.+Antonczakauthor=M.+C.+Fournie-Zaluskiauthor=B.+P.+Roques&title=A+three-dimensional+construction+of+the+active+site+%28region+507-749%29+of+human+neutral+endopeptidase+%28EC.3.4.24.11%29&doi=10.1093%2Fprotein%2F12.2.141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2F12.2.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252F12.2.141%26sid%3Dliteratum%253Aachs%26aulast%3DTiraboschi%26aufirst%3DG.%26aulast%3DJullian%26aufirst%3DN.%26aulast%3DThery%26aufirst%3DV.%26aulast%3DAntonczak%26aufirst%3DS.%26aulast%3DFournie-Zaluski%26aufirst%3DM.%2BC.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26atitle%3DA%2520three-dimensional%2520construction%2520of%2520the%2520active%2520site%2520%2528region%2520507-749%2529%2520of%2520human%2520neutral%2520endopeptidase%2520%2528EC.3.4.24.11%2529%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D1999%26volume%3D12%26spage%3D141%26epage%3D149%26doi%3D10.1093%2Fprotein%2F12.2.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaspard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhenc-Gelas, F.</span></span> <span> </span><span class="NLM_article-title">Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">9496</span>– <span class="NLM_lpage">9503</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=7683654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK3sXktVekt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=9496-9503&author=E.+Jaspardauthor=L.+Weiauthor=F.+Alhenc-Gelas&title=Differences+in+the+properties+and+enzymatic+specificities+of+the+two+active+sites+of+angiotensin+I-converting+enzyme+%28kininase+II%29.+Studies+with+bradykinin+and+other+natural+peptides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Differences in the properties and enzymic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides</span></div><div class="casAuthors">Jaspard, Emmanuel; Wei, Lei; Alhenc-Gelas, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9496-503</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Angiotensin I-converting enzyme (ACE, E.C.3.4.15.1) has been recently shown to contain two very similar domains, each of which bears a functional active site hydrolyzing Hip-His-Leu or angiotensin I (AI).  The substrate specificity of the two active sites of ACE was compared using wild-type recombinant ACE and mutants, where one active site is suppressed by deletion or inactivated by mutations of 2 histidines coordinating an essential zinc atom.  Both active sites converted bradykinin (BK) to BK1-7 and BK1-5 with similar kinetics and with Kmapp at least 30 times lower and kcat/Kmapp 10 times higher than for AI.  The carboxyl-terminal active site, but not the amino-terminal site, was activated by chloride; however, chloride activation was minimal compared with AI.  Both domains also hydrolyzed substance P and cleaved a carboxyl-terminal protected dipeptide and tripeptide.  The carboxyl-terminal active site was more readily activated by chloride and hydrolyzed substance P faster.  Luteinizing-hormone releasing hormone was hydrolyzed by both active sites, but hydrolysis by the amino-terminal active site was faster.  It performed the endoproteolytic amino-terminal cleavage of this peptide at least 30 times faster than the carboxyl-terminal active site.  Both active sites cleaved a carboxyl-terminal tripeptide from LH-releasing hormone.  Thus, both active sites of ACE possess dipeptidyl carboxypeptidase and endopeptidase activities.  However, only the carboxyl-terminal active site can undergo a chloride-induced alteration that greatly enhances the hydrolysis of AI or substance P, and the amino-terminal active site possesses an unusual amino-terminal endoproteolytic specificity for a natural peptide.  This suggests physiol. important differences between the subsites of the two active centers, and different substrate specificity, despite the high degree of sequence homol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDfIaBdRuIgLVg90H21EOLACvtfcHk0liAiYgxTiyvNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVekt7Y%253D&md5=472186440cc10fbf168a059ef314462c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJaspard%26aufirst%3DE.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DAlhenc-Gelas%26aufirst%3DF.%26atitle%3DDifferences%2520in%2520the%2520properties%2520and%2520enzymatic%2520specificities%2520of%2520the%2520two%2520active%2520sites%2520of%2520angiotensin%2520I-converting%2520enzyme%2520%2528kininase%2520II%2529.%2520Studies%2520with%2520bradykinin%2520and%2520other%2520natural%2520peptides%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D9496%26epage%3D9503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corradi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitapi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">The structure of testis angiotensin-converting enzyme in complex with the C-domain specific inhibitor RXPA380</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5473</span>– <span class="NLM_lpage">5478</span>, <span class="refDoi"> DOI: 10.1021/bi700275e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi700275e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1Kntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=5473-5478&author=H.+R.+Corradiauthor=I.+Chitapiauthor=B.+T.+Sewellauthor=D.+Georgiadisauthor=V.+Diveauthor=E.+D.+Sturrockauthor=K.+R.+Acharya&title=The+structure+of+testis+angiotensin-converting+enzyme+in+complex+with+the+C-domain+specific+inhibitor+RXPA380&doi=10.1021%2Fbi700275e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The Structure of Testis Angiotensin-Converting Enzyme in Complex with the C Domain-Specific Inhibitor RXPA380</span></div><div class="casAuthors">Corradi, Hazel R.; Chitapi, Itai; Sewell, B. Trevor; Georgiadis, Dimitris; Dive, Vincent; Sturrock, Edward D.; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5473-5478</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Angiotensin I-converting enzyme (ACE) is central to the regulation of the renin-angiotensin system and is a key therapeutic target for combating hypertension and related cardiovascular diseases.  Currently available drugs bind both active sites of its two homologous domains, although it is now understood that these domains function differently in vivo.  The recently solved crystal structures of both domains (N and C) open the door to new domain-specific inhibitor design, taking advantage of the differences between these two large active sites.  Here we present the first crystal structure at a resoln. of 2.25 Å of testis ACE (identical to the C domain of somatic ACE) with the highly C-domain-specific phosphinic inhibitor, RXPA380.  Testis ACE retains the same conformation as seen in previously detd. inhibitor complexes, but the RXPA380 central backbone conformation is more similar to that seen for the inhibitor captopril than enalaprilat.  The RXPA380 mol. occupies more subsites of the testis ACE active site than the previously detd. inhibitors and possesses bulky moieties that extend into the S2' and S2 subsites.  Thus the high affinity of RXPA380 for the testis ACE/somatic ACE C domain is explained by the interaction of these bulky moieties with residues unique to these domains, specifically Phe391, Val379, and Val380, that are not found in the N domain.  The characterization of the extended active site and the binding of a potent C-domain-selective inhibitor provide the first structural data for the design of truly domain-specific pharmacophores.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorNz6kJtEO_7Vg90H21EOLACvtfcHk0lgglEuEwk1mUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1Kntb8%253D&md5=804714644ac98552f2f877a37a2ed371</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fbi700275e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi700275e%26sid%3Dliteratum%253Aachs%26aulast%3DCorradi%26aufirst%3DH.%2BR.%26aulast%3DChitapi%26aufirst%3DI.%26aulast%3DSewell%26aufirst%3DB.%2BT.%26aulast%3DGeorgiadis%26aufirst%3DD.%26aulast%3DDive%26aufirst%3DV.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DThe%2520structure%2520of%2520testis%2520angiotensin-converting%2520enzyme%2520in%2520complex%2520with%2520the%2520C-domain%2520specific%2520inhibitor%2520RXPA380%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D5473%26epage%3D5478%26doi%3D10.1021%2Fbi700275e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jullien, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makritis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yiotakis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, V.</span></span> <span> </span><span class="NLM_article-title">Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1021/jm9010803</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9010803" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlymtbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=208-220&author=N.+Jullienauthor=A.+Makritisauthor=D.+Georgiadisauthor=F.+Beauauthor=A.+Yiotakisauthor=V.+Dive&title=Phosphinic+tripeptides+as+dual+angiotensin-converting+enzyme+C-domain+and+endothelin-converting+enzyme-1+inhibitors&doi=10.1021%2Fjm9010803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphinic Tripeptides as Dual Angiotensin-Converting Enzyme C-Domain and Endothelin-Converting Enzyme-1 Inhibitors</span></div><div class="casAuthors">Jullien, Nicolas; Makritis, Anastasios; Georgiadis, Dimitris; Beau, Fabrice; Yiotakis, Athanasios; Dive, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">208-220</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of phosphinic inhibitors able to interact with both angiotensin-converting enzyme (ACE) C-domain and endothelin-converting enzyme-1 (ECE-1), while sparing neprilysin (NEP), has been developed.  The most potent and selective inhibitor in this series (compd. 8F2) displays Ki values of 0.65 nM, 150 nM, 14 nM and 6.7 μM toward somatic ACE C-domain, ACE N-domain, ECE-1, and NEP, resp.  Remarkably, in this series, the inhibitor's ability to discriminate between ECE-1 and NEP was obsd. to depend on the stereochem. of the residue present in the inhibitor's P1' position.  After iv administration, compd. 8F2 (10 mg/kg) lowered mean arterial blood pressure by 24 ± 2 mmHg in spontaneously hypertensive rats, as compared with controls.  Mixed ACE/ECE-1 inhibitor may lead to a new generation of vasopeptide inhibitors that should reduce the levels of angiotensin-II and endothelin-1, without interfering with bradykinin cleavage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hR7yZw_SuLVg90H21EOLACvtfcHk0lgglEuEwk1mUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlymtbrE&md5=8669922da99511db6fdbb67b7660aa5c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm9010803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9010803%26sid%3Dliteratum%253Aachs%26aulast%3DJullien%26aufirst%3DN.%26aulast%3DMakritis%26aufirst%3DA.%26aulast%3DGeorgiadis%26aufirst%3DD.%26aulast%3DBeau%26aufirst%3DF.%26aulast%3DYiotakis%26aufirst%3DA.%26aulast%3DDive%26aufirst%3DV.%26atitle%3DPhosphinic%2520tripeptides%2520as%2520dual%2520angiotensin-converting%2520enzyme%2520C-domain%2520and%2520endothelin-converting%2520enzyme-1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D208%26epage%3D220%26doi%3D10.1021%2Fjm9010803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">High resolution crystal structure of substrate-free human neprilysin</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2018.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1016%2Fj.jsb.2018.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=29906506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2jsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2018&pages=19-25&author=S.+Mossauthor=V.+Subramanianauthor=K.+R.+Acharya&title=High+resolution+crystal+structure+of+substrate-free+human+neprilysin&doi=10.1016%2Fj.jsb.2018.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">High resolution crystal structure of substrate-free human neprilysin</span></div><div class="casAuthors">Moss, Stephen; Subramanian, Vasanta; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Neprilysin is a transmembrane M13 zinc metalloprotease responsible for the degrdn. of several biol. active peptides including insulin, enkephalin, substance P, bradykinin, endothelin-1, neurotensin and amyloid-β.  The protein has received attention for its role in modulating blood pressure responses with its inhibition producing an antihypertensive response.  To date, several inhibitor bound crystal structures of the human neprilysin extracellular domain have been detd., but, a structure free of bound inhibitor or substrate has yet to be reported.  Here, we report the first crystal structure free of substrate or inhibitor for the extracellular catalytic domain of human neprilysin at 1.9 Å resoln.  This structure will provide a ref. point for comparisons to future inhibitor or substrate bound structures.  The neprilysin structure also reveals that a closed protein conformation can be adopted in protein crystals absent of bound substrate or inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUuVQEv0Psg7Vg90H21EOLACvtfcHk0lgglEuEwk1mUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2jsr7M&md5=6f1c9c2b31964684decb80bb4c2eea32</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2018.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2018.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DV.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DHigh%2520resolution%2520crystal%2520structure%2520of%2520substrate-free%2520human%2520neprilysin%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2018%26volume%3D204%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.jsb.2018.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waterman, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildea, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkhurst, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewster, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauter, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, G.</span></span> <span> </span><span class="NLM_article-title">Diffraction-geometry refinement in the DIALS framework</span>. <i>Acta Crystallogr., Sect. D: Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1107/S2059798316002187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS2059798316002187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFSkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=558-575&author=D.+G.+Watermanauthor=G.+Winterauthor=R.+J.+Gildeaauthor=J.+M.+Parkhurstauthor=A.+S.+Brewsterauthor=N.+K.+Sauterauthor=G.+Evans&title=Diffraction-geometry+refinement+in+the+DIALS+framework&doi=10.1107%2FS2059798316002187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Diffraction-geometry refinement in the DIALS framework</span></div><div class="casAuthors">Waterman, David G.; Winter, Graeme; Gildea, Richard J.; Parkhurst, James M.; Brewster, Aaron S.; Sauter, Nicholas K.; Evans, Gwyndaf</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Structural Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">558-575</span>CODEN:
                <span class="NLM_cas:coden">ACSDAD</span>;
        ISSN:<span class="NLM_cas:issn">2059-7983</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Rapid data collection and modern computing resources provide the opportunity to revisit the task of optimizing the model of diffraction geometry prior to integration.  A comprehensive description is given of new software that builds upon established methods by performing a single global refinement procedure, utilizing a smoothly varying model of the crystal lattice where appropriate.  This global refinement technique extends to multiple data sets, providing useful constraints to handle the problem of correlated parameters, particularly for small wedges of data.  Examples of advanced uses of the software are given and the design is explained in detail, with particular emphasis on the flexibility and extensibility it entails.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmCZHkbbl6bVg90H21EOLACvtfcHk0lj8fSk2a5hmXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFSkurs%253D&md5=0041260941cd2e0581c8a1db0b5add97</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1107%2FS2059798316002187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2059798316002187%26sid%3Dliteratum%253Aachs%26aulast%3DWaterman%26aufirst%3DD.%2BG.%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DGildea%26aufirst%3DR.%2BJ.%26aulast%3DParkhurst%26aufirst%3DJ.%2BM.%26aulast%3DBrewster%26aufirst%3DA.%2BS.%26aulast%3DSauter%26aufirst%3DN.%2BK.%26aulast%3DEvans%26aufirst%3DG.%26atitle%3DDiffraction-geometry%2520refinement%2520in%2520the%2520DIALS%2520framework%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Struct.%2520Biol.%26date%3D2016%26volume%3D72%26spage%3D558%26epage%3D575%26doi%3D10.1107%2FS2059798316002187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span> <span> </span><span class="NLM_article-title">How good are my data and what is the resolution?</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1204</span>– <span class="NLM_lpage">1214</span>, <span class="refDoi"> DOI: 10.1107/S0907444913000061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444913000061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=23793146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVejsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=1204-1214&author=P.+R.+Evansauthor=G.+N.+Murshudov&title=How+good+are+my+data+and+what+is+the+resolution%3F&doi=10.1107%2FS0907444913000061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">How good are my data and what is the resolution?</span></div><div class="casAuthors">Evans, Philip R.; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1204-1214</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Following integration of the obsd. diffraction spots, the process of  data redn.' initially aims to det. the point-group symmetry of the data and the likely space group.  This can be performed with the program POINTLESS.  The scaling program then puts all the measurements on a common scale, avs. measurements of symmetry-related reflections (using the symmetry detd. previously) and produces many statistics that provide the first important measures of data quality.  A new scaling program, AIMLESS, implements scaling models similar to those in SCALA but adds some addnl. analyses.  From the analyses, a no. of decisions can be made about the quality of the data and whether some measurements should be discarded.  The effective  resoln.' of a data set is a difficult and possibly contentious question (particularly with referees of papers) and this is discussed in the light of tests comparing the data-processing statistics with trials of refinement against obsd. and simulated data, and automated model-building and comparison of maps calcd. with different resoln. limits.  These trials show that adding weak high-resoln. data beyond the commonly used limits may make some improvement and does no harm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreOyPAR8GLBrVg90H21EOLACvtfcHk0lj8fSk2a5hmXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVejsL8%253D&md5=3f649426c21e9d423f94ef8d7c568233</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1107%2FS0907444913000061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444913000061%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DHow%2520good%2520are%2520my%2520data%2520and%2520what%2520is%2520the%2520resolution%253F%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2013%26volume%3D69%26spage%3D1204%26epage%3D1214%26doi%3D10.1107%2FS0907444913000061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Collaborative
Computational Project Number 4</span> <span> </span><span class="NLM_article-title">The CCP4 suite: programs for protein crystallography</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1107/S0907444994003112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=15299374" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=760-763&author=Collaborative%0AComputational+Project+Number+4&title=The+CCP4+suite%3A+programs+for+protein+crystallography&doi=10.1107%2FS0907444994003112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520CCP4%2520suite%253A%2520programs%2520for%2520protein%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2FS0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lj8fSk2a5hmXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span> <span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lj8fSk2a5hmXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkoczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lg_S_O8MDezeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lg_S_O8MDezeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immormino, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom structure validation for macromolecular crystallography</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1107/S0907444909042073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444909042073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=20057044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=12-21&author=V.+B.+Chenauthor=W.+B.+Arendallauthor=J.+J.+Headdauthor=D.+A.+Keedyauthor=R.+M.+Immorminoauthor=G.+J.+Kapralauthor=L.+W.+Murrayauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+structure+validation+for+macromolecular+crystallography&doi=10.1107%2FS0907444909042073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom structure validation for macromolecular crystallography</span></div><div class="casAuthors">Chen, Vincent B.; Arendall, W. Bryan, III; Headd, Jeffrey J.; Keedy, Daniel A.; Immormino, Robert M.; Kapral, Gary J.; Murray, Laura W.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MolProbity is a structure-validation web service that provides broad-spectrum solidly based evaluation of model quality at both the global and local levels for both proteins and nucleic acids.  It relies heavily on the power and sensitivity provided by optimized hydrogen placement and all-atom contact anal., complemented by updated versions of covalent-geometry and torsion-angle criteria.  Some of the local corrections can be performed automatically in MolProbity and all of the diagnostics are presented in chart and graphical forms that help guide manual rebuilding.  X-ray crystallog. provides a wealth of biol. important mol. data in the form of at. three-dimensional structures of proteins, nucleic acids and increasingly large complexes in multiple forms and states.  Advances in automation, in everything from crystn. to data collection to phasing to model building to refinement, have made solving a structure using crystallog. easier than ever.  However, despite these improvements, local errors that can affect biol. interpretation are widespread at low resoln. and even high-resoln. structures nearly all contain at least a few local errors such as Ramachandran outliers, flipped branched protein side chains and incorrect sugar puckers.  It is crit. both for the crystallographer and for the end user that there are easy and reliable methods to diagnose and correct these sorts of errors in structures.  MolProbity is the authors' contribution to helping solve this problem and this article reviews its general capabilities, reports on recent enhancements and usage, and presents evidence that the resulting improvements are now beneficially affecting the global database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIjgsh59dO-7Vg90H21EOLACvtfcHk0lg_S_O8MDezeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D&md5=b5fc7574f43f01dd6e43c3663ca4f779</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444909042073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909042073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520structure%2520validation%2520for%2520macromolecular%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D12%26epage%3D21%26doi%3D10.1107%2FS0907444909042073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Presenting your structures: the CCP4mg molecular-graphics software</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">386</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1107/S0907444911007281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=10.1107%2FS0907444911007281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=21460457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=386-394&author=S.+McNicholasauthor=E.+Pottertonauthor=K.+S.+Wilsonauthor=M.+E.+Noble&title=Presenting+your+structures%3A+the+CCP4mg+molecular-graphics+software&doi=10.1107%2FS0907444911007281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Presenting your structures: The CCP4mg molecular-graphics software</span></div><div class="casAuthors">McNicholas, S.; Potterton, E.; Wilson, K. S.; Noble, M. E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">386-394</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">CCP4mg is a mol.-graphics program that is designed to give rapid access to both straightforward and complex static and dynamic representations of macromol. structures.  It has recently been updated with a new interface that provides more sophisticated atom-selection options and a wizard to facilitate the generation of complex scenes.  These scenes may contain a mixt. of coordinate-derived and abstr. graphical objects, including text objects, arbitrary vectors, geometric objects and imported images, which can enhance a picture and eliminate the need for subsequent editing.  Scene descriptions can be saved to file and transferred to other mols.  Here, the substantially enhanced version 2 of the program, with a new underlying GUI toolkit, is described.  A built-in rendering module produces publication-quality images.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdtflrxrILlbVg90H21EOLACvtfcHk0lir-sBdddHfrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqurw%253D&md5=d96403a39bc723a66f11a730f81f76c3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007281%26sid%3Dliteratum%253Aachs%26aulast%3DMcNicholas%26aufirst%3DS.%26aulast%3DPotterton%26aufirst%3DE.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DPresenting%2520your%2520structures%253A%2520the%2520CCP4mg%2520molecular-graphics%2520software%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D386%26epage%3D394%26doi%3D10.1107%2FS0907444911007281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laskowski, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swindells, M. B.</span></span> <span> </span><span class="NLM_article-title">LigPlot+: multiple ligand-protein interaction diagrams for drug discovery</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2778</span>– <span class="NLM_lpage">2786</span>, <span class="refDoi"> DOI: 10.1021/ci200227u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200227u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1KjtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2778-2786&author=R.+A.+Laskowskiauthor=M.+B.+Swindells&title=LigPlot%2B%3A+multiple+ligand-protein+interaction+diagrams+for+drug+discovery&doi=10.1021%2Fci200227u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery</span></div><div class="casAuthors">Laskowski, Roman A.; Swindells, Mark B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2778-2786</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe a graphical system for automatically generating multiple 2D diagrams of ligand-protein interactions from 3D coordinates.  The diagrams portray the hydrogen-bond interaction patterns and hydrophobic contacts between the ligand(s) and the main-chain or side-chain elements of the protein.  The system is able to plot, in the same orientation, related sets of ligand-protein interactions.  This facilitates popular research tasks, such as analyzing a series of small mols. binding to the same protein target, a single ligand binding to homologous proteins, or the completely general case where both protein and ligand change.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYuWvYH7Nel7Vg90H21EOLACvtfcHk0lir-sBdddHfrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1KjtrzP&md5=576e59ad4f0c4304d01c6c80301ecf39</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fci200227u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200227u%26sid%3Dliteratum%253Aachs%26aulast%3DLaskowski%26aufirst%3DR.%2BA.%26aulast%3DSwindells%26aufirst%3DM.%2BB.%26atitle%3DLigPlot%252B%253A%2520multiple%2520ligand-protein%2520interaction%2520diagrams%2520for%2520drug%2520discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2778%26epage%3D2786%26doi%3D10.1021%2Fci200227u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GID" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GID','PDB','6GID'); return false;">PDB: 6GID</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK','PDB','6SUK'); return false;">PDB: 6SUK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP','PDB','6XVP'); return false;">PDB: 6XVP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY','PDB','6SVY'); return false;">PDB: 6SVY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVY','PDB','6XVY'); return false;">PDB: 6XVY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1DMT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1DMT','PDB','1DMT'); return false;">PDB: 1DMT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZR5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZR5','PDB','4ZR5'); return false;">PDB: 4ZR5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V48" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V48','PDB','5V48'); return false;">PDB: 5V48</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JMY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JMY','PDB','5JMY'); return false;">PDB: 5JMY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVP','PDB','6SVP'); return false;">PDB: 6SVP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5X','PDB','6H5X'); return false;">PDB: 6H5X</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6H5W','PDB','6H5W'); return false;">PDB: 6H5W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9V','PDB','6F9V'); return false;">PDB: 6F9V</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9T" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9T','PDB','6F9T'); return false;">PDB: 6F9T</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9R','PDB','6F9R'); return false;">PDB: 6F9R</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9U" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F9U','PDB','6F9U'); return false;">PDB: 6F9U</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i21"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00441">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_60452"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00441?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00441</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00441/suppl_file/jm0c00441_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00441/suppl_file/jm0c00441_si_001.csv">jm0c00441_si_001.csv (0.3 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The atomic coordinates and structure factors for omapatrilat–NEP, sampatrilat–NEP, and samASP–NEP complexes have been deposited in the RCSB Protein Data Bank with codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SUK">6SUK</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XVP">6XVP</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SVY">6SVY</a>, respectively. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00441&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00441%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-10" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00441" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                10MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a9e230e201995","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
